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1 Introduction
1.1 Age-related neurodegenerative disorders
In the aging population of the western world, an increasingly common cause of disability
is the degeneration of the central nervous system. Age-related neurodegenerative disease is
the common term for a set of diseases that affects the elderly, that progresses with advanced
age and in which a loss of function, structure or death of neurons occurs. The most common
include Alzheimer’s disease (AD) and Parkinson’s disease (PD). In both of these diseases the
causes and mechanisms are still not well understood and only in a low number of cases
is there a known inherited genetic mutation behind the pathology. Nevertheless, shared
themes such as protein aggregation and neuronal loss through common programmed cell
death (PCD) pathways occur in both of these diseases as well as in others such as adult onset
Huntington’s disease (Rubinsztein, 2006; Bredesen et al., 2006). This suggests the possibility
of common mechanisms that when discovered, could lead to progress in treating many if not
all neurodegenerative disorders.
1.1.1 Parkinson’s disease
History and symptoms
In 1817 the British physician James Parkinson published “An essay on the shaking palsey”
(Parkinson, 2002) where he characterized the symptoms of Parkinson’s disease (PD). In 1919
the loss of neurons in the substantia nigra pars compacta (SNpc) had been described and
in 1959, the hypothesis that PD patients experience their symptoms because of a lack of
dopamine. This was confirmed when trials in treating the symptoms by administration of
the dopamine pre-cursor L-dopa were successful some years later (Fahn, 2008). Today, PD is
recognized as the second most common neurodegenerative disorder after AD and it affects
between 1 and 2% of the population over 65 years of age. The incidence increases to between
1
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3 and 5% in people over 85 (Nuytemans et al., 2010). The common symptoms of PD include:
tremors at rest, rigidity, bradykinesia and posture instability. The clinical diagnosis of PD
is based on the verification of two out of these four symptoms and of the positive response
to L-dopa treatment. Before or after the onset of these motor symptoms, nonmotor symp-
toms such as olfactory dysfunction, sleep abnormalities and depression might be observed
(Jankovic, 2008; O’Sullivan et al., 2008). The average age of onset for idiopathic PD is ∼70
years and it has been observed that motor symptoms start to become apparent when ∼70% of
dopaminergic neurons in the SNpc are degenerated. At birth, the total number of dopamin-
ergic neurons in the SNpc is approximately 400000 and a “healthy” brain loses these at a rate
of ∼2400 per year (Uversky and Eliezer, 2009). That means that a person who lives to be 120
years old would acquire PD related motor symptoms from normal loss of neurons.
Lewy bodies and Lewy neurites
Another hallmark of PD which is not required for diagnosis is the formation of intracellular
inclusions called Lewy bodies (LBs) and Lewy neurites (LNs). These inclusions are present
in the cell bodies and neurites of neurons throughout the brain, including surviving neurons
of the SNpc (Braak et al., 2003). As the disease progresses the region of the brain with the
highest concentration of inclusions changes according to the stages laid out by Braak et al.
(2003). The major component of LBs and LNs is aggregated α-Synuclein (αS) (Spillantini et
al., 1997).
Causes
Most cases of PD are classified as idiopathic but genetic mutations have been found in some
patients. So far, 18 genes, called PARK genes, have been linked to PD (Eschbach and Danzer,
2013). The connection to PD for some of these genes were inconclusive in follow up studies
but evidence for a causal relation have been shown for at least five of the genes (Nuytemans
et al., 2010). These are SNCA (PARK1), parkin (PARK2), P-TEN-induced putative kinase 1
(PINK1), leucine-rich repeat kinase 2 (LRRK2) and DJ-1 (PARK7).
SNCA is the gene coding for αS. Mutations in SNCA are rare but several point mutations
and gene duplications and triplications are known to cause autosomal dominant forms of PD
(Polymeropoulos et al., 1997; Nuytemans et al., 2010). Because αS is the main topic of this
thesis, the known properties of αS are further described in section 1.2.
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Another gene with known mutations that cause autosomal dominant PD is LRRK2. It codes
for the very large (2527 amino acid (aa)) protein lrrk2. LRRK2 was the second gene with a
causal relationshipwith PD to be discovered after that of SNCA.Multiplemutations in LRRK2
have been associated with PD with G2019S being the most common (Singleton et al., 2013).
Loss of dopaminergic neurons in the SNpc as well as the appearance of LBs are common
features in the pathology associated with LRRK2 mutations (Singleton et al., 2013). The lrrk2
protein is expressed in various brain regions including cortex, cerebellum and hippocampus
(Mandemakers et al., 2012) and in many other tissues although at lower levels (Paisán-Ruíz et
al., 2004). The transcript has 51 exons containing several different functional protein domains
suggesting both GTPase and kinase activity as well as protein protein interactions (Nuyte-
mans et al., 2010; Singleton et al., 2013). Physiological function and pathological mechanisms
of LRRK2 are still mostly unknown.
Homozygous or compound heterozygous mutations in the parkin gene causes up to half of
the known familial PD cases with recessive inheritance and early onset. Early onset is a typ-
ical feature in patients with mutations in parkin as well as good response to treatment with
L-dopa and otherwise benign disease development. Parkin disease causing mutations are
usually not associated with the appearance of LB however, suggesting a different mechanism
or action at a later point in the pathway of pathology compared to classical PD (Singleton
et al., 2013). The Parkin gene codes for parkin, a 456 aa large protein with four major func-
tional domains. These corresponds to parkins role as a E3 ubiquitin ligase (Shimura et al.,
2000). It has been demonstrated that parkins role in the ubiquitin proteasome system (UPS)
is that of targeting no longer functional or excessive proteins for proteasome degradation.
Homozygous mutations associated with early-onset PD have also been found in the PINK1
gene. Mutations in PINK1 are so far rarer than parkin mutations (Puschmann, 2013). The
gene consists of eight exons and encodes a 581 aa protein. It is ubiquitously expressed in
tissues (Unoki and Y Nakamura, 2001).
Another gene that is foundwithmutations in very rare cases of recessive PD is DJ-1. Most pa-
tients with mutations in DJ-1 have early-onset PD (Puschmann, 2013). DJ-1 has been demon-
strated as acting as an antioxidant (Mitsumoto and Nakagawa, 2001) in response to oxidative
stress and has been shown to readily oxidize in cultured cells (Canet-Aviles et al., 2004).
In the beginning of the 1980s, it was discovered that drug users from Northern Califor-
nia had developed an acute state of akinesia. The drug they had injected was 1-methyl-
4-phenyl-4-propionoxypiperidine (MPPP), an analog of the synthetic opioid meperidine. It
3
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was eventually recognized that the preparation of MPPP was contaminated by 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which had been inadvertently produced during
the clandestine manufacture (Langston et al., 1983). MPTP has since been used in a variety
of mammalian species to model PD (Bove et al., 2005). The symptoms produced by MPTP
in humans correspond to those of PD. This includes tremors at rest, rigidity, bradykinesia
and posture instability (Bove et al., 2005). However, LBs does not appear in MPTP induced
parkinsonism (Forno et al., 1993). After administration, MPTP crosses the blood brain bar-
rier. In the brain, it is metabolized by monoamine oxidase (MAO) by non-dopaminergic cells
to 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+) and then further to the toxic species
1-methyl-4-phenylpyridinium (MPP+) through spontaneous oxidation. MPP+ is then released
into the extracellular space through an unknown mechanism (Przedborski and Vila, 2001).
Due to its strong polarity MPP+ can not freely cross the plasma membrane. However, MPP+
shows high affinity for the dopamine active transporter (DAT) located in the plasma mem-
brane of dopaminergic neurons (Mayer et al., 1986). Inside dopaminergic neurons, MPP+ can
either stay within the cytosol, enter synaptic vesicles through vesicular monoamine trans-
porter (VMAT) transport (Y Liu et al., 1992) or concentrate within mitochondria (Ramsay and
Singer, 1986). Neurons transfected to overexpress VMAT become MPP+ toxicity resistant (Y
Liu et al., 1992) and conversely, mutant mice with lower expression are more sensitive to
MPTP induced toxicity (N Takahashi et al., 1997), suggesting toxicity from MPTP to occur
when it remains in the cytosol or is taken up by themitochondria. In the mitochondria, MPP+
will inhibit complex I of the electron transport chain (ETC) at or near the same binding site
as another inhibitor, rotenone (Przedborski and Vila, 2001).
Rotenone, commonly used as a pesticide, is another complex I inhibitor which is routinely
used as amitochondrial poison in cell culture and in vivo research (Bove et al., 2005). Rotenone
rapidly breaks down by exposure to sunlight and in soil and water and has a half-life of about
1-3 days (Hisata, 2001). Thus it seems unlikely for environmental exposure to rotenone from
its use as a pesticide to be a major cause of PD. However, systemic administration of rotenone
in rats and mice have been used as a model for PD. Stereotaxic injection of rotenone into the
median forebrain bundle of rats depletes both striatal dopamine and serotonin (Heikkila et
al., 1985) and rotenone causes dopaminergic cell loss in rats treated with rotenone by intra-
venous infusion (Bove et al., 2005). Rotenone administered this way has also been shown to
cause proteinaceous inclusions that stain positive for αS in some of the remaining substantia
nigra dopaminergic neurons (Sherer et al., 2003). Behavioral symptoms also match those of
PD, such as reduced mobility. This has however been reported for rats without nigrostriatal
dopaminergic lesion as well, thus it is not clear that they occur because of nigrostriatal dam-
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age, casting doubt on the validity of rotenone as a model for PD in these experiments (Bove
et al., 2005).
Evidence suggests that the common pathway for the toxicity or pathological mechanism
behind all of these causes for PD involves the mitochondria. What is known about the role
that mitochondria plays in the generation of PD is summarized in section 1.3.
1.2 The synuclein family of proteins
1.2.1 History, identification and classification
The first isolation and characterization of a synuclein protein was done by Maroteaux et al.
(1988). They used antiserum raised against purified cholinergic synaptic vesicles from the
pacific electric ray (Torpedo californica) to identify a 143 aa protein. They found this pro-
tein to localize both to presynaptic nerve terminals and to a portion of the nuclear envelope.
Because of this they named the protein synuclein (SY-NUCLEin). Later examinations of the
composition of amyloid-beta (Aβ) plaques from AD patients found a peptide that was unre-
lated to Aβ and hence got the name non-Aβ component (NAC). Later studies have questioned
whether NAC is actually a part of Aβ plaques (Culvenor et al., 1999) but the precursor for
this peptide, NAC protein (NACP), was found to be homologous with rat α-Synuclein (αS)
(Uéda et al., 1993). NACP is therefor referred to as human αS. A little later, another synuclein
protein, initially described as a 14 kDa phosphoneuroprotein, was identified in cattle (Nakajo
et al., 1990). This protein was also found to have a human ortholog, distinct in structure from
NACP. NACP and this protein are since referred to as human αS and β-Synuclein (βS) respec-
tively (Jakes et al., 1994). Since then, a third member of the human synuclein protein family
has been identified. It was first characterized from human breast carcinoma as the expres-
sion product of the BCSG1 gene (Ji et al., 1997). Shortly thereafter this protein was identified
as being highly homologous to human αS and was named γ-Synuclein (γS) (Lavedan et al.,
1998). As it turned out, the synuclein originally isolated from Torpedo californica is actually
most closely related to γS (Lavedan, 1998).
Synucleins have since been identified in other organisms but so far only in vertebrates
(George, 2002; Surguchov, 2013). Synelfin is the αS ortholog in the Atlantic Canary (Seri-
nus canaria) and PNP14, the phosphoneuroprotein mentioned above, is the βS ortholog in
Cattle (Bos taurus). All characterized synuclein proteins so far can be assigned to one of
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the three protein groups, αS, βS or γS (Lavedan, 1998; Surguchov, 2013). The human genes
coding for these proteins are called SNCA, SNCB and SNCG for αS, βS and γS respectively.
1.2.2 Structure, conformation and interactions
All three members of the synuclein family of proteins, α-, β- and γS, are small ∼127-140 aa
proteins. The N-terminal region is highly conserved both between species and between the
different members of the synuclein family. The C-terminal region contains many highly
charged and acidic residues and shows high variability between the different familymembers.
Another common feature of all characterized synucleins is their complete lack of cysteine and
tryptophan residues.
The aa sequence of αS comprises 140 residues and it can be divided into three regions.
Residues 1-60 contains four repeats of 11-aa with a KTKEGV consensus sequence. Residues
61-95 contains the hydrophobic NAC region plus another two repeats. Residues 96-140 con-
tains a highly charged acidic region with low sequence similarity to β- and γS (George, 2002;
Uversky and Eliezer, 2009).
Early attempts at characterizing the structure of αS found it to lack secondary structure but
to have an elongated shape. It was also found that its structure did not change in response to
treatments such as different concentrations, boiling, changes in pH, salt and other chemical
denaturants and it was suggested that the conformation of αS is unfolded in solution (Wein-
reb et al., 1996). Later studies confirmed αS to be mostly disordered. However, it was found
to be more compact than that predicted of a completely random coil, suggesting the possibil-
ity for conformational changes and placing it in the class of proteins called natively unfolded
proteins (Uversky et al., 2001). Assuming that the unfolded conformation of αS is due to its
low hydrophobicity and high net charge, changes in these two environmental factors could
induce structure in the protein. This was confirmed by Uversky et al. (2001) in experiments
were they neutralized the charge by lowering the pH and increasing the hydrophobicity by
increasing the temperature. Both of these factors were found to introduce secondary struc-
ture to αS and make it more compact suggesting the folding into β-structure. The structure
introduced was reversed by going back to physiological pH and temperature (Uversky et al.,
2001).
The A30P, E46K and A53T mutations have also been studied for their impact on the structure
of αS. Very small to no differences compared to the wild type (WT) protein in terms of the
unfolded structure have been observed (J Li et al., 2001; Fredenburg et al., 2007). The A30P
6
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mutant however, as can be expected from the steric hindrance introduced by proline, reduces
the propensity for α-helical structure (Bussell and Eliezer, 2001).
That parts of αS can assume α-helical structure was observed in studies of membrane affin-
ity. The binding to synthetic vesicles containing negatively charged acidic phospholipids
produced large conformational changes and the formation of two bent antiparallel α-helices
(Davidson et al., 1998; Chandra et al., 2003). These changes were localized to the N-terminal
region with repeated aa sequence whereas the acidic C-terminal region remained unstruc-
tured (Jao et al., 2004). The helical structure induced by membrane binding has been shown
to be dependent on lipid particle size (Borbat et al., 2006) and in the most extreme case a
single linear α-helical conformation of the N-terminal region have been described (Jao et al.,
2004; Georgieva et al., 2008).
The periodicity demonstrated by the stretches of 11-aa repeats in the N-terminal region of
αS is characteristic of another group of proteins namely the apolipoproteins. These pro-
teins have the same 11-aa repeat periodicity in their amphipathic lipid binding α-helical
domains. The rules that have been developed for determining the secondary structure of
apolipoproteins predict four consecutive class A2 helices in αS. In apolipoproteins this helix
class mediates exchangeable lipid binding, suggesting that membrane binding is a physiolog-
ical property of αS. αS have in comparison to apolipoproteins a highly conserved sequence
that might indicate conserved specificity for a particular type of membrane (Clayton and
George, 1998).
In general, the structure of αS seems to be able to take on many different conformations and
be sensitive to modification by many different kind of factors. Metal ions, salts, pesticides
and simple and fluorinated alcohols are some of the stimuli that has been shown to confer
changes in conformation to αS and it can also undergo spontaneous oligomerization (Uversky
and Eliezer, 2009).
Recently the notion that αS exists as a natively unfolded protein in solution has been chal-
lenged. Instead, a conformation as a helically folded soluble tetramer that resist aggregation
has been suggested (Bartels et al., 2011; W Wang et al., 2011). This has proven controver-
sial however and other groups have published data showing αS to exist predominantly as a
unfolded monomer (Fauvet et al., 2012).
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1.2.3 Physiological function
The physiological function(s) of αS is so far not well understood. Nevertheless, several ideas
have been put forth based on findings made during the last ∼20 years of αS research. Since
αS was initially described as a presynaptic protein (Maroteaux et al., 1988), its function has
often been assumed to be involved in synaptic vesicle handling. However, αS is not only
found in the brain and a large fraction of it is located throughout the cytosol and not only at
the synapse, suggesting a broader role. αS has been reported to make up as much as 0.5-1% of
cytosolic protein in the brain (Iwai et al., 1995). This figure was different for different areas,
with cortex, hippocampus and striatum reported as having the highest levels of αS.
In support of the idea that αS plays a role in synaptic regulation is the property of αS to bind
and interact with membranes. In the presence of membranes with acidic phospholipids, the
N-terminal domain of αS undergoes conformational changes and folds into a α-helical struc-
ture (Davidson et al., 1998; Chandra et al., 2003). This seemed to go well in hand with the
finding that αS could inhibit phospholipases, something which was suggested to play a role
in synaptic vesicle cycling (Jenco et al., 1998). Later studies were unable to find a direct role
of αS in inhibiting phospholipases however, casting doubt on this function for αS (Rappley
et al., 2009). Nevertheless, other studies have found other interactions of αS with synap-
tic vesicle handling. Experiments on αS knock out (KO) mice, demonstrated that these mice
have enhanced dopamine release at nigrostriatal terminals as well as reduced total dopamine
content compared toWTmice, the effects were small however (Abeliovich et al., 2000). Other
experiments using antisense oligonucleotides to deplete αS led to reduced synaptic vesicle
pool at the presynapse as observed in electron micrographs (Murphy et al., 2000). Cysteine
string protein α (CSPα) is another synaptic protein with largely unknown function. A con-
nection to αS was made with the observation that the rapidly neurodegenerative phenotype
of CSPα KO mice was rescued by αS overexpression (Chandra et al., 2005). Chandra et al.
(2005) also showed that deletion of CSPα inhibits soluble N-ethylmaleimide sensitive fusion
protein (NSF) attachment protein (SNAP) receptor (SNARE) complex assembly. In another
paper they later examined the effects of αS on the SNARE complex and found that αS too was
required for proper maintenance and assembly. Removal of 44 residues from the C-terminal
of αS abolished this ability. This suggests that αS and CSPα have complementary or redun-
dant roles in the assembly of the SNARE complex. The ability of αS to rescue the phenotype
of CSPα KOmice has since been observed by another group who also found that γS lacks this
ability (Ninkina et al., 2012). More recently, overexpression of αSwas shown to inhibit neuro-
transmitter release through a reduction in size of the synaptic vesicle pool due to inhibition
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of synaptic vesicle reclustering after endocytosis (Nemani et al., 2010). Strangely enough,
this effect of αS was not dependent on the C-terminal part of the protein, suggesting a differ-
ent mechanism to that of SNARE complex assembly. It did require the full α-helix forming
ability however, as evident by the lack of inhibition of synaptic transmission from the A30P
mutant. It seems reasonable to assume that αS plays a role in some type of vesicle regulation
considering these reports and its established ability to associate with membranes.
George et al. (1995) observed changes in the expression of ribonucleic acid (RNA) for αS
during song learning in the Zebra finch songbird. Based on their findings, they suggested
that αS is involved in vertebrate neural plasticity.
αS has been shown to interact with other proteins. Synphilin-1, a protein with unknown
function, was initially described after it was found to interact with αS in a yeast two-hybrid
screen (Engelender et al., 1999).
The 14–3-3 protein family shares some sequence homologywith synucleins and has been sug-
gested to interact with αS (Ostrerova et al., 1999). 14–3-3 proteins are cytoplasmic chaperones
with known interactions with Bcl-2-associated death promoter (BAD) and Bcl-2-associated X
protein (BAX), proteins involved in the regulation of apoptosis (Datta et al., 2000; Lim et al.,
2013) and this suggests a possible connection between αS and PCD.
αS has been demonstrated to be able to be phosphorylated at residues S87, S129, Y125, Y133
and Y136 (Okochi et al., 2000; Pronin et al., 2000; Negro et al., 2001; Fujiwara et al., 2002).
Phosphorylation of αS in normal brain tissue occurs at low levels and has only been demon-
strated at S87, S129 and Y125. In LBs, αS is found to be hyperphosphorylated at S129 (Fu-
jiwara et al., 2002; Anderson et al., 2006). Regulation occurs by polo-like kinases (PLKs) in
vivo and possibly casein kinase 1 (CK-1), casein kinase 2 (CK-2) and G protein-coupled re-
ceptor (GPCR) kinases (GRKs) (Braithwaite et al., 2012). Interestingly, the N-terminal region
is essential for phosphorylation of S129 by PLKs and only PLK2 is able to phosphorylate βS
(Mbefo et al., 2010). None of the PLKs are able to phosphorylate γS. The residue most often
found to be phosphorylated in vivo, S129, is located in the C-terminal region of αS. It would
therefor not be expected to interfere with membrane binding and this has been confirmed for
the WT form of αS (Visanji et al., 2011). However, both the A30P and A53T mutants showed
increased membrane association upon phosphorylation.
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1.2.4 Relation to Parkinson’s disease
α-Synuclein
LBs are, as mentioned above, a hallmark in brains of PD patients and these intracellular
protein aggregates consist to a major extent of αS (Spillantini et al., 1997). Also, several point
mutations as well as duplications and triplications in SNCA have been found in patients with
PD.
In 1996 a point mutation, A53T was found in members of a large Italian-American family
(Golbe et al., 1996) as well as in three families from Greece (Polymeropoulos et al., 1997).
These patients show similar symptoms to patients with idiopathic PD except for lower preva-
lence of tremors. Average age of onset is lower at ∼46 years of age but the progression is not
generally faster (Polymeropoulos et al., 1997; Papapetropoulos et al., 2003).
A year after that, another point mutation, A30P was described in a German family (Krüger
et al., 1998). Age of onset ∼54 years and fast progression with bradykinesia and rigidity were
reported for mutation carrying members of this family. Recently, the first brain of a diseased
patient carrying the A30P mutation have been studied. Neuronal loss in the substantia nigra,
locus coeruleus and dorsal motor vagal nucleus as well as occurrences of αS immunoposi-
tive LBs, LNs and glial aggregates throughout the brain was observed. In general, the neu-
ropathology was more severe than in a typical brain from a patient with idiopathic PD (Seidel
et al., 2010).
Later, in 2004, a E46K mutation was found among members of a large family from the Basque
region in northern Spain (Zarranz et al., 2004). These patients have shifting impairment of
frontal lobe function, memory dysfunction, tremors, bradykinesia and postural abnormali-
ties. Average age of onset is reported as ∼60 years of age. Later they develop severe dementia.
Analysis of brains for diseased patients carrying the E46K mutation revealed neuronal loss
in the substantia nigra and numerous cortical and subcortical LBs that stained positive for
αS (Somme et al., 2011).
In 2003, triplications of the SNCA genomic locus was reported for the first time (Singleton
et al., 2003) and one year later duplications (Chartier-Harlin et al., 2004; Ibáñez et al., 2004).
The patients with a triplication had symptoms ranging from those typical of PD to typical de-
mentia with Lewy bodies (DLB) and a very early average age of onset at ∼34 years. Analysis
of brains from diseased patients revealed profound pathology and extensive LBs (Singleton
et al., 2003). The patients with duplications, had symptoms more closely resembling those of
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idiopathic PD and an average age of onset of ∼50 years. Because of this, a relation between
disease onset and severity of progression and gene dosage has been suggested (Chartier-
Harlin et al., 2004; Ibáñez et al., 2004).
β- and γ-Synuclein
In contrast to αS, no genetic connection between βS or γS and PD has been described so
far. And neither βS nor γS is detectable in LBs or LNs. Wild type βS has been shown to act
as a scavenger for αS aggregation and neurotoxicity in a variety of experimental systems in
vitro and in vivo (Hashimoto et al., 2001; Uversky et al., 2002; Hashimoto et al., 2004; Fan
et al., 2006). Since both βS and γS are present in axonal lesions in the hippocampus in PD
and in DLB (Galvin et al., 1999), their possible contribution to neurodegenerative disease
should not be ignored. Also, the DLB-linked mutation P123H in SNCB, the gene coding
for βS, have been demonstrated to produce progressive neurodegenerative symptoms such
as axonal swelling, astrogliosis and behavioral abnormalities in transgenic (TG) mice. And
when these mice were cross-bred with αS TG, but not αS KO mice, these symptoms were
aggravated (Fujita et al., 2010). Thus it seems likely that βS can play a role in the pathogenesis
of neurodegenerative disease. In fact, in a recent publication by our group (Taschenberger
et al., 2013), we demonstrate that βS is neurotoxic for primary neuronal culture and produces
aggregates as well as neuronal degeneration in rats in vivo.
Pathological mechanism
The pathological mechanism that leads to the development of symptoms in PD is, just like
the physiological function of αS so far not well understood. Due to the presence of αS in
LBs and LNs, it has been extensively studied as an agent in the pathology of the disease.
Since the αS found in LBs is of a fibrillar form, major focus of these studies has been on the
properties of its aggregation. In general, aggregation is thought to occur when hydrophobic
patches present themselves during folding of a protein. These patches would prefer other
such patches because of the hydrophobic effect and thus lead to dimeric, oligomeric and
larger aggregates that eventually become insoluble (Fink, 1998). This predicts that condi-
tions or interacting agents that favors a partially folded intermediate state where the patches
are present, also favors aggregation. Since αS is most probably a natively unfolded protein
in solution, it is highly influenced by its environment and the range of conditions that favors
such aggregation prone intermediate states should be wide (Uversky and Eliezer, 2009). This
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model fits with in vitro examinations of fibril formation in αS where conditions such as agi-
tation, increased concentration and certain anions and cations among other factors are able
to accelerate the fibril formation (Uversky and Eliezer, 2009). An increase in concentration
would increase the probability for the partially folded state and the probability for interac-
tion with another protein in such a state. This fits with the dose relationship of αS and the
severity of PD seen with gene duplications and triplications (Polymeropoulos et al., 1997;
Nuytemans et al., 2010).
Several findings already mentioned point to aggregation being important in the pathology
of PD. Early onset PD is caused by higher expression of αS due to duplication or triplication
of the gene, the familial point mutations increase the propensity for aggregation (Fink, 1998)
and αS is present in aggregated form within LBs. The aggregation of αS follows a sigmoidal
curve with an initial lag phase which is followed by exponential growth and finally a plateau.
During the lag phase, transient soluble oligomeric forms of αS forms (Fink, 2006) and it is
some set of these, called protofibrils, that are proposed to be the neurotoxic species (Stefanis,
2012) and there is some experimental support for this idea. The A53T and A30P mutants
form more protofibrils and at a faster rate than WT in vitro (Conway et al., 2000). And ex-
periments with artificial mutants that favors the formation of soluble oligomers over fibrils
in neuronal cell culture and invertebrate models showed higher toxicity for these mutants
compared to WT (Karpinar et al., 2009; Winner et al., 2011). What exact specie of oligomer is
toxic and whether monomeric αS can become toxic without aggregation through some gain-
of-function is still under debate however. It also seems likely that over time, the presence
of large intracellular aggregates, especially in neurites where they might block trafficking,
would be detrimental to the normal functioning of the cell as well.
Some studies have been made on the interaction of αS with the cytoskeleton and possible
effects on trafficking within cells. It has been demonstrated that αS negatively influences
tubulin polymerization (Lee et al., 2006; L Chen et al., 2007; Zhou et al., 2010). And genome-
wide association studies (GWASs) have linked both tau and αS as major risk factors for devel-
oping PD (Nalls et al., 2011). Phosphorylation of tau has been demonstrated to be facilitated
by αS (Jensen et al., 1999; Haggerty et al., 2011) and tau and αS can seed the aggregation of
each other (Giasson et al., 2003).
In section 1.2.3 a possible function for αS in the regulation of the synapse was described. It is
also possible that these functions are active in causing disease symptoms. The inhibition of
synaptic vesicle recycling shown by Nemani et al. (2010) or changes in the levels of several
critical presynaptic proteins which precedes neuronal degeneration in rats overexpressing
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αS demonstrated by (Chung et al., 2009) could both be explanations for decreased synaptic
transmission and the symptoms associated with PD. However, they are not explanations for
the aggregation or destruction of neurons andmight therefor contribute to disease in its early
stages but is unlikely to be the major toxic mechanisms.
In solution, evidence suggest that αS is a natively unfolded protein. However, as was dis-
cussed in section 1.2.2, αS acquires secondary structure upon association with membranes.
Together with the idea that it is a oligomeric, “protofibril” (page 12) conformation of αS and
not mature fibrils that are toxic and the fact that these protofibrils take on pore like appear-
ance in atomic force microscopy (AFM) and electron microscopy (EM) images (Ding et al.,
2002; Lashuel et al., 2002) that resemble the structures of pore forming bacterial toxins (Wal-
lace et al., 2000), led researchers to examine the effect of these oligomers on membranes.
Several groups have observed membrane permeability due to these oligomers. Early on,
permeability was observed in vitro by the leakage of fluorescent dyes from vesicles formed
from different phospholipids after the addition of αS oligomers (Volles et al., 2001; Volles and
Lansbury, 2002). Later, permeability was also demonstrated in intact cells using both elec-
trophysiology and fluorescent techniques (Furukawa et al., 2006; Tsigelny et al., 2012). Most
groups report that the A53T and A30P mutants both produce similar membrane permeability
but greater than WT αS (Volles and Lansbury, 2002; Furukawa et al., 2006).
A consequence of membrane permeability would be increased ion conductance and this has
been demonstrated both in phospholipid vesicles (Volles et al., 2001) and in intact cells (Fu-
rukawa et al., 2006). Calcium would be one ion that might pass through such pores and this
could have detrimental effects if it means that calcium homeostasis is affected. Not only is
calcium influx important in the release of synaptic vesicles but prolonged elevated calcium
levels within cells can cause apoptosis (Weiss, 2011). Elevated calcium levels have been ob-
served in cell lines overexpressing αS as well as in cell lines that are exposed to preformed
oligomeric αS. Furukawa et al. (2006) found increased basal Ca2+ levels and increased levels
after high potassium depolarization for the A53Tmutant and to a lesser degree the A30P mu-
tant in SH-SY5Y cells. In the same cell line, Hettiarachchi et al. (2009) confirmed the effect of
increased peak calcium from high potassium depolarization but found the opposite situation
in regards to the mutant A53T which they found was significantly less affected than WT.
They also show the increased calcium uptake to be inhibited by blocking L-type voltage-
dependent Ca2+ channels. This suggests a different effect on calcium uptake by αS, one that
is mediated by Ca2+ channels and not directly due to influx of Ca2+ through αS pores. A
third study found elevated cytosolic calcium levels upon extracellular addition of prefibrillar
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oligomeric αS to both SH-SY5Y and primary cortical neurons. The response was as fast and
with similar amplitude as when they added ionomycin, a known ionophore (Danzer et al.,
2007).
In addition to its localization in the cytosol and at the synapses, a portion of the αS is present
also at the mitochondria, as evident in EM images with immunogold stained αS as well as in
western blots from purified mitochondria (Perez et al., 2002; Martin et al., 2006; Devi et al.,
2008; K Nakamura et al., 2008; G Liu et al., 2009; Loeb et al., 2010). The distribution of αS
in mitochondria seem to be different depending on brain region with higher levels present
in mitochondria from striatum (G Liu et al., 2009). αS can associate with the outside of the
outer mitochondrial membrane (OMM) but has also been found to be present both in the
intermembrane space and the matrix. This localization seems to be variable however, with
αS found in the intermembrane space in mice and HEK293 cells (WW Li et al., 2007; Parihar
et al., 2008) and in both the intermembrane space and matrix in human and rat neurons
and SH-SY5Y cells (WW Li et al., 2007; Parihar et al., 2008; G Liu et al., 2009). Devi et al.
(2008) found that uptake of αS into purified mitochondria was energy dependent and could
be blocked by antibodies (ABs) against the mitochondrial import channel.
MPTP is a potent complex I inhibitor and is used in PD research for its ability to induce
parkinsonian symptoms and dopaminergic cell loss. Studies have found the dopaminergic
cell loss from MPTP administration to be reduced in αS KO animals (Dauer et al., 2002;
Robertson et al., 2004; Klivenyi et al., 2006), suggesting the interaction of αS with MPTP.
Conflicting reports are available for the opposite case, increased presence of αS however.
Some reports suggest no increase in toxicity (Rathke-Hartlieb et al., 2001; Dong et al., 2002)
or even protective effect (Pérez-Sánchez et al., 2010), while others suggest increased toxicity
(Song et al., 2004; Nieto et al., 2006; Yu et al., 2008). Qian et al. (2008) found that αS WT was
protective against MPTP toxicity in PC12 cells but that the A30P and A53T mutants both
increased the toxicity. It might be that αS is protective by preventing MPTP from binding to
complex I but that the mutant forms and possibly higher levels of the WT protein eventually
acquires the same inhibitory effect as MPTP itself. In fact, αS was found to impair complex I
activity (Devi et al., 2008; G Liu et al., 2009; Chinta et al., 2010) and increase reactive oxygen
species (ROS) levels (Hsu et al., 2000; Junn and Mouradian, 2002) in several studies. Elevated
ROS levels are in turn linked to apoptosis (Sinha et al., 2013).
αS also alters mitochondrial morphology. Enlarged and roundedmitochondria in αS TGmice
treated with MPTP was initially described by (Song et al., 2004). Later, Martin et al. (2006)
observed degenerating mitochondria in A53T TG mice. In SH-SY5Y cells transfected with
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a plasmid coding for the expression of αS, which presumably produced higher expression
levels than those in TG mice, αS was found to produce fragmented mitochondria (Kamp et
al., 2010). K Nakamura et al. (2011) later confirmed fragmentation of mitochondria to occur
also in HeLa cells and primary hippocampal rat neurons. Both groups found the fragmen-
tation to occur independent of the mitochondrial fission protein dynamin related protein 1
(Drp1), suggesting that it is not occuring through the normal fission/fusion processes of the
mitochondria but as a direct effect of αS. The effects of mitochondrial fragmentation by αS
is not clear but the normal processes of mitochondrial fusion and fission is important in the
regulation of PCD by the mitochondria (Westermann, 2010; Chan, 2012), suggesting another
possible mechanism for how αS might contribute to toxicity.
1.3 Mitochondria, the common link behind Parkinson’s
disease
1.3.1 Mitochondrial dynamics
Mitochondria are dynamic structures that move and change shape in response to their envi-
ronment and the needs of the cell. Their shape is regulated by the rate of fission and fusion
and this is controlled by proteins of the Dynamin family with GTPase domains (Bliek et al.,
2013). Drp1 is responsible for fission of mitochondria by self-assembly into spirals and asso-
ciation with constriction sites on mitochondrial membranes (Knott et al., 2008). The reverse,
fusion, is mediated by mitofusins, of which there are two homologs in mammals, mitofusin
1 (Mfn1) and mitofusin 2 (Mfn2). A suggested mechanism for their action is binding to op-
posing sides of OMM and pulling them together in a SNARE like mechanism (Koshiba et
al., 2004). Fusion of mitochondria serves to increase the efficiency of energy distribution
throughout cells (Skulachev, 2001) and motility is necessary for redistribution along neurites
in neurons (MacAskill and Kittler, 2010). Increased intracellular calcium levels and calcium
uptake by the mitochondria are both associated with mitochondrial fission (Szabadkai and
Duchen, 2008). For example, Drp1 has been shown to translocate to the OMM in response to
elevated cytoplasmic Ca2+ levels (Cribbs and S Strack, 2007). Regulation of fission/fusion is
also important in the regulation of PCD pathways involving the mitochondria (Westermann,
2010; Chan, 2012).
Another aspect of mitochondria is their motility. In cells such as neurons, that are polarized
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and have long processes, and where high energy requirements are needed in localized re-
gions i.e. synapses, the proper movement of mitochondria can be assumed to be especially
important. Most mitochondria moves along microtubules using the kinesin/dynein motor
proteins (Hollenbeck and Saxton, 2005). This occurs through the Miro1 and Miro2 adapter
proteins on the OMM (Reis et al., 2009). Also, mitochondrial movement is inhibited by in-
creased calcium levels (Rintoul et al., 2003). This is facilitated through the EF-hand motifs
of the miro proteins and this sequesters the mitochondria at locations of increased need for
ATP (X Wang and Schwarz, 2009).
All of this indicates a complicated interplay between mitochondrial fission/fusion, move-
ment, energy metabolism, calcium signaling and PCD.
1.3.2 Toxins, the mitochondria and apoptosis
Pore formation of mitochondrial membranes is important in apoptosis. When the intrin-
sic apoptotic pathway is activated, pro-apoptotic members of the BCL-2 class of proteins
(BAX, BAK, BOK) inserts into the OMM and oligomerizes, permeabilizing the membrane
(Venderova and Park, 2012). This leads to the release of cytochrome c from the intermem-
brane space. Cytochrome c release in turn leads to the formation of the apoptosome and
activation of caspase-9 (Ott et al., 2007). Another mechanism for initiation of apoptosis in
the mitochondria is that of the mitochondrial permeability transition (MPT), this causes a
pore opening in the inner mitochondrial membrane (IMM) causing swelling, loss of mito-
chondrial membrane potential and release of cytochrome c, causing apoptosis (Petit et al.,
1998; Büki et al., 2000).
The connection between αS and the mitochondria was established on page 14. However, αS
is not the only suspected cause of PD that are linked to the mitochondria. In fact, all of the
causes described in section 1.1.1 are believed to interact with some part of the mitochondria
either directly or indirectly. For two of the toxins used to model PD symptoms, rotenone and
MPTP the direct mode of toxicity is through inhibition of complex I of the ETC (Przedborski
and Vila, 2001; Bove et al., 2005). This is also one possiblemechanism behind αS toxicity (Devi
et al., 2008; G Liu et al., 2009; Chinta et al., 2010). Inhibition of complex I leads to reduced
ATP production, but it is elevated ROS levels that are believed to be responsible for toxicity
since only a transient 20% reduction in ATP levels have been observed in vivo (Przedborski
and Vila, 2001). Increased ROS production in the mitochondria is in turn believed to cause
apoptosis but the mechanism behind it is still a matter of discussion. Oxidation/damage of
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mitochondrial deoxyribonucleic acid (DNA) (Ricci et al., 2008) and oxidation of the phospho-
lipid cardiolipin in the OMM (Ott et al., 2007) have been suggested as mediators that will lead
to formation of the MPT pore and release of cytochrome c and subsequent formation of the
apoptosome. For an up to date review on ROS in apoptosis, see Sinha et al. (2013).
1.3.3 The PARK genes and the mitochondria
PINK1 has a predicted mitochondrial targeting sequence in its first 34 aa and a conserved
protein kinase domain with high homology to serine/threonine kinases of the calmodulin
family (Valente et al., 2004) and a mechanism in the mitochondrial response to cellular and
oxidative stress have been proposed (Valente et al., 2004). Gandhi et al. (2009) found that
PINK1 deficient cultured neurons exhibit lowered mitochondrial calcium capacity. They also
found these neurons to have increased ROS production and a lower threshold for opening of
the MPT pore and apoptosis. Recent studies have suggested a common pathway for parkin
and PINK1 in the regulation of mitophagy (Narendra et al., 2010; Lazarou et al., 2013). This
regulation is proposed to work as follows. Damaged mitochondria undergo fission mediated
by Drp1. Lowered mitochondrial membrane potential leads to accumulation of PINK1 which
recruits parkin to the mitochondria. Parkin then ubiquitinates proteins in the OMM and
targets the mitochondria for removal by the autophagosome. The healthy part of the mito-
chondria from the previous fission step can then undergo mitofusin mediated fusion (Kubli
and Gustafsson, 2012).
DJ-1 is found in the cytosol as well as both the intermembrane space and the matrix of mi-
tochondria. It has been proposed to translocate to the mitochondria in response to oxidative
stress (AHV Schapira and Gegg, 2011). Another suggested role for DJ-1 is as part of a com-
plexwith parkin and PINK1. This complexwould promote ubiquitination of parkin substrates
including parkin itself and synphilin-1 (sph1) (Xiong et al., 2009).
LRRK2 is found primarily in the cytosol but has also been shown to associate with the OMM
(West et al., 2005). An interaction between LRRK2 and parkin has been described (Smith et al.,
2005) and expression of parkin in Drosophila melanogaster protected dopaminergic neurons
from LRRK2 G2019S mutant induced neurodegeneration.
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1.3.4 Mitochondrial impairment in Parkinson’s disease patients
Themost convincing evidence for a role of the mitochondria in PD comes from the described
presence of mitochondrial dysfunction in cells from PD patients. A reduction in complex I
protein as well as activity in neurons from the SNpc was found early on (Mizuno et al., 1989;
A Schapira et al., 1989). Later, deficiency of mitochondria in other tissues including muscles
and platelets has been described as well (Shoffner et al., 1991; Yoshino et al., 1992).
1.4 Genetically encoded sensors
To study physiological processes and the effects on those created by pathological conditions
such as neurodegenerative diseases, tools are needed that can report on changes in phys-
iological states within cells. Traditionally, cellular states and functions have been studied
in a static way using biochemical or immuno-fluorescence and immuno-cytochemical meth-
ods. These methods have given great insight into the components of cells and in what ways
the components can interact. What they lack however, is the ability to show the dynamics
of a system. They work “retrospectively” on a frozen in time state of the cell or tissue. In
other words, they can have great spatial resolution but lack temporal resolution. Live cell
time-lapse microscopy on the other hand, works in real-time, showing dynamic changes of
proteins as they occur in individual cells and compartments (Bunt andWouters, 2004; Palmer
et al., 2011). To accomplish this, tools are required that respond to changes in the state of
the system being studied, and that provides an optical readout that can be sampled using a
microscope. Fluorescence provides a high contrast signal that is suitable for live cell imaging
and modifying either the intensity, spectral characteristics or life-time of the fluorescence
provides a sensitive readout. Coupling such a change in the properties of the fluorescence to
a state change within a physiological system of interest, provides a readout for information
about that state change.
1.4.1 Fluorescent Proteins
The discovery of green fluorescent protein (GFP) in Aequoria victoria by Shimomura et al.
(1962) and its subsequent cloning by Prasher et al. (1992) provided the necessary building
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blocks for the creation of genetically encoded sensors (GESs). GFP exhibits bright fluores-
cence when fused to other proteins and can be expressed in a wide variety of cells and tis-
sues (Tsien, 1998). The usefulness of GFP was furthered by engineering to provide increased
brightness and spectrally modified variants ranging from blue in blue fluorescent protein
(BFP) to yellow in yellow fluorescent protein (YFP) (Heim and Tsien, 1996). This made it
possible to use different variants of GFP to label different cellular structures or cell types
and record them simultaneously. Producing a red-shifted variant of GFP has so far not been
successful but the discovery of fluorescent proteins (FPs) from a multitude of other marine
animals such as anemones and corals (Shagin et al., 2004) have provided red variants.
Figure 1.1: Green Fluorescent Protein
Cartoon (left) and ribbon rendering (right) of the crystal structure of enhanced green fluorescent
protein (EGFP). The ribbon rendering shows the chromophore in the center of the β-barrel. The N-
and C-terminals are colored red and blue respectively. Rendering is based on PDB entry 1KYS.
1.4.2 Single fluorescent protein based sensors
Two general approaches are available for constructing GESs based on a single FP. The first
approach involves exploiting the sensitivity of GFP to its environment. Since the fluorescence
of GFP is dependent on protonation, it is sensitive to changes in pH (Tsien, 1998) and sensors
have been created that utilize this (Kneen et al., 1998; Miesenböck et al., 1998). The second
approach is to move the N- and C-terminals of a FP to an position within the β-barrel. The
result of such a transformation is referred to as “circular permutation” (cp). This new position
for the N- and C-terminals are more sensitive to perturbations than the original and fusing
a binding domain such as calmodulin to these positions have successfully generated GESs
capable of reporting on changes in free-Ca2+ concentrations (Baird et al., 1999; Nakai et al.,
2001). The crystal structure for this type of sensor revealed that upon binding of Ca2+, the
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binding domain (calmodulin and M13) undergoes a conformational change such that solvent
is blocked from the inner side of the β-barrel and the chromophore is effectively deprotonated
(Akerboom et al., 2009). This means that the second approach also exploits the dependence
of GFP on protonation, leaving these types of sensors sensitive to large shifts in pH, limiting
or complicating their use in certain applications. Further developments on this theme has
produced genetically encoded calcium indicator (GECI) with high affinity and fast kinetics,
allowing the resolution of Ca2+ influx from single action potentials in vivo (Hires et al., 2008;
Akerboom et al., 2012). A schematic representation of this type of sensor can be seen in
figure 1.2a. These single FP GESs have several advantages over GESs incorporating two
FPs. They are smaller, meaning that they are less bulky when fused with other proteins
and thus less likely to interfere with the properties of the fusion protein. They also show
high dynamic range and because of their narrower spectra can be easier to use together
with other FPs or labels. They come with some disadvantages as well however. As already
mentioned, they are sensitive to pH, and since this stems from an exposed chromophore, they
are sensitive to other changes in their environment as well, such as oxidation. Most variants
are not ratiometric due to the difficulty in creating a single FP sensor that will switch between
fluorescent states as opposed to fluorescent/non-fluorescent in response to induced changes.
However, ratiometric single FP GECI and pH sensitive sensors are available, proving that the
concept is viable Miesenböck et al. (1998) and Baird et al. (1999).
1.4.3 FRET based sensors
Another type of GESs exploits the phenomenon of Förster resonance energy transfer (FRET)
between two FPs with overlapping spectra. FRET occurs when an excited donor fluorophore
is in close proximity to a suitable acceptor. This leads to a reduction in the donor fluorescence
and increase in acceptor fluorescence. The efficiency of FRET is steeply dependent on the
distance between the donor and acceptor according to the following relationship first laid
out by Főrster (1959):
E =
1
1 + (R/R0)6
where E is the FRET efficiency, R the current distance and R0 the distance at which half
of the energy is transferred from the donor, a constant which is unique for each donor/ac-
ceptor pair and strongly dependent on their relative orientation (Selvin, 2000). The most
common FRET pair in GESs are cyan fluorescent protein (CFP) and YFP or variants thereof.
Figure 1.2b shows a schematic representation of a FRET based GESs that responds to changes
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in free-Ca2+. The same binding domain consisting of calmodulin and the M13 peptide as are
used for many single FP GECIs are attached as a linker between CFP (donor) and YFP (ac-
ceptor). Binding of Ca2+ to calmodulin facilitates the binding to M13 which decreases the
distance between the FPs, increasing the FRET efficiency which can be read out as the ratio
of the fluorescence between the acceptor and the donor. Another example for how FRET
between two FPs can be exploited in a GESs is given in figure 1.2c. A short peptide cleavage
sequence linker connects the donor with the acceptor and upon activation of the enzyme
that cleaves the linker, FRET is abolished. The advantages of FRET sensors are their inherent
ratiometric nature as well as being straight forward to construct. But due to their larger size,
they can be difficult to target to subcellular locations and use as fusion constructs. Their
broader spectra also limits the number of other sensors/FPs that can be used in the same
experiment. Also, the equipment needed to measure signals from a FRET sensor is slightly
more complicated than for single wavelength sensors. Acquisition requires either splitting
the optical path to record two channels simultaneously or very fast switching of optical filters
for fast sequential recording.
1.4.4 Advantages of genetically encoded sensors
Since GESs are genetically expressed and because of their relatively low toxicity, they can
be used in experiments over long time spans. By substituting the promoter used for expres-
sion and by fusing targeting sequences or complete other proteins to the GESs, it is possible
to have them expressed only in specific cell types and subcellular compartments. It is also
possible to generate TG animals with constitutive or induced expression of the GESs of in-
terest (Guerrero and Isacoff, 2001; Griesbeck, 2004). These features make them superior to
traditional small molecule fluorescent indicators.
1.5 Hypothesis and aim of thesis
The evidence presented above shows how the mitochondria is involved in much of what is
known about the pathology of PD. There are only few studies where the function of mito-
chondria have been directly studied in the presence of elevated levels of αS however and
none of those dealt directly with ATP consumption, production and basal levels in intact
neurons. With the role of βS and to some extent γS becoming more important in PD re-
search, I wanted to examine the effects of αS on mitochondrial function and compare them
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Figure 1.2: Different types of genetically encoded sensors
An overview showing different ways that FPs can be exploited to generate GESs. (a) Sensor based
on a single FP where the N- and C- terminals have been moved from their original position through
“circular permutation” (cp) which opens up the β-barrel. In the unbound state, the chromophore
is exposed to and quenched by water and protons. When calmodulin binds Ca2+, binding to M13
is facilitated and the β-barrel closes, promoting fluorescence which is registered as an increase in
brightness. (b) A FRET based sensor in which two FPs with overlapping spectra are linked by a
binding domain. Upon binding of Ca2+ to calmodulin, binding to M13 is facilitated which induces
a conformational change that reorients and decreases the distance between the two FP, increasing
the FRET efficiency. (c) A variant of the FRET sensor in which the two FPs are linked by a peptide
cleavage linker. When caspase-3 is activated during apoptosis, it cleaves the DEVD sequence and
FRET between the two FPs is abolished.
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to the possible effects of β- and γS. Because αS has been shown to impair complex I activity
and this complex is part of the ETC which is responsible for generation of ATP in the mi-
tochondria through the process of oxidative phosphorylation, the hypothesis when starting
out was for a possible reduction in ATP levels or impairment in ATP production due to αS.
The recent availability of a novel GESs for ATP dynamics provided additional rationale for
these measurements in the form of reproducible measurements of ATP consumption, pro-
duction and basal levels. Several studies of the possibility of membrane permeability by αS
have been made, but none of those have examined the possibility of induced ion permeability
on the mitochondrial membranes in intact neurons. The hypothesis was that if αS can enter
the mitochondria and integrate or associate itself with the mitochondrial inner membrane
in such a way that it becomes permeable to ions, this permeability might also induce the
MPT. To test this hypothesis, it was decided to examine the properties of calcium handling
in the mitochondria. If the mitochondrial inner membrane is permeable to calcium ions, an
elevated calcium level in the cytosol should lead to increased uptake and impaired efflux of
calcium by the mitochondria.
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2 Materials and Methods
2.1 Buffers and reagents
aCSF-H 1x: 128mm NaCl, 3mm KCl, 1mm MgSO4, 1mm NaH2PO4, 30mm HEPES, 10mm
Glucose, sterile filtered. Prepared fresh every week from stock solutions.
aCSF-H-K+ As aCSF-H but with 128mm KCl and 3mm NaCl. Diluted with aCSF-H to make
64mm KCl before use for depolarization of neurons.
CMF 50mL 10x Hanks balanced salt solution (HBSS), 450 ml Ampuwa H2O, pH 7.3 adjusted
with sterile sodium bicarbonate.
DNA loading buffer (6x) 15% Ficoll 400 DL, 100mm LiCl, 2% glycerol, 100mm EDTA, pH
8.0; 0.6% SDS, 0.03% BPB in H2O.
FCS fetal calf serum (FCS) was thawed, pre-warmed to 37℃ and incubated for 30min at
56℃ (heat inactivation). Aliquots were stored at −20℃.
HCN 5 µgmL−1 transferrin, PSN (Penicillin 50 µgmL−1, Streptomycin 50 µgmL−1, Neomycin
100 µgmL−1), 2mm L-Glutamin, 2% B-27 supplement in neurobasal medium (NBM).
LB agar 40 g LB agar dissolved in 1000mL H2O, autoclaved with appropriate antibiotic
added during cooling shortly before pouring in Petri dishes. Stored at 4℃.
LB media 25 g of LB powder dissolved in 1000mL H2O. Stored at 4℃ (autoclaved).
ligation buffer 1x: 10mm MgCl2, 1mm ATP, 10mm DTT, 25 µgml
−1 BSA, 50mm Tris-HCl,
pH 7.5.
PBS 9.55 g of PBS powder in 1 L millipore H2O (autoclaved).
24
Buffers and reagents
SOC++ 2% bacto-tryptone, 0.5% yeast extract, 10mm NaCl, 2.5mm KCl, 10mmMgCl2, 10mm
MgSO4, 20mm glucose, pH 7.0. Glucose added after autoclaving.
TBE 42mm Boric Acid, 10mm EDTA, 50mm Tris-HCl, pH 8.0 (autoclaved).
TE 10mm Tris-HCl, 1mm EDTA, pH 8.0.
2.2 Chemicals
Applichem: acrylamide, agarose for gel, ampicillin, boric acid, calcium chloride, chloro-
form, D-(+) glucose, dimethyl sulfoxide (DMSO), ethylenediaminetetraacetic acid (EDTA),
ethanol absolute, Ficoll, glycerol, glycin, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), isopropanol, kanamycin, potassium chloride (KCl), LB Agar, LB media, magnesium
sulfate, methanol, modified Eagle’s medium (DMEM), phosphate buffered saline (PBS), potas-
sium chloride (KCl), phenol equilibrated stabilized, sodium azide, sodium chloride (NaCl),
sodium dodecyl sulfate (SDS), sodium metabisulfite, sodium phosphate, sucrose, TRIS, Tri-
ton X
Fermentas: Hind III Lambda DNA
Gibco: B27 supplement, neurobasal medium (NBM), fat milk, hydrogen peroxide, magne-
sium chloride, perchloric acid, trichloroacetic acid, PS-N
Life technologies: Fura-2 AM, tetramethylrhodamine-methylester (TMRM), MitoTracker
Red FM, MitoTracker Green FM
New England Biolabs (NEB): 2-Log DNA marker, broad range protein marker, dNTPs, re-
striction enzymes and buffers, bovine serum albumin (BSA)
PAA cell culture company: FCS, PS (penicillin/streptomycin), trypsin for HEK 293 cells
Macherey-Nagel: NucleoBond PC2000 Mega Kit
Sigma: dithiothreitol (DTT), ethidiumbromide, carbonyl cyanide 4-(trifluoromethoxy)phenyl-
hydrazone (FCCP), kainate, laminin, poly-l-ornithine, transferrin, Triton X-100, trypsin for
primary cell culture
2.3 Equipment
25
Buffers and reagents
Equipment Supplier
Arduino Uno Arduino, Italy
Autoclave Systec, Germany
Axio Examiner microscope stage Zeiss, Germany
Binocular microscope Zeiss, Germany
Biophotometer Eppendorf, Germany
CCD camera AxioCam MRm Zeiss, Germany
Colibri LED illumination Zeiss, Germany
Cell culture hood HeraSafe HS18, Heraeus, Germany
DNA electrophoresis chambers BioRad, Germany
Electrophoresis power supply BioRad, Germany
Freezer −80℃ Heraeus, Germany
Gene Pulser II BioRad, Germany
Heat block Eppendorf, Germany
Heating controller TC-344B Warner Instruments, USA
Heating platforms PH-1, PH-3 Warner Instruments, USA
Ice machine Scotman, Italy
Imaging chambers RC-25, RC-26GLP Warner Instruments, USA
Incubators B. Braun, Germany
In line heater SHM-8 Warner Instruments, USA
Instruments for dissection Fine Science Tools, Germany
Objective W Plan-Apochromat 20x/1.0 DIC M27 75mm Zeiss, Germany
Objective W Plan-Apochromat 63x/1.0 M27 Zeiss, Germany
pH-meter Sartorius, Germany
Perfusion system VC-8T Warner Instruments, USA
Pipettes Eppendorf, Germany
Pipetboy, accu-jet pro Brand, Germany
Scales Sartorius, Germany
Table centrifuge Eppendorf, Germany
Thermocycler MJ Research Biozym, Germany
Transluminator Bio-Rad, Germany
Western blot Electrophoresis chambers BioRad, Germany
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2.4 Vectors
AAV6-s-SEWB
5’ 3’
SmaI
ITR
XbaI
TB
XbaI
hSyn
NheIBamHIAgeI
eGFP
NotIHindIII
WPRE bGH pA
SmaI
ITR
1
17
3
36
5
66
5
88
1
11
81
14
81
16
20
19
20
22
37
24
69
Adeno-associated virus (AAV) vector plasmid provided by Sebastian Kügler. This plas-
mid was used as a backbone by first removing the GFP insert when cloning sensors
and synucleins. Transcription of the insert is driven by the human synapsin promoter
(hSyn). The insert is followed by a woodchuck hepatitis virus (WHP) posttranscrip-
tional regulatory element (WPRE) to enhance expression. The promoter and WPRE
sequences are flanked by inverted terminal repeat (ITR)s. The ITR can have promoter
like activity and a transcription blocker is placed between the ITR and the hSyn to
supress this.
AAV6-3TB-EWB
5’ 3’
SmaI
ITR
XbaI
TB
XbaI
TB
XbaI
TB
BamHI
eGFP
NotIHindIII
WPRE bGH pA
SmaI
ITR
1
20
8
43
3
63
0
81
3
11
13
14
13
15
52
18
52
21
69
24
01
AAV vector used throughout this thesis as a control for toxicity of AAV vector trans-
duction. The promotor is replaced by a transcription blocker (TB) sequence in tripli-
cate, preventing transcription of the GFP.
AAV6-s-ATeam1.03-WB
5’ 3’hSyn
NheIBamHI
ATeam1.03
tCFP
ClaI
F0F1ε
EcoRI
cpVenus
EcoRIHindIII
WPRE
1
30
1
51
2
81
2
11
12
12
02
15
02
16
10
19
10
22
10
23
91
26
91
AAV vector coding for the expression of ATeam1.03. ATeam1.03 is a FRET based GES
with the ε-subunit of F0F1-ATP synthase placed between CFP and cpVenus. This sen-
sor is sensitive to changes in ATP levels between 1 and 10mm and has a reported Kd
of 3.3mm (Imamura et al., 2009). The sensor was provided by Hiromi Imamura and
Hiroyuki Noji.
AAV6-s-D3cpV-WB
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5’ 3’hSyn
NheIBamHI
D3cpV
tCFP
NsiI
CaM m
13 cpVenus
HindIII
WPRE
1
30
1
51
5
81
5
11
15
12
02
15
02
16
64
17
39
20
39
23
39
25
24
28
24
AAV vector coding for the cytosolic expression of D3cpV. The binding sites of the
calmodulin (CaM) and m13 domains have been mutated for decreased endogenous
binding (Palmer et al., 2006).
AAV6-s-4mtD3cpV-WB
5’ 3’hSyn
NheI
m
ts
m
ts
AgeI
m
ts
m
ts
BamHI
D3cpV
HindIII
WPRE
1
30
1
49
4
59
0
69
2
78
8
89
6
11
96
14
96
17
96
20
96
23
96
26
96
29
05
32
05
AAV6-s-D3cpV-WB modified for mitochondrial expression. Four copies of the mito-
chondrial targeting sequence (MTS) from cytochrome c oxidase (COX) subunit VIII
was placed N-terminally of the sensor.
AAV6-s-GCaMP3.5-WB
5’ 3’hSyn
NheIBamHIAgeI
GCaMP3.5
6xHis
SalI
m
13
XhoI
GFPct
KpnI
GFPnt
MluI
CaM
HindIII
WPRE
1
30
1
52
9
63
1
70
0
98
8
12
88
14
29
17
29
18
83
21
83
AAV vector coding for the expression of GCaMP35. GCaMP35 is a GECI based on
a circularly permuted eGFP flanked by CaM and m13 peptide domains. GCaMP35 is
GCaMP3 without CaM-N60D mutation (Nagai et al., 2001; Akerboom et al., 2013).
AAV6-s-RCaMP1e-WB
5’ 3’hSyn
NheIBamHI
RCaMP1e
m
13
SacI
mRubyct
KpnI
mRubynt
AfiIII
CaM
HindIII
WPRE
1
30
1
51
5
59
3
86
6
11
66
12
98
15
98
17
61
20
61
AAV vector coding for the expression of RCaMP1e. RCaMP1e is a GECI based on a
circularly permuted mRuby flanked by CaM and m13 peptide domains (Akerboom et
al., 2013). RCaMP1e was provided by Loren Looger.
AAV6-s-mtRCaMP1e-WB
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5’ 3’hSyn
NheI
m
ts
BamHI
RCaMP1e
HindIII
WPRE
1
30
1
50
8
61
6
91
6
12
16
15
16
18
16
18
62
21
62
AAV6-s-RCaMP1e-WB modified for mitochondrial expression. A single copy of the
MTS from COX subunit VIII was placed N-terminally of the sensor.
AAV6-s-aSynWT-WB
5’ 3’hSyn
NheI
h αSynWT
NotI
WPRE
1
30
1
51
7
81
7
95
8
12
58
AAV vector coding for the expression of human wild type α-Synuclein.
AAV6-s-aSynWT-SEIS-WB
5’ 3’hSyn
NheI
EGFP
NotI
INTR.
SalI
SV40
polyA
MluI
hSyn
NheI
h αSynWT
NotI
WPRE
1
30
1
50
7
80
7
11
07
12
30
13
75
15
61
18
61
20
77
23
77
25
18
28
18
Bicistronic variant of AAV6-s-aSynWT-WB with GFP coexpressed as a reporter label
for transduction.
AAV6-s-bSynWT-WB
5’ 3’hSyn
NheI
h βSynWT
NotI
WPRE
1
30
1
50
7
80
7
93
0
12
30
AAV vector coding for the expression of human wild type β-Synuclein.
AAV6-s-bSynWT-SEIS-WB
5’ 3’hSyn
NheI
EGFP
NotI
INTR.
SalI
SV40
polyA
MluI
hSyn
NheI
h βSynWT
NotI
WPRE
1
30
1
50
7
80
7
11
07
12
30
13
75
15
61
18
61
20
77
23
77
25
00
28
00
Bicistronic variant of AAV6-s-bSynWT-WB with GFP coexpressed as a reporter label
for transduction.
AAV6-s-gSynWT-WB
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5’ 3’hSyn
NheI
h γSynWT
NotI
WPRE
1
30
1
51
7
81
7
91
9
12
19
AAV vector coding for the expression of human wild type γ-Synuclein.
AAV6-s-gSynWT-SEIS-WB
5’ 3’hSyn
NheI
EGFP
NotI
INTR.
SalI
SV40
polyA
MluI
hSyn
NheI
h γSynWT
NotI
WPRE
1
30
1
50
7
80
7
11
07
12
30
13
75
15
57
18
57
20
73
23
73
24
75
27
75
Bicistronic variant of AAV6-s-gSynWT-WB with GFP coexpressed as a reporter label
for transduction.
2.5 Cloning of sensors into AAV-plasmids
The first step done when cloning a new sensor was to do virtual cloning using SECentral
(Scientific & Educational Software, NC, US). This consisted of the loading of a vector map for
the sensor to be cloned and a vector map for the backbone to clone in to. Then finding proper
cloning sites by searching the multiple cloning site (MCS) for sites that uniquely opened the
backbone and cut on both sides of the sensor. In most cases no such sites were found and the
strategy then turned to adding new cloning sites using polymerase chain reaction (PCR). For
this purpose two sets of primers were designed in SECentral. The first set served as templates
for the insertion of new restriction sites through overhangs. The second set was designed as
sequencing primers of ∼8 bp that bound ∼200 bp upstream of the insert and the same down-
stream (reverse direction). Since PCR is error prone, these sequencing primers were used for
sequencing of the cloned plasmid to ensure integrity of the original sequence. When design
of restriction sites were necessary, the design was made in such a way as to ensure that the
Kozak consensus sequence, CCACC(ATG)(Kozak, 1986), was present between the restriction
site and the cDNA start codon of the insert. As a reference, most procedures were done
according to those described in “Molecular Cloning: A Laboratory Manual” (Sambrook and
Russell, 2001). All restriction nucleases used were from New England Biolabs.
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2.5.1 PCR amplification
PCR amplification of cDNA sequences of interest was carried out on a PTC-150 MiniCycler
thermocycler. Initially an optimization PCR was carried out with different (0, 1.5 and 3mm)
magnesium chloride (MgCl2) concentrations and different annealing temperatures (between
60 and 72℃ in order to establish optimal conditions. While most sensors have similar size
and are composed of mostly fluorescent proteins which are very similar in structure, it was
quickly noticed that this step for most cloning could be skipped. If nothing special was
required 3mm MgCl2 and an annealing temperature of 72℃ was used. 50 µL PCR reaction
mix then contained:
1. 27 µL millipore H2O
2. 10 µL reaction buffer (Phusion HF 5x)
3. 1 µL backbone template (5 ng µL−1)
4. 5 µL forward primer (4 pmol µL−1)
5. 5 µL reverse primer (4 pmol µL−1)
6. 1.5 µL dNTP mix (dATP, dCTP, dGTP, dTTP 10 pmol µL−1)
7. 0.5 µL Phusion polymerase (2UµL−1)
The thermocycler was programmed according to the following:
initial separation
30 s at 98℃
separation
30 s at 98℃
annealing 30 s
at 60-72℃
elongation
30 s at 72℃
cooling ∞ at 4℃
25x
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Meaning that separation, annealing and elongation was done for the given time at the given
temperature and that it was repeated 25 times. The last step meant that the PCR reaction
was cooled to 4℃ after finishing and could thus be run over night if needed.
After amplification the reaction was analyzed for the correct size with agarose gel elec-
trophoresis (see section 2.5.3).
2.5.2 Restriction of DNA
Restriction of DNAwas done according to the enzymemanufacturers (New England Biolabs)
intructions. Enzymes and DNAwere mixed in the correct buffer and incubated in water bath
at the recommended temperature for 60min. Restriction was done in a total volume of 50 µL
with 5 µg plasmid backbone or ∼1 µg PCR reaction, 5 µL buffer and 1.5U restriction enzyme
per µg DNA. In the case that the temperature and activity in the same buffer was at least
75% enzymes for both restriction sites were both added to the reaction. If the temperatures
did not match, incubation with the enzyme with lower optimal temperature was done first,
the second enzyme then added and the temperature raised to the new optimal. If the buffers
had to be switched the reaction was first restricted with one enzyme, purified using a PCR
purification kit (Qiagen) and then prepared again with the second enzyme in the new buffer
and incubated again.
2.5.3 Agarose gel electrophoresis
Agarose gel electrophoresis was used to analyze the fragments from DNA restriction digests
for purity, quantity and size. The gel was prepared byweighing the proper amount of agarose,
dissolving it in 1x TBE buffer by heating in a microwave oven. When completely dissolved,
the bottle was held under cold flowing water for about one minute to reduce the time taken
for polymerization. 1 µL ethidium bromide per 50mL solution was then added, mixed and
poured into a gel tray. A lane comb was inserted and the gel left to polymerize for ∼30min
at room temperature. The amount of agarose was chosen based on the size of the fragment
of interest. For fragments smaller than ∼500 bp a 2% gel was used. For fragments between
∼500 bp and ∼1000 bp 1.5% and for fragments larger than ∼1000 bp 1%. The gel tray was put
in the gel chamber and 1x TBE was added to cover the gel. Samples were mixed with DNA
loading buffer (6x) and TE to a final volume appropriate for the wells of the gel and pipetted
in the wells. The gel chamber was closed and connected to a power supply which was set
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to deliver direct current of 80V and left to run until sufficient separation of the fragments of
interest had occurred. The DNA bands in the gel was then visualized under UV-illumination
on a Gel Documentation 2000 UV-transilluminator with a camera connected to a computer
runningQuantity One (BioRad) software.
2.5.4 DNA production, extraction and purification
In cases were the DNA from a agarose gel electrophoresis was to be further used, the band
was cut out under low-intensity UV illumination and purified using a QIAquick Gel Extrac-
tion Kit according to the manufacturers instructions. For mini preps, extraction of DNA from
lysed bacteria was done using a QIAquick Mini Prep Kit according to the manufacturers in-
struction. The DNA was eluted in 36 µL 10mm Tris-buffer of which 6 µL could be used to
determine the concentration. The purity of the sample after extraction with either of these
two kits was high enough that no further purification such as precipitation was necessary
for sequencing, ligation or transformation of bacteria.
To obtain plasmid DNA in milligram quantities, a mega-prep was done using a Macherey-
Nagel NucleoBond PC2000 kit on two liters of bacterial culture cultivated over night from a
1mL mini-prep aliquot. The procedure was the same as the one given in the manufacturers
manual with the exception that the column was used twice. After the first run through and
elution the column was washed with the right buffer and the second half of the batch was
loaded. The plasmid DNA extraction procedure consists of the following steps:
1. pelleting of bacteria by centrifugation
2. resuspension in resuspension buffer supplemented with 100 µgml−1 Rnase A to de-
grade
3. alkaline lysis of bacterial cells (1% SDS, 10mm EDTA, 200mm NaOH)
4. precipitation of SDS, proteins and protein associated DNA and removal by centrifuga-
tion (2.8m KAc, pH 5.1) supernatant contains plasmid DNA
5. binding to a pre-equilibrated anion-exchange resin column
6. washing of the column to remove chromosomal DNA and proteins (100mm Tris-HCL,
15% ethanol, 1.15m KCl, pH 6.3)
7. elution (100mm Tris-HCL, 15% ethanol, 1m KCl, pH 8.5)
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After elution, plasmid DNA from large scale production was concentrated and desalted first
by isopropanol precipitation and subsequently again by ethanol precipitation. Finally the
pellet from ethanol precipitation was resuspended in 1x TE buffer over night.
2.5.5 DNA concentration determination
The concentration of DNA was determined by measuring the optical density on a spectrom-
eter at 260 nm. A ratio of the optical density measured at 260 and 280 nm of more than 2
was taken as indicative of low protein contamination of the DNA sample. In cases were
the DNA-concentration was to low to be recorded on the spectrometer, the concentration
was assessed on a agarose gel. In this case, a λHindIII digest was used as reference. Bands
in the sample of similar size to those in the standard was compared to the intensity of the
bands in the standard. Those that most closely matched in intensity was assumed to have
the concentration of the corresponding band in the standard.
2.5.6 Ligation and transformation of bacteria
The restricted backbone and insert was ligated and transformed into bacteria for growing and
selecting of clones. First the concentration of restricted backbone and insert was assessed as
described in section 2.5.5. Then a total amount of between ∼150-250 ng backbone and insert
wasmixed in a 1:3molar ratio together with T4 ligation buffer and 2000UT4DNA ligase with
sterile water added to a final volume of 20 µL. The ligation reaction was left to react at room
temperature for 20min. To control for religation events of the backbone due to insufficient
separation or purification from gel extraction, a second ligation was set simultaneously with
the first were the insert DNA was not added. After ligation, the reactions were put on ice
before being used to transform bacteria.
For transformation, electroporation cuvettes were pre-cooled on ice. 70 µg electrocompe-
tent bacteria suspension was thawed on ice. DH5α E.coli cells (ElectroMAX) was used when
pre-cloning of received vectors had to be done. Otherwise, since all cloning was done in or-
der to create pAAV vectors, electroporation-competent cells, “stop unwanted rearrangement
events” (SURE) E.coli cells were used in order to reduce the number of clones with corrup-
tion of ITR sequences in the plasmid genome. 4 µL ligation reaction was transferred to the
vessel containing the E.coli, mixed carefully and left for 1min on ice. The full volume of
bacteria/ligation mix was then transferred to the electroporation cuvette. The outside of the
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cuvette was quickly wiped with a paper napkin to remove ice and moisture. The cuvette was
then placed in the electroporator (Bio-Rad Gene Pulser II) and flashed with 1.8 kV potential,
200Ω resistance and 25 µF capacitance. Immediately after flashing, 800 µL SOC++ medium
was added to the cuvette, carefully mixed and transferred to a 1.5mL eppendorf tube. The
procedure was repeated for all ligation reactions after which the tubes with the flashed bac-
teria suspension were incubated at 37℃with vigorous shaking for 45min to let them recover
and initiate expression of the antibiotics resistance protein encoded for by the plasmid before
being exposed to antibiotics.
For plating, LB agar plates with the proper antibiotics (e.g. ampicillin 100were pre-warmed
to room temperature and 200 µL bacteria suspension plated with the help of a bent Pasteur
pipette. For difficult ligations, the rest of the bacteria suspension was centrifuged shortly,
300 µL supernatant removed, the rest resuspended and plated on a second agar plate. The
samewas done with any control reactions. The plates were then incubated at 37℃over-night
for at least 15 hours or until colonies were easily seen by the naked eye.
2.5.7 Picking of clones and verification of plasmid
The number of clones on LB agar plates from control ligation were compared with the proper
ligation. In most cases the ratio of proper to control was > 100 and about 8 colonies were
picked and cultivated in 4mL LBmedia over night. From this, 2mLwas usedwith a QIAquick
Mini Prep Kit (QIAGEN) (see section 2.5.4) to prepareDNA for checking plasmid integrity and
sequencing of PCR insert fragment. 100 ng from this preparation was restricted with SmaI
restriction nuclease (NEB) and analyzed using agarose gel electrophoresis (see section 2.5.3)
to verify the integrity of the ITRs of the AAV plasmid. A virtual restriction was done to infer
the correct size of the bands from SmaI restriction and the bands on the gel was compared to
these. Corrupted ITRs were evident as the wrong band from that expected due to SmaI not
restricting in corrupted regions.
Since PCR amplification is an error prone process, the amplified fragment was sequenced in
order to assure that it had the correct sequence. After mini-prep (section 2.5.4) and ITR in-
tegrity verification, a sample was sent for sequencing with the company SEQlab. The service
at SEQlab used was “extended hotshot 800” which sequences ∼800 bp in one stretch with high
fidelity. SEQlab was supplied with 600 ng plasmid DNA and 20 pmol primer in 10mm Tris-
HCL. For PCR products that were longer than 800 bp a second sample with a primer for the
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reverse direction was used. For really long inserts, were sequencing in the forward and re-
verse directions from the ends of the insert was not sufficient, additional sequencing primers
were designed either from the vector map or if not at hand, from a previous sequencing step
done from the ends of the insert.
2.6 Primary cell culture
Primary neuronal cortex culture was prepared from E18 rat embryos according to Varon and
Raiborn Jr. (1969) and Yavin and Menkes (1973). All surgical procedures were performed on
ice. In brief, cortex tissue pieces were collected in ice-cold Ca2+/Mg2+-free (CMF) medium
and centrifuged at 800 rpm for 4min at 4℃. The medium was removed and the pellet in-
cubated in 750 µL 0.25% trypsin for 15min at 37℃. Trypsin activity was then blocked by
addition of 700 µL ice-cold FCS (inactivated) supplemented with 25 µL DNAse to dissolve
DNA-aggregates released from damaged cells. The pellet was then mechanically dissociated
by gentle up-down pipetting trough a Pasteur pipette with fire-polished opening. After cen-
trifugation at 800 rpm for 4min, the pellet was resuspended in warm HCN culture medium.
Cells were seeded in poly-L-ornithine/laminin coated 24-well culture plates at a density of
250 000 cells/well. Cultures were maintained at 37℃ in 5% CO2 and 95% humidity in HCN
medium.
Cells were initially fed every third day by removing 250 µL and re-adding 300 µL fresh, equi-
librated HCN media. Upon comparison of culture that was fed at said interval with culture
where the media was not replenished, no difference in cell size, cell number or dendrite net-
work density could be could be detected. Because of this finding, no replenishing of the
media was conducted for any of the experiments with this cell culture listed in the results.
2.7 Adeno-associated virus vectors
Recombinant AAV vectors were prepared according to standard protocols (Kugler et al.,
2007). Serotype 6 vectors were propagated in HEK293 cells, purified by iodixanol step gra-
dient ultracentrifugation and heparin affinity fast protein liquid chromatography (FPLC),
followed by extensive dialysis against phosphate buffered saline (PBS). Genome copies were
determined by quantitative real time PCR and purity > 99% by SDS gel electrophoresis and
silver staining. All prepared AAV vectors are listed in section 2.4.
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2.8 Western blots
Western blots for the determination of relative levels of protein expression were done ac-
cording to Towbin et al. (1979) and Burnette (1981).
Quantification of integrated gray levels in order to determine approximate overexpression
levels and relative levels of expression increase between different multiplicity of infection
(MOI) were done as follows. Images of the blots were taken on the day of the respective AB
incubation with an exposure time of 10 s on a transluminator from Bio-Rad. Images were
exported as raw data in 16-bit TIFF format from the Quantity One software from Bio-Rad
and loaded into the Fiji distribution of ImageJ. The gel analysis tools of Fiji were used to
quantify the integrated density of the gray level from individual bands in the lanes of the
blots. The data from Fiji for each blot was saved to a single tab separated .dat file and was
further analyzed within R. To calculate the estimate of overexpression of a protein compared
to the endogenous expression, the integrated gray level value of the endogenous band was
subtracted from the band with overexpression. This was then divided by the value of the
endogenous band to give the overexpression factor.
2.9 Imaging
Imaging protocols for the different GESs are described in their respective sections in the re-
sults chapter. The protocol for the determination of changes in mitochondrial membrane
potential is described in the text in section 3.2.9. The methods for determination of mito-
chondrial fragmentation and movement speed are likewise described in section 3.2.3 and
section 3.2.4 respectively.
2.9.1 Microscope setup
Life-cell fluorescence imaging was done on a Zeiss Examiner microscope stage equipped
with a Colibri LED light source with LED modules of 360, 455, 505, 590 nm wavelength. The
microscope stage was adapted to accommodate two MRm (Zeiss) CCD cameras for simul-
taneous dual wavelength recordings. Emission light was directed to a second dichroic filter
cube that directed light to respective camera. For imaging of cell culture on coverslips 20 or
63x magnification objectives were used depending on the structure of interest. With sensors
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expressed in the cytosol, images were captured using a 20x objective whereas for sensors
expressed in mitochondria a 63x objective was used. Except for overview snapshots imaging
was usually done using 2x2 binning of the cameras which gave a full frame resolution of
692x512 pixels. For the 20x objective and from the camera manufacturer (Zeiss) stated pixel
pitch of 6.45 µm this gave a distance between pixels in the recorded image of 0.645 µm. For
the 63x objective the distance was 0.205 µm. Acquisition was controlled using Axiovision
software from Zeiss.
2.9.2 Perfusion
For temperature controlled administration of bathing media and application of drugs a grav-
ity fed VC-8T perfusion system from Warner Instruments was used. This system included
eight polytetrafluoroethylene (PTFE) valves for switching between solutions. Application
was done as follows, two large 200mL reservoirs for bathing media and six 20mL reservoirs
were placed at a level that produced a flow of 4mlmin−1. Perfusion was started and switch-
ing controlled using a custom built valve controller, see section 2.9.4. Tubes from the valves
were attached to inputs of a SHM-8 in-line heater connected to a TC-344B heating controller
(both from Warner Instruments). The output was connected by a short tube (∼2 cm) to BNC
connector inputs of the imaging chamber. Two imaging chambers were used, RC-25 allowed
complete fixation of a 12 or 13mm coverslip and was used for most experiments. For ex-
periments with field stimulation, a RC-26GLP chamber that was adapted to accommodate
platinum electrodes was used instead. This chamber had a glass bottom and the coverslip
was put within and kept in place using only capillary forces. Both chambers were from
Warner Instruments. These two chambers were mounted on the microscope stage in their
respective heating platforms (PH-3, PH-1). The heating platforms were connected to the
TC-344B heating controller.
Both channels of the TC-344B heating controller were set to hold the temperature at 37℃
which with perfusion at a rate of 4mlmin−1 resulted in a stable temperature in the chambers
of 34℃. All solutions were pre-heated to room temperature before being put in the perfusion
reservoirs.
Perfusion lines that were not used during an experiment were filled with sterile filtered H2O
during experiments. After experiments were finished for the day, all perfusion lines were
flushed with sterile filtered H2O, excavated and blown dry. All tubing used was PE-160 from
Warner Instruments.
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2.9.3 Field stimulation
For field stimulation two platinum electrodes were placed in a RC-26GLP imaging cham-
ber parallel to each other with a separation of 15mm. The electrodes were shaped in such
a way that a 1 cm long stretch of each electrode was submerged in the bathing solution to
the level of the coverslip on the bottom of the imaging chamber. A SIU-102 stimulus isola-
tion unit (Warner Instruments) was used to supply voltage clamped at 10V cm−1 electrode
separation. The stimulus isolation unit was triggered using a custom built function gener-
ator (section 2.9.4). The stimulus isolation unit was set to output bipolar current meaning
that a 500 µs pulse width trigger from the function generator translated to 1000 µs over the
electrodes but with the sign reversed after 500 µs.
2.9.4 Perfusion valve controller interface and function generator
For computer controlled operation of the perfusion valves a valve controller interface was
constructed using an Arduino Duemilanove1 single-board microcontroller. The Arduino al-
lows interaction with a computer over a serial-over-usb interface and has 14 digital 5V out-
puts. Eight of these outputs were directly connected to the inputs of the VC-8T valve con-
troller. When the three-position switch of a valve on the valve controller is set in its lower
position the valve can be opened by setting the BNC input to high at 5V. This allowed indi-
vidual control of all eight valves of the perfusion system. A computer program was written
in Python(et al., 2013) for timed control of the perfusion valves through this valve controller
interface. This program includes a simple graphical user interface where individual valves
can be opened or closed, a cleaning program started or loading of a program from file that
when started opens or closes valves at specific time points. An example of the contents of a
file containing such a program is given below:
FCCP application
1::120
6:180:600
Here the first line,
FCCP application
1http://www.arduino.cc
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simply states the name of the program and is ignored by the interface software. The remain-
ing lines contains instructions for the interface on what valve to open and for how long.
1::120
instructs the interface to open valve 1 for 120 seconds.
6:180:600
is similar but opens valve 6 for 180 seconds then closes the valve and opens valve 6’s corre-
sponding wash valve for 600 − 180 = 420 seconds.
The definition of wash valves and a description of what solution and concentration is cur-
rently inwhat reservoir is defined in a separate valves definition file. Here follows an example
of the contents of such a file:
1:aCSF-H:::
6:FCCP:2:120:1
The first line defines valve 1 with a bathing/wash media with fields separated with ‘:’. 1 is
the valve number, aCSF-H the name of the solution in the reservoir connected to valve 1
and the three last fields are empty. The next line defines valve 6. Here the first two fields
are the same, with the difference that the name field can contain multiple names separated
by ‘;’. The third (2) field however designates the concentration in micro liter of the drug
or other addition that this solution contains, again multiple concentrations can be given
separated by ‘;’. The fourth field (120) is the default time in seconds to open this valve. And
the last field (1) is the valve definition that corresponds to the solution in which this drug
was dissolved/added. This example then states that the reservoir connected to the first valve
contains HEPES buffered artificial cerebrospinal fluid (aCSF-H). The reservoir connected to
the sixth valve contains FCCP with a concentration of 2 µm in aCSF-H that should be applied
for 120 seconds if nothing else is stated.
The second function that this interface has was that of a function generator for a SIU-102
stimulus isolation unit (Warner Instruments) used for field stimulation. A second Arduino
was programmed to output a square wave with configurable pulse width, frequency and
duration. The software for the valve controller interface was adapted to accept a new line in
the program definition for applications:
9:1;10;500:180
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meaning to trigger field stimulation (“valve” 9) for 1 second at 10Hz with a pulse width of
500 µs. For field stimulation the bath solution defined for the “valve” was never turned of
and in this example continued for 179 seconds after field stimulation would stop. A valve
definition for “valve” 9 would then look like this:
9:FieldStimulator::1;10;500:1
where 9 is the “valve” thatmust be activated/triggered from the programfile. FieldStimulator
is the name of this definition. No concentration since it is not defined for field stimulation.
Then the default parameters (length;frequency;pulse width) and finally the bathing solution
(valve) that should be opened during the field stimulation. If field stimulation was to be ap-
plied with different bathing solutions a second or third (or fourth and so on) definition could
be used with successively higher valve numbers and the right bathing media valve at the
end.
2.9.5 Typical imaging experiment
A typical imaging experiment was conducted in the following way. A plate containing cover-
slips with cultured neurons was taken out from an incubator located next to the microscope.
A coverslip was removed from one of the wells of the plate and either fixed to the bottom
using a clamp or put on the floor of the imaging chamber depending on the chamber (sec-
tion 2.9.2). 500 µL of pre-heated bathing media was then carefully pipetted to the imaging
chamber and perfusion with bathing media started. A region of the coverslip slightly off cen-
ter was located using the oculars of the microscope in brightfield or fluorescence light and
when the desired spot with cells were found the microscope was switched to camera mode.
Focus was readjusted while cells were observed with the cameras on the computer screen
and an overview snapshot was taken at 1x1 binning. An experiment was then started in the
fast acquisition mode of the Axiovision software and recorded for the desired time. Axio-
vision was configured to set one of the transistor–transistor logic (TTL) output ports of the
Examiner microscope to high upon starting an experiment. This output port was connected
to the valve controller interface (section 2.9.4) which was programmed to start its loaded
application program upon this trigger.
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2.10 Data analysis
2.10.1 Acquisition and preprocessing
Time-lapse data was acquired using Axiovision (Zeiss) software. After imaging the image
stacks were transfered to a workstation using portable hard drives and the .zvi files con-
verted to .tiff + metadata using LOCI tools (Linkert et al., 2010). These files were semi-
automatically preprocessed in ImageJ to correct for misalignment in dual channel images
and movement due to instability of the coverslip. Custom macros/plugins and the TurboReg
package was used for this purpose.
The image stacks were then again loaded into ImageJ and appropriate region of interests
(ROIs) were created using either the ellipse or freehand tools. These ROIs were saved for
later use. The average intensities were measured from these regions in all frames of the
stack. The background intensity was estimated for each frame as the average of the lower
(in brightness) 5% of all pixels. A custom macro was written for this purpose which excluded
pixels with an initial value of 0 from the calculation. Usually, the measurement of manually
created ROIs and calculation of background was done using a script for all image stacks of
an experiment.
2.10.2 Evaluation
Next, the .csv files were read into data.frame structures in R(R Development Core Team,
2011) for further analysis. For ΔF/F0, F0 was taken as the mean average of at least 10 data
points preceding any stimulation that fell within the inter-quartile range of values. The
calculation was then done for any time point t as:
(Ft − BGt) − (F0 − BG0)
F0 − BG0
The FRET-ratio R was calculated as:
R =
(Act − AcBgt)
(Dot − DoBgt)
where Act is the integrated “acceptor” emission at time point t, AcBgt the background, Dot
the “donor” emission and DoBgt its background.
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The dynamic range of ratiometric sensors are given as:
Rmax/Rmin
where Rmax and Rmin are the maximum and minimum FRET ratios as taken from in vitro
values from the literature or determined in cell where possible.
2.10.3 Statistics
Results from any statistical analysis presented in this thesis was made using R (R Devel-
opment Core Team, 2011) with additional packages. t-tests were carried out using base R.
Analysis of variance (ANOVA) and linear regression was carried out using the CAR (Fox and
Weisberg, 2011) and nlme (Pinheiro et al., 2013) packages. Post-hoc tests were done with ei-
ther base R or the multcomp (Hothorn et al., 2008) package. Where necessary or appropriate,
pre-tests were carried out. Normality was tested for with the Shapiro-Wilks test using the
shapiro.test R function. Homogeneity of variance was tested for with Levene’s test using
the leveneTest function of the CAR package. Data is reported as mean±standard devia-
tion (SD) unless stated otherwise in the text. A p-value < 0.05 was considered as significant
difference from the mean.
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The results section of this thesis is divided into two parts. The first part deals with the creation
of mitochondrially targeted genetically encoded sensors (GESs) as well as characterization
of both targeted and cytosolic variants. The characterization of the ATP sensor ATeam1.03
has been given extra space and includes results from measurements using that sensor. The
second part covers experiments in primary cortical cell culture that is overexpressing α-
Synuclein (αS), β-Synuclein (βS) or γ-Synuclein (γS). These experiments focus on the impact
of the synucleins on the mitochondria relative to each other and uses GESs for physiological
measurements.
Throughout this chapter, eachmajor section ends with a box like this, containing a short summary
of the results that were presented.
3.1 Targeting and characterization of genetically
encoded sensors
To study neuronal physiology in living cells, a significant number of adeno-associated virus
(AAV) vector constructs were created that coded for the expression of different fluorescent
GESs. Schematic representations with descriptions of the different vector constructs are
given in section 2.4. Because the properties of such sensors are sensitive to their environment
it is important to characterize them in every new system were they shall be used. This means
characterization for each new cell/tissue type but also for every compartment where the
sensor might be targeted for expression. The most important factor is to ensure that the
dynamic range of the sensor is large enough to reliably report on the changes that are of
interest. For these reasons, characterization of the sensors used was considered an important
part of this thesis and is described in the following sections.
44
3 Results
3.1.1 Construct design
The constructs created for expression of GESs were based off of AAV6-s-SEWB, a AAV vec-
tor plasmid provided by Sebastian Kügler. This plasmid drives the expression of the target
protein using human synapsin promoter (hSyn) for neuron specific expression. See Kügler
et al. (2003) for the properties of the hSyn promoter in viral vector constructs. A GES gene
was introduced by subcloning from the original plasmid using sites present in the multiple
cloning site (MCS) flanking the green fluorescent protein (GFP) gene of AAV6-s-SEWB. This
procedure is described in section 2.5. In the case of GESs targeted to the cytosol, the se-
quence of the sensor followed the promoter in frame after the MCS and the Kozak consensus
sequence.
3.1.2 Targeting to mitochondria
Previously, free Ca2+ in mitochondria has been assessed in live cell imaging using rhodamine
based calcium indicators that accumulate in mitochondria with intact membrane potential.
The drawback of these are increased unspecific signal when the mitochondria loses their
membrane potential, difficulties with overloading and most importantly for the purposes of
this thesis, the lack of cell type specificity. To test the suitability of different genetically
encoded calcium indicator (GECI) as mitochondrial calcium sensors and to examine calcium
homeostasis and activity in neurodegenerative diseases, these sensors were targeted to the
mitochondria.
Mitochondrial targeting sequence
Targeting to the mitochondria was accomplished by attaching a mitochondrial targeting se-
quence (MTS) through molecular cloning N-terminally to the sensor proteins. The MTS cho-
sen was from subunit VIII of cytochrome c oxidase (COX) due to its already proven effi-
ciency in targeting GFP to the mitochondrial matrix (Rizzuto et al., 1995). Upon integration
into the mitochondrial matrix the MTS peptide is cleaved of by the mitochondrial processing
peptidase leaving only the cargo protein with a few extra residues on the N-terminal side
(Mukhopadhyay et al., 2002).
Single fluorescent protein (FP) based GESs such as GCaMP35 or RCaMP1e contain on only
one FP plus a binding domain. This gives them amolecular weight (MW) that is slightly lower
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than twice that of GFP (∼27 kDa). When these sensors were targeted to the mitochondria
using the MTS of subunit VIII from COX they showed very specific targeting. An example
of this can be seen in figure 3.1d. Förster resonance energy transfer (FRET) based sensors
have an additional FP which gives them a MW of at least twice but often close to three
times that of GFP depending on the size of the binding domain of the sensor. Since the
MW of the complete subunit VIII is only ∼8 kDa, including the MTS (Van Kuilenburg et al.,
1988), FRET based sensors are very large proteins in comparison. For these, only one copy
of the MTS proved unable to target the protein to the mitochondria with high specificity.
This corresponds with what has been shown previously by others for some GECI (Filippin
et al., 2005). To avoid time-consuming cloning of repeated structures a 4xMTS sequence was
designed and ordered from GeneArt. A schematic of the 4xMTS is given in figure 3.1a. This
sequence was designed with a restriction site after the first two MTSs such that they could
be removed leaving only a 2xMTS sequence. With 4xMTS there was no visible leakage of
targeted sensor from the mitochondria to the cytosol (figure 3.1c) for any of the FRET based
sensors.
Functional characterization of the specificity of mitochondrial targeting
To further assess the specificity of targeting to the mitochondria the GECI mtRCaMP1e was
expressed in neuronal cell culture and a train of 10 action potentials (APs) at 10Hz (pulse
width 1ms) was applied. Traces of the change in fluorescence intensity resulting from influx
of Ca2+ was compared between different regions (with and without mitochondria) and those
from RCaMP1e expressed in the cytosol and is shown in figure 3.2b. The shape of traces
from regions with no visible structure had the same general shape (amplitude and slope of
the rising and falling part of the trace) as those from mitochondria whereas the shape of the
response from cytosolic RCaMP1e was completely different (larger amplitude, faster rising
as well as falling parts of the trace). This implied that the response seen from regions without
structure is out of focus light from sensor proteins located in mitochondria rather than from
sensor proteins that have leaked from the mitochondria to the cytosol.
Also, the average intensity levels of region of interests (ROIs) covering mitochondria, sur-
rounding cytoplasmic region or image background was quantified from images of neurons
that coexpressed mtRCaMP1e with cytosolic GCaMP35. The average intensity of a ROI cov-
ering a part of a neurite without mitochondrial structure from the mtRCaMP1e channel
showed no significant difference in value to a region outside the neurite. This is shown
in figure 3.2c,d.
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Figure 3.1: Mitochondrial targeting sequence
Schematic of the MTS and images of GES targeted to mitochondria of neurons in neuronal primary
cell culture. (a) Schematic of the MTS (top). The 4x repeated MTS construct necessary for targeting
bulky GES (bottom). (b)The calcium sensor D3cpV (∼73 kDa) with only one copy of the MTS added,
showing unspecific targeting and leakage to the cytosol. (c) D3cpV with a 4x repeated MTS. (d)
GCaMP35 (∼49 kDa) targeted to the mitochondria with only one copy of the MTS.
Adapting multiplicity of infection for expression in the mitochondria
It is known that GFP can exhibit cytotoxic effects due to generation of reactive oxygen species
(ROS), a phenomena called phototoxicity (HS Liu et al., 1999; Greenbaum et al., 2000; Dixit
and Cyr, 2003). Another source of toxicity of FPs is a tendency for aggregation and due to
higher propensity for aggregation of red FPs, they can be more toxic than GFP (RL Strack
et al., 2008). Additionally, since the total volume of mitochondria within a neuron can be
assumed to be significantly smaller than the volume of the cytosol, expression of a protein
within the mitochondria at the same expression levels as for the cytosol can produce levels
of protein expression that will overload the mitochondria. Therefor the protocol used for
expression of mitochondrially targeted proteins must be adapted from that used for cytoso-
lic expression. To test what expression levels were appropriate for mitochondrially targeted
GESs, primary cortical neuronswere transducedwith differentmultiplicity of infection (MOI)
47
3 Results
a
-20 0 20 40 60
time (s)
in
te
n
si
ty
cyt
mito
nuc
(b)
c
roi intensity (red chan.)
1 424
2 169
3 168
(d)
Figure 3.2: Specificity of mitochondrial targeting
Mitochondrial targeting was assessed in terms of its specificity. (a) Image showing targeting of
RCaMP1e to the mitochondria. Mitochondria are clearly seen without visible fluorescence from cy-
tosolic regions, indicating highly specific targeting. (b) cyt: an example trace from another recording
with the same stimuli where RCaMP1e was present in the cytosol showing the shape of the cytosolic
response for comparison. mito: time-lapse trace from (a) with a ROI drawn over visible mitochondria.
nuc: as mito but with the ROI drawn over the dark region created by the nucleus where there are no
visible mitochondria. The nuc andmito traces have the same general shape and there is no visible cyt
component in the nuc trace. This indicates that the fluorescence measured from the nuc ROI comes
from out of focus light from mitochondria and not from cytosolic sensor due to leakage from the mi-
tochondria. (c) ROIs in an image showing mitochondria in neuronal neurite:
1) mitochondria in neurite.
2) ROI shaped as in 1 but from a region without mitochondria.
3) region outside of neurite (background).
(d)Average intensity measured from the red channel of the ROIs in (c). There is a clear higher average
intensity in ROI but no differences between ROI 2 and 3 indicating again that there is no leakage of
sensor from the mitochondria to the surrounding cytosol.
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and the mitochondrial morphology was assessed qualitatively at 6 and 12 days post trans-
duction (DPT).
Figure 3.3 shows that when RCaMP1e is expressed in the mitochondria using AAV with the
same MOI as used for cytosolic expression (∼2400), changes in mitochondrial morphology
occurs. This was true in both young and old cultures (figure 3.3c,f). Virus concentrations
were subsequently reduced and with MOI 600 there were consistently no visible changes
after 6 DPT and only moderate changes in a fraction of cells at 12 DPT. This MOI level was
tested for all sensors that were expressed in mitochondria with the same results. Because
of this all further experiments with mitochondrially targeted sensors used a MOI for AAV
vector transduction of 600.
• Targeting to the mitochondria of single FP GESs was efficient with a single copy of the
MTS from subunit VIII of COX
• FRET based GESs required repeats of the MTS and a 4x repeat was sufficient for efficient
targeting
• expression of GESs within mitochondria initially causedmorphological changes which was
overcome by reducing the expression level
3.1.3 Genetically encoded calcium sensors
There is no lack of choice when it comes to GECI, numerous groups have produced sensors of
different types that covers a range of Kd values and exhibits different kinetics (Miyawaki et al.,
1997; Palmer et al., 2006; Akerboom et al., 2012). Recently, GECIs based on other FPs thanGFP
has become available including red variants with spectra that can be optically separated from
sensors based on GFP, enabling simultaneous imaging of different GECI without the need
for spectral unmixing or other post processing of the signal (Zhao et al., 2011; Akerboom
et al., 2013). When these were targeted to different cell types or compartments of cells,
we previously showed that they can be used to examine interactions of calcium dynamics
between these cells or compartments during the same experiment (Akerboom et al., 2013).
During the work for this thesis several GECIs were used to assess calcium dynamics in neu-
rons and this section contains a description of how these sensors were used and the charac-
teristics that were observed while using them.
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Figure 3.3: Toxicity of RCaMP1e expressed in mitochondria
Cortical primary neuronal cell culture transduced with a AAV vector coding for mitochondrially tar-
geted RCaMP1e at differentMOI. (a)MOI 600, 6 DPT.Mitochondria in soma had elongated shape. Very
fewmitochondria in neurites had rounded appearance. (b)MOI 1200, 6 DPT. Most soma still had elon-
gated mitochondria but some had a fragmented shape. Mitochondria in neurites still had a elongated
appearance (c) MOI 3600, 6 DPT. Many more soma had fragmented mitochondria. A higher number
of mitochondria in neurites were rounded. Arrows point to clusters of fragmented mitochondria in
soma. (d) MOI 600, 12 DPT. Mitochondria in soma were still mostly elongated. Many mitochondria
in neurites were rounded. (e)MOI 1200, 12 DPT. More soma than in both (c) and (d) had fragmented
mitochondria. Many mitochondria in neurites were rounded. (f)MOI 3600, 12 DPT. Most but not all
soma had mitochondria with fragmented shape. The neuron in the top of the image shows normal
elongated mitochondria. The mitochondrial network in the soma of the neuron below is completely
fragmented. Most mitochondria in neurites were rounded. Top arrow points to a fragmented/swollen
mitochondria in the neurites. Bottom arrow points to fragmented/swollen mitochondria within soma.
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3.1.4 FRET based GECI D3cpV
As described in section 1.4, the calmodulin and calmodulin binding peptide that are used in
most GECIs can bind to endogenous calmodulin and calmodulin peptide, especially in parts of
the cell where these are present in high concentrations such as close to the plasmamembrane.
This can lead to perturbation of the sensor that introduces inaccuracies or artifacts in the
measurements. To solve this problem, Palmer et al. (2006) produced a set of GECIs with
a reengineered binding interface between the calmodulin and calmodulin binding peptide.
One of these sensors was D3cpV which had its binding domain inserted between a CFP and
circularly permuted Venus FP which also increased its dynamic range.
Maximum range of D3cpV
To understand what kind of stimuli of a neuron that produces a response of the sensor that
lies within the sensors dynamic range, the sensor was expressed in the cytosol of primary
cortical cell culture from rat embryos using the AAV vector AAV6-s-D3cpV-WB. Different
stimuli were then applied using either the perfusion system described in section 2.9.2 for
drug delivery or field stimulation (FS) with the system described in section 2.9.3.
Ionomycin is a ionophore that raises intracellular calcium levels and equilibrates the intracel-
lular concentration with that of the extracellular media (A Takahashi et al., 1999). If calcium
is removed from the bathing solution, Ca2+ will leak out of cells that have been treated with
ionomycin. This allows estimation of the sensor response to the zero Ca2+ level. When cal-
cium is readministered, the cell is flooded with Ca2+ and the sensor is saturated, showing the
maximum response that the sensor will produce. This gives values for Rmin and Rmax that can
be used to calculate the dynamic range, Rmax/Rmin of the GECI.
Figure 3.4 shows the response of the sensor to:
1. depolarization of primary neurons with 64mm K+ (first part of trace)
2. treatment with 10 µm ionomycin (second part of trace, low ratio values)
3. treatment with ionomycin together with 10mm Ca2+ (second part of trace, sudden in-
crease to high ratio values)
The average maximum and minimum FRET ratios (FRET/CFP) measured during this experi-
ment were 18.2 and 4.6 respectively. This gives an effective dynamic range of ∼4 fold increase
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Figure 3.4: Response to high potassium depolarization and saturation of the D3cpV calcium
sensor
Primary cortical cell culture transduced with a AAV vector coding for cytosolic expression of the
D3cpV calcium sensor with a MOI of 1200. The neurons were imaged at 14 DPT with 1 frame per
second. (a)Overview of a subset of cells from one imaged coverslip. (b)Traces from a larger set of cells
from the same coverslip. Before stimulation the cells exhibit an initial baseline ratio representative
of the free-Ca2+ level of the resting neuron with a mean and standard deviation (SD) of 5.68 ± 0.382.
After 2min, 64 µm K+ is applied for 60 s to estimate the maximum Ca2+ uptake from depolarization
of the cells. The mean and SD of the peak sensor signal during high potassium depolarization was
16.6 ± 1.21. After the high potassium stimulus, 10 µm ionomycin in 0Ca2+-media is applied to wash
out the intracellular Ca2+. This eventually reduces the signal of the sensor to the minimum which
had a mean and SD of 4.6 ± 0.319. During continued application of ionomycin, 10mm Ca2+ is added
which produces a rapid saturation of the sensor. This gives a max value for the sensor range which
was measured to have a mean and SD of 18.2 ± 0.871. n = 30.
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in FRET ratio, comparable to published data for D3cpV by Palmer et al. (2006). These val-
ues were used as a reference in order to ensure that a stimuli produced a response that was
within the dynamic range of the sensor. To do this, the FRET ratio from the sensor readout
was normalized between these two values and the response was expressed as percentage of
the dynamic range.
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Figure 3.5: Response of D3cpV to field stimulation
Primary cortical cell culture transduced with a AAV vector coding for cytosolic expression of the
D3cpV calcium sensor with a MOI of 1200. The neurons were imaged at 6 DPT with 20 frames per
second. (a) Overview of the FRET ratio, FRET and CFP emision from one one cell of a coverslip. (b)
Example trace showing response to 1 AP (left trace) and 10 AP FS at 10Hz. No individual peaks can
be seen with the 10Hz stimuli.
The condition of prolonged complete depolarization of the plasma membrane by reversal of
the ion concentrations for Na+ and K+ does not occur under physiological conditions. Be-
cause of this, high potassium depolarization can not be regarded as a physiological stimuli. A
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better stimuli for examining the properties of calcium handling in neurons is field stimulation
(FS). FS allows generating stimuli with defined properties such as pulse-width, frequency and
exact duration. The result of applying an electrical field over the neurons is to depolarize the
plasma membrane for a defined duration, simulating the triggering of an action potential.
There was a visible response of the sensor to stimuli as low as one AP (1ms pulse-width).
This response had a very slow rate of decay meaning that any subsequent stimulation added
to the initial response leading to accumulation of sensor signal and blurring of the individual
APs. This can be seen in figure 3.5 were a overview and trace from applying 1 or a train
of 10 APs with 10Hz is shown. No individual peaks can be distinguished even though the
frame rate of the acquisition was 20 frames per second (FPS). Applying longer trains further
increased the peak of the response but the increase was successively smaller. Going from 10
to 30 to 50 AP resulted in average peak responses of 44.67, 50.66 and 54.88 percent sensor
range respectively.
Response of D3cpV targeted to the mitochondria
Using a 4x repeat of the MTS, it was possible to efficiently target D3cpV to the mitochondria
(figure 3.1c). The AAV vector created for targeting of D3cpV to the mitochondria was called
AAV6-s-4mtD3cpV-WB. It was not possible to use ionomycin to acquire the total range of
the sensor when targeted to the mitochondria, possibly due to low penetration of ionomycin
to the mitochondria in the neuronal cell cultures used. Figure 3.6 shows the response of the
mitochondrially targeted variant of D3cpV (4mtD3cpV) to high potassium depolarizing stim-
uli. In terms of maximum response, this stimuli had similar characteristic to the response of
the cytosolic sensor. From this it was concluded that any response lower than the maximum
seen with high potassium depolarization was within the sensor range.
• A ∼4-fold dynamic range for D3cpV was measured in cell
• The response to high potassium depolarization was close to saturation of the sensor
• FS at 10Hz produced only ∼50% saturation of the sensor
• A response to single AP stimuli was visible but peaks in trains of 10Hz were not distin-
guishable
• D3cpV showed efficient targeting to the mitochondria with a 4x repeat of the MTS
• It was not possible to use ionomycin to acquire Rmax within the mitochondria
• Potassium depolarization produced a response in the mitochondria corresponding to ∼75%
saturation of the cytosolic variant
Using FS at 10Hz as a stimuli, it is possible to use D3cpV both in the cytosol and the mitochondria
for sensitive measurement of relative differences in calcium influx.
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Figure 3.6: Response of D3cpV expressed in mitochondria to high potassium depolarization
Primary cortical cell culture transduced with a AAV vector coding for mitochondrial expression of
the D3cpV (4mtD3cpV) calcium sensor with a MOI of 600. The neurons were imaged at 14 DPT with
1 frame per second. (a) Overview of a subset of cells from one imaged coverslip. 64 µm K+ was
applied for 60 s which caused the increase in FRET-ratio seen in the trace in (b). The baseline ratio
before application had a mean and SD of 5.56 ± 0.286. During depolarization with high potassium,
the maximum ratio measured had a mean and SD of 14.5 ± 0.695. After washing with aCSF-H, the
FRET-ratio returned to the initial baseline within four minutes. The mean and sd of the final baseline
was 5.68 ± 0.4. n = 34.
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3.1.5 RCaMP1e: a red GECI
The use of GECIs has previously been limited by the lack of sensors with spectral character-
istics other than in the green range. This was due to GECI all being based on one form or
other of GFP. In 2011, Zhao et al. (2011) published a paper on the creation of the first GECI
based on a red FP called R-GECO1. In 2013, we co-authored a paper describing a new red
GECI called RCaMP1e, based on a circularly permuted mRuby FP (Akerboom et al., 2013).
We found that compared to R-GECO1, RCaMP1e exhibited reduced photobleaching and no
photoswitching, issues that complicates the usage of R-GECO1. Having access to a red GECI
enables measurement of free-Ca2+ together with many common green fluorophores and FPs
used for labeling cells. Also, since most sensors are based on GFP in one form or another, red
GECI can be usedwith these for dual readouts. Two examples of this are given in section 3.1.7
and figure 3.14. Further examples as well as spectra for one and two-photon excitation for
RCaMP1e can be found in Akerboom et al. (2013).
Expression of RCaMP1e in primary cortical cell culture using AAV vectors with MOI of 3600
led to fluorescence under 590 nm excitation in approximately four days. This fluorescence
could not be seen by eye and was only barely detectable with a Zeiss MRm charge-coupled
device (CCD) camera at sub-second exposure times. The fluorescence increased upon fur-
ther expression and at 7 DPT the fluorescence intensity was enough to be seen by eye and
usable for Ca2+-imaging experiments (sub-second exposure times). The intensity remained
very weak compared to that emitted by D3cpV or GCaMP35. RCaMP1e exhibited very little
photobleaching with this excitation and was usable for long term measurements. The sen-
sor was not excluded from the nucleus as with D3cpV and GCaMP35, as seen by the lack of
distinguishable nucleus in figure 3.7a.
Dynamic range of RCaMP1e
As for D3cpV (section 3.1.4), proper usage of RCaMP1e requires knowing the dynamic range
of the sensor in the system were it is to be used. To test this, the cytosolic variant was ex-
pressed in neuronal primary cell culture using AAV and ionomycin was applied together
with 10mm Ca2+, leading to equilibration of the 10mm extracellular calcium concentration
with the inside of the cell. This led to rapid saturation of the sensor which can be seen in
figure 3.7c. The sensor signal was normalized by converting to ΔF/F0 and the maximum in-
tensity increase over baseline measured was 351 ± 19.6%. This was taken as the maximum
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Figure 3.7: Response of RCaMP1e to ionomycin+Ca2+, high potassium and field stimulation
Primary cortical cell culture transduced with a AAV vector coding for cytosolic expression of the
RCaMP1e red calcium sensor with a MOI of 1200. (a) Overview of a subset of cells from one imaged
coverslip. FS applied for 1 s with 10Hz at 1min. FS applied again for 5 s with 10Hz at 2min. Neurons
depolarized with high potassium at 3min. The neurons recover between stimuli. (b) Trace from
recording in (a) with one frame per second. Peak responses: FS1s = 113 ± 13.1, FS5s = 236 ± 16.8,
KCl = 321 ± 25.3. n = 42. (c) Trace of response from RCaMP1e to treatment with 5 µm ionomycin
and 10mm Ca2+. Max response: 351 ± 19.6. n = 12. Values are mean±standard deviation.
response of the sensor and was used as a upper limit of sensor range for further experi-
ments.
Response of RCaMP1e to FS
As described in section 3.1.4 for D3cpV, FS was used as a physiological stimuli leading to
accumulation of Ca2+ in the cytoplasm. In figure 3.7a,b, the typical response of RCaMP1e in
the cytoplasm to 10 and 50AP at 10Hz is shown. Also shown is the response to depolarization
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with 64mm K+ for 30 s. The peak influx after high potassium depolarization was 323 ± 25.3,
close to the maximum of about 351 meaning the sensor is close to saturation with this type
of stimuli. FS at 10Hz on the other hand produced responses both with 10 and 50 AP that
were in the middle of the sensor range (113 ± 13.1 and 236 ± 16.8 respectively).
Response of RCaMP1e targeted to the mitochondria
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Figure 3.8: Response ofmtRCaMP1e to field stimulation and high potassium depolarization
Primary cortical cell culture transduced with a AAV vector coding for mitochondrial expression of
the RCaMP1e red calcium sensor with a MOI of 600. (a) Images of a typical cell. Cell at rest (top
image). FS applied again for 5 s with 10Hz (middle image). Recovery of the cell one and a half
minute after application of stimuli. (b) Trace from recording in (a) with one frame per second. Peak
response: FS5s = 94.2 ± 18.9. n = 19. (c) Typical trace from a neuron expressing mtRCaMP1e that
has been depolarized with 64mm K+ for 30 s. Peak response: K+ = 263 ± 21.7. n = 16. Values are
mean±standard deviation.
RCaMP1e was targeted to the mitochondria using a single copy of the MTS (mtRCaMP1e).
The targeting was specific as expected for a circularly permuted single FP sensor. The fluo-
rescence intensity was higher when expressed in the mitochondria compared to the cytosol
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and imaging could be done with lower excitation light intensities. Both FS and high potas-
sium stimuli was tested with this variant of the sensor and typical traces are presented in
figure 3.8. Upon a stimuli of 50 AP, calcium was accumulated in the mitochondria and the
fluorescence intensity of the sensor increased. The intensity readout was normalized by con-
verting to ΔF/F0 and the peak increase was measured to be approximately 94.2 ± 18.9. The
peak fluorescence intensity increase upon 30 s depolarization with 64mm K+ was higher at
263 ± 21.7.
This shows that also for the mitochondrially targeted variant of RCaMP1e, a stimulus of 50
AP at 10Hz was enough to evoke a robust response but did not saturate the sensor. The
high potassium response on the other hand was lower than in the cytosol but since the abso-
lute range of RCaMP1e in the mitochondria is unknown, the response from high potassium
depolarization was regarded as at least close to saturating.
• The baseline fluorescence of RCaMP1e is weak, especially in the cytosol
• The max ΔF/F0 measured for RCaMP1e in the cytosol was ∼351%
• The response to high potassium depolarization reached a ΔF/F0 of ∼321% which was close
to saturation
• FS at 10Hz never saturated the sensor
• Targeting to the mitochondria was efficient using only a single copy of the MTS
• The response of RCaMP1e in the mitochondria to FS was far below saturation
Using FS at 10Hz as a stimuli, it is possible to use RCaMP1e both in the cytosol and the mitochon-
dria for sensitive measurement of relative differences in calcium influx.
3.1.6 Genetically encoded ATP sensor
Measuring ATP levels in cells has previously been a difficult process involving biochemical
methods on cell/tissue lysates or through measuring the consumption of ATP by luciferase
bio-luminescence (Fukuda et al., 1983; Ainscow et al., 2002; Mironov, 2007). Recently, a
FRET based sensor called ATeam1.03 that can report on changes in intracellular ATP was
created by Imamura et al. (2009). At the time of writing this thesis there had only been a
few publications were the usage of this sensor was described and none of those covered the
calibration in neurons. For this reason a slightly longer description of the findings with this
sensor will follow. The best scenario for a sensor would be to be able to accurately measure
absolute levels of whatever the sensor is responsive to. To accomplish this the sensor needs
to respond linearly in the range of ligand concentrations that one hopes to measure. The
ATeam1.03 sensor is engineered to show differences in ATP concentrations between 1 × 10−4
and 1 × 10−2mm and can be used to monitor the dynamics of ATP changes with rates up
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to 0.1 s−1. This makes it suitable for measurements of cytosolic ATP concentrations that
according to the literature lie within this concentration range (Veech et al., 1979; Fukuda
et al., 1983; Ainscow et al., 2002; Mironov, 2007).
In cell calibration of ATeam1.03
In order to determine absolute intracellular ATP concentrations using a sensor such as
ATeam1.03, the intracellular response of the sensor to different known ATP concentrations
must be determined. This requires access of extracellular ATP to the cytosol of the cell. A
chemical such as β-escin which perforates the plasma membrane can be used for this pur-
pose. Application of β-escin creates pores in the plasma membrane through which intracel-
lular ATP will leak out as we have previously shown (Mollajew et al., 2013). After flushing
out the ATP from the cell, the zero level or min response of the sensor can be determined.
Next, through perfusion one can add different known ATP concentrations to the extracellu-
lar media that will then flood the cell through the pores created by β-escin. This was done
for the primary cortical cell cultures used throughout this thesis.
The calibration experiment was conducted as follows. At first, β-escin was applied to per-
forate the cell. Different concentrations and application times for β-escin was tested before
settling on 20 µm applied for 2min. This was the lowest concentration and shortest time
possible that ensured reproducible and complete depletion of ATP (as reported by sensor).
Once perforated, the neurons stayed permeable until the nuclear membrane would disinte-
grate, visible by the appearance of sensor fluorescence in the previously dark and clearly
distinguishable nuclear region. This meant that it was not necessary to continue β-escin ap-
plication after 2min. With the 20 µm concentration, at least 10min would progress before the
neurons changed morphology or the nuclear membrane became permeable. After reaching
the minimal level, different ATP concentrations were applied. The published value for Kd for
the sensor is 3.3mm (Imamura et al., 2009) and the ATP concentrations (1.1, 3.3 and 10mm)
applied during the calibration were chosen based upon this. Going from one concentration
to three times higher, such as going from 1.1mm to 3.3mm took ∼2min before reaching a
new stable baseline of the FRET ratio. Thus, 1.1mm ATP was applied for 2min, then 3.3mm
ATP and finally 10mm which according to Imamura et al. (2009) should fully saturate the
sensor.
A typical trace of the normalized ratio, FRET ratio, FRET and cyan fluorescent protein (CFP)
readouts from the sensor is given in figure 3.9a. The FRET ratio which was calculated from
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Figure 3.9: Calibration of ATeam1.03 with the perforator β-escin
Primary cortical cell culture transduced with a AAV vector coding for cytosolic expression of the
ATeam1.03 ATP sensor with a MOI of 2400. The neurons were imaged at 7 DPT and a time-lapse cap-
tured with one frame per five seconds. (a) Traces of a typical calibration experiment. 20 µm β-escin is
first applied for 2min to perforate the plasma membrane. ATP is then rapidly flushed from the cells
leading to a decrease of the FRET/CFP ratio ((a), second panel). ATP with three different concentra-
tions are then applied in sequence flooding the cells with ATP leading to a stepwise increase in the
FRET/CFP ratio. The max and min values measured from the sensor are used to normalize the ratio
between 0 and 1 ((a), top panel). The maximum ratio is present before application of β-escin and with
10mm ATP (max of sensor range) it does not recover to that level. This suggests that something hap-
pens to the sensor or the intracellular environment during the calibration, invalidating the results.
n = 13. (b) Typical appearance of neurons at the moment of β-escin application and 10min later.
(c) Hill-plot of the applied ATP concentrations versus sensor ratio response from three replicates of
the measurement in (a). The function r = [ATP]
n
Kd
n+[ATP]n
was fit to the measured values using non-linear
regression. The fitted values for the two parameters, Kd and n (hill-coefficient) were 3.13 and 2.16
respectively with residual standard error σ = 0.0742.
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the background subtracted FRET (acceptor) channel intensity divided by the background
subtracted CFP (donor) channel intensity was normalized between 0 and 1 using the maxi-
mum and minimum FRET ratio from the trace. As is evident from the figure, the FRET ratio
present in the beginning of the experiment before application of β-escin was never reached
upon reapplication of ATP. 10mm ATP should saturate the sensor but to make sure, 100mm
ATP was tried as well but this did not increase the FRET ratio.
Figure 3.9c shows the FRET ratios at the steady-state for each ATP concentration from three
different such experiments plotted with the applied ATP concentration on the x-axis and the
measured FRET ratio on the y-axis. Using non-linear regression, the equation:
RN =
[ATP]n
Kd + [ATP]n
where RN represents the normalized FRET ratio and [ATP] the ATP concentration, was fit to
the measured min, max 1.1, 3.3 and 10mm ratio values. This gave values for the parameters
Kd and n which represents the dissociation constant and hill-coefficient respectively. These
were, Kd = 3.13mm and n = 2.16which corresponded well with the already published values
of Kd = 3.3mm and n = 2.1 for ATeam1.03 (Imamura et al., 2009).
Using this calibration curve to calculate ATP concentrations from the FRET ratio, one get
cytosolic ATP concentrations in resting cells that range to above 10mmwhich seems unlikely
considering previously published values that range up to ∼3mm in neurons at rest (Fukuda
et al., 1983; Ainscow et al., 2002; Mironov, 2007). As can be seen in the figure, the points
for both 1.1 and 10mm lie under the fitted line. Also, the distance between 1.1 and 3.3mm
and 3.3 and 10mm is clearly not what it should be with a Kd of ∼3.3mm, where 3.3mm would
be right in the middle of the sensor range. Together with the observation that it was not
possible to return to the FRET ratio observed before applying β-escin, this suggests that
the calibration is not reliable. Since we are changing the intracellular environment, it is
possible that this is changing the properties of the sensor, making the FRET ratio seen after
perforation meaningless. Different Ca2+ and Mg2+ concentrations ranging between 0 and
10mm and pH between 3 and 9 was tried but with similar results. Replacing β-escin with
saponin or digitonin, two other perforators, also did not succeed in returning the FRET ratio
to initial levels upon application of 10mm or higher ATP concentrations. It might also have
been the case that perforation/permeabilization leads to intracellular changes that alter the
properties of the sensor only after some time. To test whether this was the case, β-escin and
10mm ATP was applied together to intact cells, but also this did not raise the FRET ratio
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above the initial baseline. Because of these inconsistencies, the calibration of ATeam1.03 in
this way was abandoned.
Calculating ATP concentration based only on minimum level
Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) is a chemical decoupler of
mitochondria that works by facilitating the rapid transport of protons across membranes
(Benz and McLaughlin, 1983). This leads to a complete removal of the proton gradient over
the mitochondrial inner membrane within seconds. One of the effects of this is the complete
inhibition of oxidative phosphorylation and ATP production by the mitochondria. When
2 µm FCCP was administered to neurons expressing ATeam1.03, the cytosolic ATP concen-
tration could be seen to deplete (see section 3.1.6). When a stimuli was applied together with
FCCP that increased the need for ATP by the cell, this reduced the FRET ratio to the same
low level as after 2min of β-escin application. See figure 3.10 for the comparison of FCCP
and β-escin application. This suggested that ATP was completely depleted and gave a simple,
fast and effective way of measuring the zero level of ATP within the cell without the need
for perforating agents.
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Figure 3.10: FCCP application depletes cytosolic ATP to minimal levels
Typical trace following the application of 2 µm FCCP together with 30 µm kainate to primary neurons
expressing ATeam1.03 from AAV (left panel). Compared to the trace from β-escin application (right
panel), FCCP depletes cytosolic ATP to the same levels.
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ATP concentrations could then be calculated by using the min/zero level FRET ratio from
FCCP depletion of ATP and values from the literature by rearranging the following equa-
tion:
R = Rmin +
(Rmax − Rmin)[ATP]2
K2d + [ATP]2
into:
[ATP] = Kd√
r − 1
Rmax/Rmin − r
whereKd = 3.3 and Rmax/Rmin = 2.3 (Imamura et al., 2009) and R/Rmin has been substituted for
r , representing the relative FRET ratio (change from min level). For simplicity, this assumes
a hill-coefficient of 2 (2.1 according to Imamura et al. (2009)).
Figure 3.11a shows the FCCP trace from figure Figure 3.10 converted to ATP mm values
using this equation. The resting ATP levels are once again outside the range reported in the
literature for neurons and are close to the theoretical saturation of the sensor.
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Figure 3.11: Conversion of FRET ratio into ATP concentrations
Part of the FRET ratio trace resulting from applying FCCP together with 30 µm kainate to primary
cortical cell cultures expressing ATeam1.03 using a AAV vector. (a) The FRET ratio has been con-
verted to ATP concentrations using 2.3 as a value for Rmax/Rmin. (b)The FRET ratio converted to ATP
concentrations using 3.2 instead of 2.3 for Rmax/Rmin. This gives a range of ATP concentrations closer
in line with values from the literature.
If an Rmax/Rmin of 3.2 was used in the equation instead, the resting ATP concentrations came
out as ∼3mm, see Figure 3.11a. It is perhaps possible that the neurons in the cultures used for
this thesis have very high resting ATP levels, perhaps due to conditions of the growth media.
To compare the ATP levels with another cell, hippocampal primary cell culture from mice
pups kindly provided by Nicole Hartelt, were transduced with the AAV coding for ATeam1.03
but the same FRET ratio range was acquired with these cultures. More likely there is some-
64
3 Results
thing else that changes the properties of the sensor from those published by Imamura et al.
(2009) when expressed in neurons. Since relative levels were sufficient and determining ab-
solute ATP levels was not within the scope of this thesis, no further attempts were made to
find the root of these issues. For the rest of the experiments described below, an Rmax/Rmin
of 3.2 was used in calculations of ATP concentrations. The choice of 3.2 was made purely in
order to have the calculated ATP concentration within a range that is known from previous
measurements of ATP levels in neurons (Veech et al., 1979; Fukuda et al., 1983; Ainscow et al.,
2002; Mironov, 2007).
Rates of ATP decrease and regeneration after uncoupling of mitochondria
Even without having access to absolute ATP concentrations through the ATeam1.03 sensor,
it can be useful in measuring relative levels that can be compared between cell types and
different treatments of cells.
As was seen in figure 3.10, FCCP depleted cytosolic ATP when applied together with kainate.
The samewas true for FCCP alone, but with a slower rate of depletion. This was used to study
the rate of consumption of ATP by neurons when there was no regeneration of available ATP
by oxidative phosphorylation in the mitochondria. When the FCCP was washed out, the
mitochondria was able to restore its membrane potential and resumed ATP production. This
lead to complete recovery of the FRET ratio readout from the sensor, indicating that ATP
production through oxidative phosphorylation was restored. The slopes of the falling and
rising parts of the FRET ratio after first applying and then washing out of FCCP was used as
measures for the rate of consumption and regeneration of ATP in neurons.
In figure 3.12 a typical experiment where the consumption and regeneration rates were quan-
tified is shown. Neuronal cell cultures were transduced with a AAV coding for the expression
of ATeam1.03 three days after preparation. Experiments were done seven days after trans-
duction. An experiment was typically conducted as follows. Some frames were captured of
the neurons at rest to establish the initial baseline FRET ratio. Then, 2 µm FCCP was applied
for 3min which resulted in slow reduction in ATP levels. The FCCP was then washed out
which resulted in recovery of the FRET ratio.
FCCP was then reapplied to the same cells but this time together with a stimuli that requires
consumption of ATP. In the figure, 10 µm kainate was used. This again resulted in depletion
of ATP but this timewith a higher rate. After again washing out the FCCP, the ATP recovered
completely and with a higher rate than during the depletion.
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Figure 3.12: Difference in rate of ATP consumption at rest and during activity
Primary cortical cell culture transduced with a AAV vector coding for cytosolic expression of the
ATeam1.03 ATP sensor with a MOI of 2400. The neurons were imaged at 7 DPT with one frame
captured every five seconds. (a) Overview of the typical response of one neuron to stimulation and
recovery of 2 µm FCCP and 2 µm FCCP+10 µm kainate applied in succession. (top) A lookup table
(LUT) applied to the grayscale values of the ratio image to visualize the local and temporal differ-
ences in FRET ratio. FRET ratio calculated by dividing the FRET channel (middle row) with the CFP
channel (bottom). (before stim. ) initial part of fccp trace similar to that in (b), (+fccp) lowest point
of fccp trace, (recovery) initial part of fccp+kn trace, (+fccp+kn) lowest point of fccp+kn trace, (re-
covery, second) end of fccp+kn trace. (b) Typical traces of the average response from all cells of one
coverslip treated as in (a). Shaded areas represent the parts of the traces used for determining the con-
sumption and regeneration rates respectively. (c)Quantification of the initial and min measured ATP
concentrations. init = 2.91 ± 0.242 and min = 2.02 ± 0.201. (d) Quantification of consumption and
regeneration rates (slope of falling and rising parts of trace, shaded regions). consfccp = 0.288 ± 0.152
, prodfccp = 0.445 ± 0.0906 , consfccp+kn = 0.884 ± 0.184 and prodfccp+kn = 1.2 ± 0.265.
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If FCCPwas applied a third time, now again without kainate, ATP once more depleted slower
than with FCCP and kainate together but significantly faster than the first time. This sug-
gested that there was some residual effect from the first two applications that made the re-
quirement for ATP higher than before any stimuli with kainate. This was true also if the order
of the applications were reversed, with FCCP+stimuli applied before only FCCP. In any case,
applying FCCP alone always resulted in slower rate of decrease than FCCP+stimuli. For all
further experiments, the order of applications were FCCP alone then FCCP+stimuli.
When the consumption and regeneration rates from FCCP and FCCP + 10 µm kainate exper-
iments were quantified (figure 3.10d), both consumption and regeneration rates were consis-
tently higher when kainate was administered together with FCCP. Interestingly, the regen-
eration rate after washout of FCCP was consistently higher than the measured consumption
rate. This shows that the neuron has a large potential to increase its ATP production in
response to increased energy requirements. Please see section 3.1.6 for more results with
different stimuli.
Kainate activates the kainate receptor, a ionotropic glutamate receptor channel (Huettner,
2003). This depolarizes the neuron leading to influx of sodium but also calcium (Lerma et al.,
2001; Mollajew et al., 2013). Both sodium and calcium is then removed from the cytosol in
ATP dependent processes. Sodium over the plasma membrane (PM) via the Na+/K+-ATPase
(Howarth et al., 2012) and calcium over the PM via plasma membrane Ca2+-ATPase (PMCA)
or into endoplasmic reticulum (ER) via sarco/endoplasmic reticulum Ca2+-ATPase (SERCA)
(Nicholls, 1986). These are the same processes involved in recovering the resting membrane
potential after synaptic firing and as such, kainate application is emulating the state that
intense firing sets the neurons in. The difference between the rate of ATP consumption
between kainate stimulated and non-stimulated cells can then be seen as a measure of the
difference in ATP requirement by a neuron that is being activated and one which is at rest.
Applying only kainate, that is, without simultaneous application of FCCP, at up to 30 µm
did not reduce ATP in cell cultures as measured by ATeam1.03. This makes sense consider-
ing that the regeneration rate was always higher than the consumption rate and suggests
that increases in oxidative phosphorylation can immediately compensate for increased ATP
requirements of the neuron.
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ATP consumption and regeneration with different stimuli
Figure 3.13 shows the results from experiments with different stimuli applied together with
FCCP. These other stimuli are compared with 10 µm kainate (blue trace) or no stimuli (red
trace).
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Figure 3.13: Differences of rates in response to different stimuli
Primary cortical cell culture transduced with a AAV vector coding for cytosolic expression of the
ATeam1.03 ATP sensor with a MOI of 2400. Neurons imaged at 7 DPT with one frame captured
every five seconds. Comparison of different treatments that together with decoupling of oxidative
phosphorylation in the mitochondria with FCCP depletes cytosolic ATP. Treatments are compared to
those of applying only FCCP (red) and FCCP+10 µm kainate (blue). (green) More pronounced/faster
ATP consumption in subpopulation of cells treated with only FCCP. Increased regeneration rate after
washout of FCCP with complete recovery at same time as cells with much smaller decrease. (purple)
The rate of consumption and regeneration is similar in neurons stimulated with 10Hz FS to that of
10 µm kainate. (orange) Increasing the concentration of kainate to 30 µm increases the rate of ATP
consumption. The rate of ATP consumption is still lower than the rate of regeneration after washout
of FCCP. Rate of regeneration is the same but the time to recovery is significantly delayed. Results
based on observations of at least 10 neurons per stimuli type.
The first panel (green trace) shows what happened in a subset of neurons, where applying
FCCP without kainate produced a much more pronounced depletion of ATP than expected
for a resting neuron. The rate of consumption was also higher, similar to the rate seen when
10 µm kainate was applied. The rate of regeneration in this subset of cells was also increased
and they recovered the original baseline faster than with 10 µm kainate. It is possible that
these cells represent neurons that are for some reason spontaneously active, and therefor
have a higher rate of consumption of ATP than the average cell.
The middle panel (purple) of the figure shows a typical trace where the stimuli was 10Hz FS.
The consumption and regeneration rates were both very similar to those with 10 µm kainate.
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Complete recovery of cytosolic ATP also occurred at a similar time point.
The last panel (orange) shows what happened when the kainate concentration was increased
from 10 to 30 µm. The consumption rate increased and there was a longer delay before re-
covery of the ATP began. The rate with which it eventually recovered was the same as for
the other stimuli but there was no complete recovery. Instead the ATP level returned to a
lower baseline level.
This shows that the ATeam1.03 sensor can report on differences in consumption and regen-
eration rates of ATP after decoupling and recoupling of oxidative phosphorylation and that
the rates reported when applying stimuli such as 10 µm kainate or 10Hz FS are comparable to
rates that occur in cells that have no artificial stimuli applied. It also shows that the regenera-
tion rate after depletion is related to the amount of depletion since there are differences in the
rate of regeneration after small depletions (∼0.5mm) compared to larger ones (> 2mm). But
it also shows that when the depletion is larger, the ATP levels regenerate with the same high
rate no matter what stimuli was used or how big the change from the initial ATP level was.
This suggests that this is the maximum rate of ATP production that is available to the cell
from oxidative phosphorylation. In all cases, this was still faster than the rate of consump-
tion, meaning that none of these stimuli would be able to deplete ATP without the addition
of FCCP in these primary neuronal cell cultures.
• ATeam1.03 is suitable for measurements of relative ATP levels within neurons
• In cell calibration of ATeam1.03 gave values for Kd and hill-coefficient that corresponded
with values from literature but it was not possible to recover the initial ratio baseline by
application of ATP
• Decoupling of the mitochondria depleted ATP from neurons
• This allowed measuring the rate of consumption of ATP as well as the regeneration rate
after washing out of FCCP
• Applying a stimuli such as kainate together with decoupling increased the rate of ATP
consumption ∼3-fold
• The rate of production of ATP through oxidative phosphorylation increased in response to
the increased rate of depletion
• This regeneration rate was always higher than the consumption rate
3.1.7 Simultaneous use of two sensors
Since most GESs are based on GFP, they have spectral overlap that prevents using them
together at the same time. Even sensors based on CFP or yellow fluorescent protein (YFP)
have large enough overlap to make it difficult to use them together. Spectral imaging and
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unmixing (Zimmermann et al., 2003) can helpwith this issue but due to the changes in spectra
and intensity that is the basis for the readout of a sensor, this can become difficult. Preferable
then, are GESs with spectra that can be completely separated from those of GFP already at
the detection stage using optical filters.
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Figure 3.14: Simultaneous use of two sensors
(a) Emission spectra from CFP, GFP, Citrine (YFP variant) and RCaMP1e. A significant part of even
the YFP peak does not overlap with that of RCaMP1e. Conversely, RCaMP1e can be isolated from YFP
and the other GFP based peaks, albeit with some loss of signal. (b,c)Organotypic slice cultures of mice
hippocampus transduced with two AAV vectors expressing RCaMP1e and ATeam1.03. (b) Removing
Mg2+ from the media induced epileptiform activity throughout the slice through activation of NMDA
receptors as recorded with RCaMP1e. This was accompanied by localized ATP depletion, recorded
from ATeam1.03. (c) Overview of the slice from (b). Top: brightfield. Middle: ATeam1.03 FRET/CFP
ratio. Bottom: RCaMP1e ΔF/F0, background subtracted. The images are from before the removal
of Mg2+. (d,e) Primary cortical cell culture transduced with AAV vectors expressing GCaMP35 and
mitochondrially targeted RCaMP1e. (d) Overview of four cells on a coverslip. Individual channels
and overlay as labeled. (e) Trace of the response when FS was applied six times with 10Hz and a
duration of 1 s with 4 s pause. The Ca2+ buffering of the mitochondria is illustrated by the saturation
and prolonged decay of the mtRCaMP1e response (red) compared to the cytosolic GCaMP35 (green).
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GCaMP35 with RCaMP1e expressed in the mitochondria
RCaMP1e provides a GECI for such applications and in section 3.2.6 results are shown from
experiments where RCaMP1ewas used together with GFP labeling for identification of trans-
duced cells. It was also possible to use RCaMP1e together with GCaMP35, another GECI
which is based on GFP. Primary cortical cell culture was transduced with AAV vectors cod-
ing for the expression of GCaMP35 (AAV6-s-GCaMP3.5-WB) and mitochondrially targeted
RCaMP1e. This produced separable emission such as in figure 3.14d. These cultures were
electrically stimulated using FS at 10Hz for 1 s multiple times with 4 s pause in between.
The cytosolic free-Ca2+ as reported on by GCaMP35 recovered between every stimuli but the
mitochondrial free-Ca2+ as reported by mtRCaMP1e did not. There was increasing satura-
tion and prolongation of the decay of the mitochondrial free-Ca2+ (figure 3.14e). This illus-
trates the calcium buffering capability of the mitochondria after accumulation of cytosolic
free-Ca2+.
RCaMP1e together with ATeam1.03 in organotypic slice cultures
It was also possible to use RCaMP1e together with CFP/YFP FRET based sensors. As can be
seen in figure 3.14a, the spectra of RCaMP1e and Citrine, a YFP variant, overlaps, but there are
portions of both spectra that gives very little bleed through. Typical ATP responses measured
by this sensor like those described in section 3.1.6, are slow in comparison to the fast changes
in Ca2+ recorded in firing neurons and thus operate on different timescales. This makes the
results from experiments were RCaMP1e have been usedwith ATeam1.03 easily interpretable
even if there is some bleed through present. For highly sensitive applications, where very
small changes in ATP needs to be separated from large changes in Ca2+ or vice-versa, proper
controls should be done were each sensor is present by itself and the bleed through in each
channel is recorded and subtracted.
Organotypic slice cultures of mice hippocampus were prepared and cultured on millipore
membranes. The slices were transduced with AAV vectors coding for the expression of
RCaMP1e and ATeam1.03 by putting a droplet (∼2 µL) of virus mixture diluted in PBS di-
rectly on top of the slice. After about one week there was robust expression of both sensors
as seen with the fluorescence microscope. In figure 3.14c an overview with labeled regions
of a transduced hippocampal slice is shown.
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The slices were imaged on an Zeiss Examiner microscope stage with Colibri LED illumina-
tion. A slice was cut out from a larger piece of millipore membrane and placed in the imaging
chamber of the microscope. The slice was then superfused with aCSF-H. When Mg2+ was re-
moved from the superfusion solution, epileptiform activity appeared throughout the slice
as seen from the changes in free-Ca2+ reported by RCaMP1e. The activity was synchronized
throughout the slice and it disappeared whenMg2+ was readministered. If Mg2+ was removed
for extended times, more than 2min, ATP was seen to start to deplete in regions of the slice.
This depletion was most pronounced in the CA1 and CA3 regions with almost no detectable
decrease of ATP present in the DG region as reported by ATeam1.03. After readministration
of Mg2+ the ATP recovered. An example trace of Mg2+ removal is shown in figure 3.14b.
• Using the novel red GECI RCaMP1e it is possible to have dual readouts in one experiment
using optical separation of signals
• RCaMP1e can be used together with GFP based sensors as well as FRET sensors using the
typical CFP/YFP pair
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3.2 Comparisons of overexpression of α-, β-, γ-Synuclein
As was laid out in section 1.1, Parkinson’s disease (PD) is characterized by the appearance
of Lewy bodies that consist in large part of the small soluble protein αS. This establishes
a connection between αS and PD. Evidence that αS is relevant for the disease comes from
the observation that several familial point mutations in SNCA (PARK1), the gene coding
for αS causes early onset of PD. The mechanisms linking αS to PD are still not properly
understood. αS has been shown to associate with isolated membranes and make membranes
permeable to ions. Pore like structures have been observed in electron migrograph images
of αS. A proposed method of action for the detrimental properties of αS would then be that
it interferes with ion homeostasis.
αS has also been shown to accumulate in mitochondria where its uptake can be prevented by
blocking import channel proteins. In isolatedmitochondria exposed to αS, reduced activity of
complex I of the electron transport chain (ETC) and an increase in the production of reactive
oxygen species has been measured.
With the help of fluorescent GESs, tools that have been developed over the last couple of
years, I wanted to study the effects of overexpression of αS in primary neuronal cell culture.
Previous studies on the pathological function of αS has been done either using biochemical
methods on cell lysates, in isolated systems such as mitochondria or in cell lines derived from
tumors. This is to my knowledge the first time that a study that uses different GESs has been
carried out to study the effects of αS directly in neurons.
During the work for this PhD-thesis our group discovered that βS, a protein closely related to
αS encoded by the SNCB gene, has toxic effects similar to those of αS (Taschenberger et al.,
2013). Previously, βS had been assumed to have a protective role in the pathogenesis of PD
due to having been shown to reduce toxicity of αS when both proteins are present together.
Because of this finding, I introduced βS and γS into this study of α-Synuclein. Several of the
findings presented here are published in Taschenberger et al. (2013).
3.2.1 Expression of synucleins using AAV vectors
For neuron specific expression of αS, βS, or γS in neuronal cell cultures, two different types of
AAV vector constructs were used. The first was the same hSyn controlled construct as used
for the construction of GES as described in section 2.5 but with the sensor insert replaced
with the gene coding for the corresponding human synuclein. These were:
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• AAV6-s-aSynWT-WB coding for human wild type (WT) αS
• AAV6-s-bSynWT-WB coding for human WT βS
• AAV6-s-gSynWT-WB coding for human WT γS
For the experiments employing these constructs, a control vector called AAV6-3TB-EWB
was used to assess the toxicity of the AAV vector itself. This vector had the promoter re-
placed with triplicate transcription blocker regions that prevented transcription of its insert
(Maddalena, 2012).
The second type of construct was a bicistronic variant of the first. In it the hSyn was re-
peated after the synuclein and woodchuck hepatitis virus (WHP) posttranscriptional regula-
tory element (WPRE) and a second gene in the form of GFP was added after it. This ensured
expression of both synuclein and GFP in cells that were transduced with this vector. These
vector constructs were:
• AAV6-s-aSynWT-SEIS-WB coding for human WT αS and GFP
• AAV6-s-bSynWT-SEIS-WB coding for human WT βS and GFP
• AAV6-s-gSynWT-SEIS-WB coding for human WT γS and GFP
For experiments in which these vectors were used, the non expressing control vector was
replaced with AAV6-s-SEWB, a construct encoding for the expression of GFP. This served as
a control for both the toxicity of the AAV itself and for GFP.
All of these AAV vector constructs are listed in section 2.4. In the text, the complete name
of the construct is not written out but they are instead referred to simply as the abbreviated
name of the protein that they code the expression for, such as αS, βS, γS, or in the case of
the bicistronic variants αS+GFP, βS+GFP or γS+GFP. Also, the word “vehicle” is used when
referring to the control vector AAV6-3TB-EWB and GFP when referring to AAV6-s-SEWB.
When the bicistronic vector constructs were used for expression of both synuclein andGFP in
the same neurons, the expression of GFP was lower than when neurons were expressing only
GFP. This can be seen in figure 3.17b,q were the exposure time in images taken of GFP only
expressing cells had to be kept at a third of that used for the bicistronic treatments in order to
prevent overexposure. As well as in figure 3.15d where the integrated gray level of bands in a
western blot were 1.5 to 2.5 times higher in lanes with lysates from GFP expressing neurons
compared to those in lanes with lysates from αS+GFP expressing neurons. This suggested a
roughly 1.5 to 3 times higher expression of GFP in these neurons. Since there was no WPRE
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behind the GFP in these constructs and a three times enhancement of expression is consistent
with previous reports for WPRE (Hlavaty et al., 2005), this was taken as the reason for this
difference in GFP expression. See section 2.4 for a schematic representation of the vector
constructs.
AAV vectors coding for the expression of human WT α-, β- and γS were used for this work.
• These are referred to as αS, βS or γS throughout the text and figures.
• For all experiments using these vectors a control plasmid was used, this is referred to as
vehicle or in some cases ctrl.
• In some experiments, bi-cistronic variants that co-express GFP were used, they are referred
to as αS+GFP, βS+GFP or γS+GFP.
• For those experiments, a vector coding for only GFP was used as control.
All vectors are listed in section 2.4.
3.2.2 Toxicity
First thing done was to establish if and at which concentration of virus, i.e. MOI, that αS
overexpression becomes toxic to the neurons. This was accomplished by transducing neu-
ronal cell culture at 3 days in vitro (DIV) with either αS+GFP or only GFP expressing AAV
at different concentrations ranging from MOI 1200 to 25200. At 7 DPT images were taken
at random positions excluding the center and edge regions of the cultures and they were
scored for remaining cell numbers and cell body area. Figure 3.15a shows the decline in re-
maining neuronal cell bodies with increasing virus concentrations. At concentrations with
MOI between 1200 and 3600, αS+GFP caused none or only a small reduction in cell numbers
compared to cultures expressing only GFP at the same MOI. Increasing the MOI two-fold
to 7200 reduced the number of remaining cell bodies per square millimeter to less than 100.
With even higher MOIs the number of remaining neurons decreased further but with a much
less rapid decline as before. There were never less than 50 neurons per square millimeter re-
gardless of the MOI used.
To confirm that high MOI / high αS expression levels does not severely interfere with neu-
ronal cell body morphology, figure 3.15b shows the cell body area of remaining cells given in
µm2 against MOI for the same cells as used in figure 3.15a. There was no significant differ-
ence in the cell body area with increasing MOI or between neurons expressing αS+GFP or
only GFP.
To check what level of overexpression occurs within the neurons and how the increase in
MOI relates to and increase in expression level, a western blot was conducted on cell lysates
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Figure 3.15: Toxicity for different MOI of αSyn AAV vectors
Primary neuronal cell culture transduced at 3 DIVwith either αS+GFP (red line) or only GFP AAV vec-
tors (blue line) with different MOI. (a) Remaining cell bodies per square millimeter at 7 DPT. Between
a αS MOI from 3600 to 7200, the remaining neurons are reduced the most. At low MOI, less than
3600, there were no significant differences in the number of remaining cell bodies between αS+GFP
and only GFP. With only GFP, cell numbers stay the same through all tested virus concentrations
(multiple linear regression p-values: moi = 0.7753; vector = 0.0028; interaction = 0.0013, R2 = 0.89).
(b) Cell body area against MOI showed no significant changes in area with increasing MOI. (multiple
linear regression p-values: moi = 0.139; vector = 0.067, R2 = 0.33). The data in (a,b) are all from
the same set of cells (n = 2 coverslips for each treatment, points and error bars are mean ± sd except
in (a) where the range is min and max). (c,d) Western blot of lysates harvested and collected from
primary neuronal culture at 4 DPT.The cultures had been transduced with either αS+GFP or GFP only
expressing AAV at different MOI. 1x in the figure corresponds to MOI 1200. In (c), the blot has been
incubated with an antibody against rat αS to label both endogenous and overexpressed αS. Calcula-
tions based on the integrated gray level of the bands gave values for overexpression of αS through
the AAV vector at a factor 9-30 with increasing MOI. The relative increases in integrated gray levels
between the different MOI bands were 1, 2.010, 2.286, 3.592. In (d), the same blot as in (c) is shown
but after incubation with an antibody against GFP. The relative increases in integrated gray levels
between the different MOI bands for GFP were 1.000, 1.812, 2.880, 3.870. The increase in expression
with increasing MOI was thus the same for αS and GFP. The ratio between the integrated gray level
between GFP fromGFP only and αS+GFP lanes ranged between 1.5 to 2.5 suggesting a increase in GFP
expression of this factor due to the WPRE. The analysis of a second blot done on cultures prepared
and transduced on another occasion gave equivalent results.
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from cultures that had been transduced with αS+GFP or GFP only expressing AAV vectors.
A series of MOIs between 1200 and 14400 were examined. The neurons were harvested at
4 DPT. Figure 3.15c shows a western blot of the lysates where an antibody (AB) against rat
αS has been used. This antibody is specific to both rat and human αS and this labels both
the endogenous rat αS and the overexpressed WT human αS. The integrated gray level of
the bands was quantified using ImageJ (section 2.8). The integrated gray level from the first
five lanes corresponding to endogenous αS was averaged and subtracted from the integrated
gray level of the last four lanes corresponding to the overexpressed αS. These four values
were then divided by the average endogenous gray level to give an estimate of the level
of overexpression of αS through AAV vectors at different MOI. The overexpression ranged
from a factor of 9 to 30 times endogenous expression. The increase in expression between the
different MOI was also calculated. The integrated gray level of each band from the last four of
the blot was divided by that of the first of those four (1x in the figure). This resulted in values
for the relative increase in expression of approximately 1, 2, 2.3 and 3.6. This corresponded
very poorlywith a direct relationship in increase of expressionwith increasingMOI. To check
whether this was unique for αS, which might have suggested an increase in protein turnover
for αS, the same calculation was done for GFP. This produced a similar series of increases,
1, 1.8, 2.9, 3.9, indicating that the difference was due to a saturation of virus uptake and/or
vector copy number within the neurons.
With the observation that there is a strong dependence on MOI for the remaining cell num-
bers I decided to settle on two different MOI for further experiments. A low MOI that lay in
the region that did not cause considerable reduction in cell numbers of the cultures i.e. led
to non-toxic expression levels of αS and a high MOI that reduced cell numbers in all cultures
i.e. led to toxic expression levels of αS.
According to figure 3.15a, the non-toxic region was located between MOI 1200 and 3600.
Images of soma, neurites and mitochondria from neuronal cell cultures that were transduced
with αS+GFP expressing AAV vectors at the level between these two, MOI 2400, showed no
visible morphological differences of these compartments compared to cells expressing only
endogenous levels of αS (see figure 3.16). MOI 2400 was therefore chosen as the MOI for
non-toxic overexpression for further experiments.
Ideally, the high MOI would have been something that could reproducibly reduce cell num-
bers to the level seen between MOI 3600 and 7200 in figure 3.15a. It would then have been
possible to know that the αS was affecting the cells strongly while still leaving most neurons
remaining in the culture. It proved difficult however to ensure that the MOI used caused a
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Figure 3.16: Integrity of neuronal soma and neurites at non-toxic αSyn expression levels
Primary cortical neurons transduced with AAV vector coding for GFP or GFP+αS with MOI 2400 and
a second AAV coding for mitochondrially targeted RCaMP1e with MOI 600 at 3 DIV. Images were
captured at 6 DPT. Scale is the same for all images. (a-c) Typical soma and mitochondria in the
soma of neuron expressing only GFP. (d-f) Typical soma and mitochondria in the soma of neuron
that express GFP and αS together. No apparent differences in mitochondrial shape were present. (g-i)
Typical neurite and mitochondria within neurite of neuron expressing only GFP. (j-l) Typical neurote
and mitochondria within neurite of neuron expressing GFP and αS together. Neurites are intact and
mitochondria are elongated and comparable to those in GFP only expressing neurites.
similar reduction every time. This was most likely due to difficulties in ensuring the viabil-
ity of the virus between experiments and differences in the number of seeded cells between
culture preparations. Due to the strong dependence on MOI these small variations would
cause great variability between experiments. For this reason the “high” MOI was chosen so
that it reproducibly reduced the cell numbers to the high degree seen with the higher MOI
in figure 3.15. The MOI finally chosen was 12000, a five times increase over the low MOI.
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Toxicity of synucleins compared
Since the control vector (vehicle) does not actually express any protein in the neurons, it
is in most cases not a suitable control. The same goes for the GFP only expressing control
vector since the GFP is expressed together with the synucleins in all the vector treatments
and not only the control. A better control would be the expression of a protein of similar
size to αS at similar levels. For this reason I added βS (14.2 kDa) and also γS (13.3 kDa) to my
experiments, both of which have similar molecular weights to that of αS. βS has previously
been described as being protective against αS toxicity (Hashimoto et al., 2001; Uversky et al.,
2002; Hashimoto et al., 2004; Fan et al., 2006), and should therefor be the perfect control for
αS toxicity and other effects due to its very close similarity in sequence to αS. γS has not
been reported to play any detectable role in PD but might instead play a role in breast cancer
(Ji et al., 1997).
An examination of αS toxicity to primary neurons in culture compared to that of βS and γS
with the high MOI 12000 was now conducted in experiments made in cooperation with Dr.
Grit Taschenberger. Neuronal cell cultures were transduced with AAV vectors coding for
the expression of αS+GFP, βS+GFP, γS+GFP and only GFP. Images from random positions
excluding the edges and center regions of the cultures were captured at 7, 10, 14, 18 and
21 DPT and the number of remaining cell bodies were counted. An overview of images of
the cultures captured at these time points is given in figure 3.17a-t. Over time, the number
of remaining neurons for αS and βS overexpressing cells decreased substantially. For γS and
GFP only expressing cultures, the number of cells stayed constant however. There was also
an increase in fluorescence intensity recorded between 7 and 10 DPT (all treatments) up until
21 DPT (γS and GFP only). This increase most likely reflects the increase in expression of GFP
(and synucleins) from the vector since it was not removed from the growth media during the
experiment.
The cell numbers remaining at the different time points were quantified and the result is
shown in figure 3.17u. After 7 DPT there was only a moderate decrease in cell numbers and
only with αS treated cells. After two weeks (14 DPT) the cell numbers for αS had decreased
further to leave only about 100 cell bodies per square millimeter, very similar to that seen in
the experiments with different MOI described above. Although βS did not cause any decrease
in cell numbers at 7 DPT, at 14 DPT it too had caused significant reduction. This reduction
increased somewhat at 18 and 21 DPT but seemed to level out, still leaving significantly more
cells in culture than did αS.
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u
Figure 3.17: Neurotoxicity of synucleins in cultured primary neurons
(a-t) Primary cortical neurons were transduced at DIV 3 with the respective bi-cistronic AAV vectors
co-expressing GFP with α-, β- or γS. GFP fluorescence was recorded with constant exposure time
from living cultures at the indicated times after transduction (7 days: a, f, k, p; 10 days: b, g, l, q; 14
days: c, h, m, r; 18 days: d, i, n, s; 21 days: e, j, o, t). Neurons expressing only GFP are shown in (a-e),
neurons expressing αS+GFP are shown in (f-j), neurons expressing βS+GFP are shown in (k-o), and
neurons expressing γS+GFP are shown in (p-t). Fluorescence in GFP only expressing neurons was
recorded with less exposure time due to the somewhat higher GFP levels expressed from this vector
as compared to GFP levels expressed from the bi-cistronic vectors, which lack the enhancing WPRE
sequence 3’ to GFP. Scale bar = 100 μm. (u)GFP fluorescent neurons in living cultures were quantified
at the indicated times after transduction. Dotted bars = GFP only expressing neurons, light grey bars
= αS and GFP expressing neurons, black bars = βS and GFP expressing neurons, hatched bars = γS
and GFP expressing neurons. Statistics performed by one way analysis of variance (ANOVA) / Tukey,
∗∗∗ p < 0.001; n = 6 independent transductions per condition.
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It was surprising to see that βS but not γS exhibited toxic properties. To further study these
effects I decided to include βS in further experiments. Since γS had similar properties to that
of the previously used control, empty vector/vehicle/GFP, it was used in further experiments
as an additional control.
• The level of overexpression of αS ranged from 9 to 30 fold depending on MOI as evident
from western blot
• αS was found to be toxic to primary cortical neurons and this increased with both expres-
sion level and age of culture
• βS but not γS was also found to be toxic but less so than αS for the same MOI
3.2.3 Mitochondrial morphology
Mitochondrial morphologywas assessed after observing that the appearance ofmitochondria
in the soma of neurons that were transduced with αS at toxic levels had a rounded appear-
ance. Neuronal cell cultures were transduced at 3 DIV with AAV vectors expressing αS+GFP,
βS+GFP, γS+GFP or only GFP. In addition, AAV6-s-mtRCaMP1e-WB was added with MOI
600 for visualization of mitochondria. At days 6 and 13 after transduction images were cap-
tured at random positions that excluded the edges and center regions of the coverslips at
63x magnification. Different sets of transduced neurons were imaged for the different time
points and at least 30 neurons from 6 coverslips were imaged for each treatment. To analyze
the data, the images had their filenames randomized using a computer script and were ana-
lyzed blind to the transduction. The mitochondria of soma were classified according to their
appearance as either “tubular”, “partially fragmented” or “fully fragmented” (figure 3.18a-c).
Only soma that had strong green fluorescence from GFP were classified. After analysis the
correct filenames were recreated using the same script. The fraction of soma with fully frag-
mented appearance was quantified and is shown in figure 3.18d. At 6 days after transduction
there was a statistically significant difference in the fraction of soma exhibiting a fully frag-
mented mitochondrial morphology for cultures expressing αS+GFP compared to the other
treatments. At this stage there were no differences seen between βS+GFP, γS+GFP or only
GFP expressing neurons. At 13 days a majority of αS expressing neurons now had the fully
fragmented mitochondrial morphology (2.5 fold increase to ∼80%). For βS it had increased 5
fold to ∼50%. For both γS and GFP treated neurons there was a smaller approximately 2 fold
increase (∼20%). The differences between αS and βS to γS and GFP at each time point was
statistically significant (see caption for figure 3.18d). Also, the difference in the fraction of
soma with fully fragmented mitochondrial morphology between the two time points, 6 DPT
and 13 DPT, was also statistically significant for all four treatments.
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Figure 3.18: α-Synuclein changes mitochondrial morphology
Cultures of cortical neurons transduced with AAV vectors expressing αS+GFP, βS+GFP or γS+GFP
with MOI 12000 were analysed for mitochondrial fragmentation (a-c). To visualise mitochondria, a
AAV vector with MOI 600 expressing mtRCaMP1e was co-transduced together with the synucleins.
(a-c) Mitochondrial morphology in soma classified as either “tubular” (a), “partially fragmented” (b)
or “fully fragmented” (c). Mitochondrial fragmentation was calculated as the percentage of neurons
per coverslip that contained a majority of fully fragmented mitochondria at 6 and 13 days post trans-
duction.The difference in fragmentation was assessed with one-way ANOVA / Tukey, ∗∗∗ p < 0.001;
∗∗ p < 0.01; ∗ p < 0.05; n = 6 coverslips per treatment. Individual Student’s t-tests for each treatment
between the different time points (6 and 13 DPT) were significant for αS (p < 0.001), βS (p = 0.0091)
and γS (p = 0.047). (e) The length/width ratio of mitochondria in neurites at 6 days post trans-
duction. A Kruskal-Wallis test revealed a significant effect of treatment AAV on the mitochondrial
length/width ratio (p < 0.001; n = 70mitochondria from 5 coverslips per treatment). Post-hoc testing
using Mann-Whitney tests with Bonferroni correction showed differences between αS-βS (p < 0.001),
αS-γS (p < 0.001), αS-GFP (p < 0.001) and βS-GFP (p = 0.004).
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In addition to the morphology of mitochondria in the soma, there was apparent rounding
of mitochondria within neurites. This was quantified by calculating the ratio between the
length and width of red mitochondria (mtRCaMP1e) located in neurites that were visible in
the green (GFP) channel. In figure 3.18e this is shown for the early (6 DPT) time point. The
situation in the neurites corresponded with that of the mitochondria in soma. There was a
clear difference between αS and the other treatments in terms of the length/width ratio. For
βS it seemed as if it had progressed slightly more towards fragmentation and this difference
was statistically significant for βS compared with GFP only expressing neurons. γS and GFP
were again similar.
• Mitochondrial morphology in neurons was classified as either tubular, partially fragmented
or fully fragmented
• At 6 DPT, ∼30% of αS overexpressing neurons had fully fragmented mitochondria in the
soma
• For the other synucleins and GFP this figure was ∼10%
• At 13 DPT, the number of neurons with fully fragmented mitochondria in the soma had
increased to ∼80% for αS
• For βS the frequency of fully fragmented mitochondria was now ∼50%
• For γS and GFP it was higher as well but still less than ∼25%
• The situation in the neurites was similar, with a stronger tendency for rounded mitochon-
dria in αS
This shows that αS and βS both are able to influence mitochondrial morphology. The level and
time of onset of increased fragmentation for βS matches that of the toxicity.
3.2.4 Mitochondrial motility
Impairment ofmitochondria and/or impairment of the neurite networkmight lead to changes
in mitochondrial motility. That this might happen became apparent while measuring mito-
chondrial morphology in the previous experiments. The average andmax speed ofmovement
in micrometers per minute was assessed by manually tracking moving mitochondria in neu-
rites using the MTrackJ plugin for ImageJ on the same data as that used in section 3.2.3.
Quantification of this movement showed that after 6 days in culture, when changes in mi-
tochondrial morphology had occurred in over 30% of neurons (see figure 3.18), there was
actually an increase in the average movement speed of mitochondria from αS+GFP overex-
pressing cells but this difference was not statistically significant. After 13 days, when mor-
phological changes were present in about 80% of αS overexpressing neurons, the average
movement speed was significantly decreased and this difference was statistically significant.
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Figure 3.19: Movement of mobile mitochondria in neurites
Themovement of individual mitochondria in neurites in cultures of cortical neurons transduced with
AAV vectors expressing αS+GFP, βS+GFP or γS+GFP with MOI 12000 was analyzed for either mean
or max speed. Mitochondria were made visible through co-transduction with mtRCaMP1e with MOI
600. Tracking was done using the MTrackJ plugin for ImageJ. The difference in either mean or max
movement speed was assessed with one-way ANOVA / Tukey, ∗∗∗ p < 0.001; ∗∗ p < 0.01; ∗ p < 0.05.
All the other treatments, βS+GFP, γS+GFP and only GFP, had similar average and max speed
movement rates at both time points. The max speed correlated with the average speed for
all treatments. See figure 3.19 for a graph of the data.
• The movement speed of mitochondria in neurites was unaffected or slightly increased for
αS at 6 DPT
• The other treatments were all the same
• At 13 DPT, the mitochondrial movement speed was significantly reduced for mitochondria
in neurites from αS overexpressing neurons
• βS and γS were the same as GFP and they were all slightly faster than at 6 DPT
3.2.5 Cytosolic and mitochondrial free-Ca2+ handling at non-toxic
expression levels
The common symptoms of PD such as tremors and rigidity, are due to degeneration of
dopaminergic neurons in motor centers of the brain. If this is due to αS there should be
some point in time before death of the neuron where αS affects the properties of the cell
but the cell is still viable. This interference between αS and the normal functioning of the
cell should be what finally leads to degeneration and cell death. Using overexpression of αS
as a model for this early stage of αS pathology, I was interested in testing the response of
neurons with moderately elevated levels of αS to stimulus that raise intracellular Ca2+ levels.
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The rationale was that if αS can produce ion permeable pores in living cells or in some other
way interferes with the regulation of ion concentrations, this should be detectable in the way
that neurons handle calcium. This change could then be measured using GECIs.
To assess the calcium handling of neurons overexpressing αS at moderate levels in primary
cortical neuronal cell culture, either D3cpV with MOI 1200 or 4mtD3cpV with 600 was co-
expressed together with αS or vehicle with 2400 using AAV vectors. Upon depolarization
with 64mm K+ for 5 s the cells responded with uptake of Ca2+ as expected. However, the
FRET/CFP ratio showed levels close to saturation of the sensor with this stimulus and this
data was not further analyzed. Instead, the classical organic calcium indicator dye Fura-
2 which has a wider dynamic range than most GECI was used. This showed a small but
significant difference in peak calcium levels upon high potassium depolarization as seen in
figure 3.20c. Decay rates were unchanged however (not shown). This challenges previous
findings by another group that were done on SH-SY5Y cells stably transfected with WT αS.
Their findings showed large increases in the cytosolic peak calcium levels, up to two-fold
increase in signal compared to control (Hettiarachchi et al., 2009). In my experiments this
was significantly lower at only about 10% signal increase.
Since high potassium depolarization is a harsh stimulus that forcefully depolarizes cells with-
out any intermittent relaxation and as such can not be regarded as physiological, I extended
the measurements to use electrical stimulation in the form of field stimulation. This type
of stimulus can be tuned to emulate the electrical depolarizations normally experienced by
neurons that undergo APs firing.
Using FS as stimulus, neurons were stimulated for 3 s at 10Hz. The peak signal and decay
rates were quantified from traces of signals recorded from cytosol (D3cpV) and mitochondria
(4mtD3cpV), see figure 3.20a,b. With FS there were no longer any difference in peak levels of
accumulated cytosolic Ca2+ between αS treated cells and control. The same was true for Ca2+
accumulated/buffered in the mitochondria. When the decay rate was quantified by fitting
a straight line to the linear part of the decay after logarithmic transformation it too was
shown to exhibit no significant differences between αS overexpressing neurons and those
transduced with only empty vector either in the cytosol or the mitochondria.
• Calcium handling in neurons expressing a non-toxic level of αS is unaffected in both the
cytosol and mitochondria in response to physiological stimuli
• Resting levels as measured with the ratiometric GECI D3cpV were also unaffected
• With high potassium depolarization there was a slight (< 10%) increase in ΔF/F0 for αS
at non-toxic levels compared to control, suggesting a corresponding increase in uptake of
calcium
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Figure 3.20: Effects on cytosolic and mitochondrial Ca2+ handling of non-toxic αSyn over-
expression
Assessment of Ca2+ handling in neurons that over-express non-toxic levels of αS. Neuronal cell cul-
tures were transduced with non-toxic (MOI 2400) concentrations of AAV vectors coding for the ex-
pression of αS or a non expressing control vector (vehicle/ctrl in the figure). The GECIs D3cpV
(MOI 1200) or its mitochondrial variant 4mtD3cpV (MOI 600), also as AAV vectors, were used for
co-transduction. (a,b) Shows typical traces measured from cytosol and mitchondria respectively. (c)
Quantification of peak influx (max signal after stimuli) of neurons labelled with Fura-2 and having
been depolarized with 64mm K+ for 5 s. These cells excibited a small but significant increase in peak
signal indicating uptake of larger amounts of Ca2+ than control. (d) Quantification of peak influx
of neurons that express the GECI D3cpV either in the cytosol or the mitochondria. The cells were
stimulated electrically using FS at 10Hz for 3 s. This produced a non-saturating uptake of Ca2+ in the
cytosol and buffering in the mitochondria. Both baseline (before stimuli) and peak levels are indi-
cated and they are both not significantly different between cells that express αS or only empty vector
(vehicle). The baseline reading also confirms that initial Ca2+ levels are not elevated which indicates
that the reading in (c) is due to an increased peak uptake and not a change in initial levels. (e) Decay
rates quantified from readings in (d). A straight line was fit to the linear stretch of the logarithmic
transformation of the decaying part of the trace. Also for the decay rates there were no significant
differences recorded between αS over-expressing neurons and those transduced with empty vector
(vehicle).
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3.2.6 Cytosolic and mitochondrial free-Ca2+ handling at toxic
expression levels
Measured in the cytosol
Calcium measurements were now repeated with the neuronal cell cultures transduced with
AAV vectors expressing either αS+GFP, βS+GFP, γS+GFP or only GFP using the MOI (12000)
that caused toxic overexpression of αS. The calcium sensor AAV6-s-RCaMP1e-WB was co-
transduced with MOI 1200. Calcium handling was assessed at 6 and 13 DPT by applying FS
at 10Hz for 5 s. The change in fluorescence intensity of the RCaMP1e sensor was recorded
and the ΔF/F0 was calculated. Peak influx was measured as the peak in signal from the traces
of individual neurons. The decay rate after stimulation was measured from a linear region
of the log transformed trace. Example traces and plots of the measured values are given in
figure 3.21. No significant differences were seen between any of the treatments for either the
peak influx or the decay rates as measured using one-way ANOVA. Also, no correlation be-
tween the decay rates and peak influx values were present (Pearson correlation). When DPT
was added as an independent variable to the statistical model for peak influx to make a two-
way ANOVA model, a significant difference in peak influx between 6 and 13 DPT was seen.
This was interpreted as that the neurons that were measured at 13 DPT took up significantly
more Ca2+ than those measured at 6 DPT.
Measured in mitochondria
The experiment in section 3.2.6 was repeated but with AAV6-s-RCaMP1e-WB replaced with
AAV6-s-mtRCaMP1e-WB with MOI of 600 for expression of the calcium sensor RCaMP1e in
the mitochondria. As can be seen from the example traces and plots of the measured values
given in figure 3.22, no significant differences between treatments were found also for the
mitochondrial calcium handling at toxic expression levels. Also there was no correlation
between peak and rate values (Pearson correlation) and in contrast to the values for the
cytosol, there was no significant difference between 6 and 13 DPT when DPT was added to
the statistical model.
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Figure 3.21: Effects on cytosolic Ca2+ handling of toxic αSyn over-expression
Primary neuronal cell culture transduced with AAV vectors coding for the expression of αS+GFP,
βS+GFP, γS+GFP or only GFP with MOI 12000. An AAV vector coding for the calcium sensor
RCaMP1e was added together with the other vectors with MOI 1200. (a,b) Example traces of the
calcium response from cytosol after field stimulation (5 s, 10Hz) at 6 and 13 DPT. (c)Quantification
of the peak response in (a) (red) and (b) (blue). One-way ANOVA showed no significant differences
in mean responses between treatments, 6 DPT: p = 0.22, n = 34; 13 DPT: p = 0.8, n = 13. When DPT
was added as an independent variable to the statistical model for peak influx, a significant difference
in peak influx between 6 and 13 DPT was seen (two-way ANOVA pdpt < 0.001; pvec = 0.19 with no
interaction pint = 0.81). (d)Quantification of the decay time constant as in (c). Given as the absolute
change in percent of ΔF/F0 over time. Again the one-way ANOVA showed no significant differences
in the mean responses between treatments, 6 DPT: p = 0.43, n = 34; 13 DPT: p = 0.74, n = 13. No
significant difference between 6 and 13 DPT (two-way ANOVA pdpt = 0.22; pvec = 0.58). Pearson
correlation coefficient between decay and peak values: r6 = 0.064; r13 = −0.0053.
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Figure 3.22: Effects on mitochondrial Ca2+ handling of toxic αSyn over-expression
Primary neuronal cell culture transduced with AAV vectors coding for the expression of αS+GFP,
βS+GFP, γS+GFP or only GFP with MOI 12000. An AAV vector coding for the calcium sensor mtR-
CaMP1e was added together with the other vectors with MOI 600. (a,b) Example traces of the calcium
response from mitochondria after field stimulation (5 s, 10Hz) at 6 and 13 DPT. (c)Quantification of
the peak response in (a) (red) and (b) (blue). One-way ANOVA showed no significant differences in
mean responses between treatments, 6 DPT: p = 0.085, n = 42; 13 DPT: p = 0.82, n = 13. There
was no significant difference between 6 and 13 DPT when DPT was added to the statistical model
(two-way ANOVA pdpt = 0.14; pvec = 0.12). (d) Quantification of the decay time constant as in (c).
Given as the absolute change in percent of ΔF/F0 over time. Again the one-way ANOVA showed no
significant differences in the mean responses between treatments, 6 DPT: p = 0.99, n = 42; 13 DPT:
p = 0.34, n = 13. No significant difference between 6 and 13 DPT (two-way ANOVA pdpt = 0.96;
pvec = 0.92). Pearson correlation coefficient between decay and peak values: r6 = 0.016; r13 = 0.097.
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• No differences in calcium handling in the cytosol or mitochondria in response to physio-
logical stimuli was found for any of the synucleins
• An increase in peak cytosolic calcium was measured for neurons at 13 DPT compared to
at 6 DPT
This shows that the mitochondria of neurons that overexpress αS and βS at toxic levels are able
to handle the large influx of calcium in response to the depolarization occurring during AP firing
3.2.7 Morphological changes of mitochondria are not correlated
with impaired Ca2+ handling
A subset of the cells for the experiment in section 3.2.3 were also stimulated with FS and
the response recorded. These cells were then used to quantify the mitochondrial calcium
response of the neurons in relation to their morphological appearance. The idea was that
even though the neurons could not be shown to have a changed mitochondrial calcium han-
dling in the previous experiments, if the difference would be small and if the number of cells
that were affected by the αS were also small, any effects might be hidden in the variance be-
tween the different mitochondrial morphological types. If one would differentiate between
the morphological classifications and correlate this with the calcium response, one might be
able to find differences that were previously hidden. The stimulation protocol was the same
as the one used in section 3.2.6. Mitochondria in soma with all three types of morphology
responded to the FS, but see below for a description of differences that were present. When
quantified, there proved to yet again be no measurable difference in calcium handling be-
tween the treatments, or between the different morphological types. The data is presented
in figure 3.23.
When analyzing the data for calcium measurements, cells were regarded as not responding
if the max ΔF/F0 measured was not higher than that of the background (same as the con-
tribution from out of focus light). In most cases this threshold was about 10%. In cultures
that were measured 6 days after transduction, more then 95% of cells were responding. In
the older cultures, those at 13 days after transduction, there was a reduction in the number
of cells that responded to field stimulation for all treatments. It was more pronounced in
αS and βS treated cultures. When the response rate of the cultures was correlated with the
morphology of the mitochondria, αS had no responding cells with a “tubular” or “interme-
diate” morphology. For βS the distribution was more or less even with a similar number of
cells responding for each of the three morphological classifications. For γS and only GFP
expressing cells, there were for cells classified as having “fully fragmented” mitochondria a
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Figure 3.23: Correlation between mitochondrial morphology and calcium handling
Field stimulation of cultured neurons co-expressing either αS+GFP, βS+GFP, γS+GFP or GFP with a
red fluorescent genetically encoded Ca2+ sensor, RCaMP1e targeted to the mitochondria, was used
to study Ca2+ handling by quantifying the influx of Ca2+ into mitochondria after action potentials
and the time necessary to pump this Ca2+ out of the mitochondria. Synucleins and GFP control was
expressed using AAV vectors with MOI 12000. The calcium sensor was also expressed using a AAV
vector but with MOI 600. Peak Ca2+ influx (a) and decay time (b) after field stimulation were quanti-
fied at days 6 or 13 for cells containing either tubular (light grey bars), partially fragmented (dark grey
bars) or fully fragmented (black bars) mitochondria. Two-wayANOVAwas used to test for differences
in peak calcium or decay time constants between treatments and morphological appearance (tubu-
lar, intermediate, fragmented). No differences could be detected. 6 DPT p-values: peakvec = 0.11;
peakmorph = 0.65; tconstvec = 0.2; tconstmorph = 0.42. 13 DPT p-values: peakvec = 0.76; peakmorph = 0.8;
tconstvec = 0.61; tconstmorph = 0.9.
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similar fraction of responding cells as for αS and βS ( 25%) but for the two less severe classi-
fications there were a lot more responding cells. For βS all three classifications had around
25% of responding cells. In figure 3.24 the percentage of responding cells for each treatment
and morphological classification at 13 days after transduction is plotted.
0
25
50
75
100
αS+GFP βS+GFP γS+GFP GFP
ce
ll
s
re
sp
o
n
d
in
g
(%
)
tubular
partially frag.
fully frag.
Figure 3.24: Relative numbers of mitochondria responding to field stimulation
Relative response frequences of mitochondria in cells expressing αS+GFP, βS+GFP, γS+GFP or only
GFP from AAV vectors (MOI 12000). Co-transduction with the calcium sensor RCaMP1e targeted to
the mitochondria. Stimulation for 5 s at 10Hz with FS at 13 DPT. Plot shows mean±max/min; n = 3
coverslips. Differences in response was significant both for treatment and morphology (Fisher’s exact
test, p < 0.001 and p = 0.0031 respectively; n = 31 per treatment).
• No significant differences in calcium handling in themitochondria for any of the synucleins
were found when the response was correlated with mitochondrial morphology
• The number of responding neurons were drastically reduced for αS and βS however
• At 13 DPT ∼25% of measured neurons overexpressing αS or βS were responding with cal-
cium uptake
• For βS the type of morphology was irrelevant
• For γS and GFP, significantly more neurons with tubular or partially fragmented morphol-
ogy were responding compared to fully fragmented
This shows that as long as a neuron can respond to depolarization the mitochondria is able to
handle calcium without impairment
3.2.8 Measurements of mitochondrial ATP production and cytosolic
turnover
An important function of mitochondria in neurons is the generation of ATP. As mentioned,
in primary neurons from rat as well as in human postmortem tissue, αS has been shown to in-
teract with the ETC by interfering with complex I (Devi et al., 2008; G Liu et al., 2009; Chinta
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et al., 2010). To test whether the morphological changes and/or interaction with complex I
has an effect on resting levels or the consumption and production of ATP within neurons a
genetically encoded sensor for ATP was packaged as a AAV vector (AAV6-s-ATeam1.03-WB)
and used to transduce neurons together with the synucleins. The sensor is called ATeam1.03,
has a reported Kd of ∼3mm and can report on cytosolic ATP levels in the range 1-10mm (Ima-
mura et al., 2009) which is within the range typically found in neurons (Veech et al., 1979;
Fukuda et al., 1983; Ainscow et al., 2002; Mironov, 2007). A characterization of ATeam1.03
in the primary cortical cell culture used for the experiments in this thesis is given in sec-
tion 3.1.6.
Three days old neuronal cell cultures were transduced with MOI 12000 with AAV vectors
coding for the expression of αS, βS, γS and “vehicle” as control. The ATeam1.03 encoding
vector AAV6-s-ATeam1.03-WB was added together with the others for co-transduction with
MOI of 1200. After 6 or 13 days, measurements were conducted on the cultures as described
in section 3.1.6. This produced data from which the baseline level, consumption rate without
depolarizing stimuli, consumption rate during depolarizing stimuli, regeneration rate with-
out depolarizing stimuli, regeneration rate after depolarizing stimuli and the minimum level
at rest of cytosolic ATP could be assessed. Two types of stimuli were used to simulate activity
in the neurons. Either FS at 10Hz or stimulation of ionotropic glutamate receptors with the
application of 10 µm kainate. Because the results with both types of stimuli were the same,
only kainate were used for the later time point of 13 days and only these results are pre-
sented. A figure showing the traces from neurons stimulated with FCCP or FCCP+kainate is
shown in figure 3.12b. The shaded regions show what parts of the trace corresponds to the
consumption rate (cons) and regeneration rate (regen) respectively.
At 6 days after transduction the initial baseline levels (figure 3.25a, init panel) of cytosolic
ATP were the same for all three of the synucleins but were lower than in those cultures that
had been transduced with only “vehicle”. At 13 days the level for the control was the same
but βS and γS had increased to similar levels as that of control. The ATP level for αS had also
increased compared to at 6 days but were still significantly lower than that of control and
now also the other two synucleins. During FCCP application a new baseline was reached
in cells that were not also stimulated (figure 3.25a, min panel). These values correlated with
the initial baseline levels at both 6 DPT and 13 DPT. In table 3.1 the mean values ± standard
deviation are presented.
When mitochondria were uncoupled through the application of FCCP the consumption rate
of cytosolic ATP was slightly lower for αS than for the other treatments at 6 days after trans-
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duction. At 13 days, the consumption rate of αS had increased to the same levels as for the
other synucleins. The vehicle control had at 13 days, about 60% increase in its consumption
rate of ATP.When kainate was applied together with the FCCPwhich depolarizes the plasma
membrane, the consumption rate increased compared to at rest for all neurons. At 6 days, the
increase was most pronounced for αS for which it was more than 4 fold. For the three other
treatments the increase was approximately 2.5 fold. In the older cultures, at 13 days, the
increase in consumption rate when kainate was applied was about 4 fold for all treatments
except γS were it was instead approximately 3 fold. See table 3.1 for all the values.
While recovering after washing out the FCCP, the regeneration rate without kainate was
approximately 0.5mmmin−1 for all treatments and vehicle for both 6 and 13 days old cultures.
The exception was vehicle at 13 days, here it was almost twice that of the other treatments.
When kainate was applied, all regeneration rates at both time points were very similar at
about 1.3mmmin−1 and with the exception of vehicle the increase over the resting state
was about 2.5 fold. See table 3.1 for the mean values. This shows that even though there
exists slight differences in the rate of consumption of ATP in neurons overexpressing the
different synucleins, the ability to produce ATP by oxidative phosphorylation as seen from
the regeneration rate of ATP during the experiments is not impaired and is the same for all
synucleins and control.
• Lower cytosolic resting levels were found for all three synucleins at 6 DPT
• At 13 DPT, neurons with βS and γS had increased their resting levels to those of control
• The consumption of ATP within the neurons either without or with kainate stimulation
was similar for the synucleins with the exception of αS without kainate at 6 DPT where it
was significantly lower
• The consumption rate for control was consistently higher
• Regeneration of ATP after washing out of FCCP was very similar for all treatments includ-
ing control
• One exception was control without kainate at 13 DPT which had significantly higher re-
generation rate
Regeneration of ATP following FCCP application was similar for all synucleins. Together with
kainate which increased the regeneration, the rates were all very similar. This shows that the
capacity for ATP production through oxidative phosphorylation in the mitochondria was not
impaired by any of the synucleins.
3.2.9 Mitochondrial membrane potential
An important measure of mitochondrial viability is the mitochondrial inner membrane po-
tential (ΔΨm). The ΔΨm can be measured using positively charged, lipophilic fluorescent dyes
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Figure 3.25: Properties of ATP generation by oxidative phosphorylation
Primary neuronal cell culture transduced with AAV vectors coding for the expression of αS, βS, γS
or empty vector with MOI 12000 and co-transduced with the cytosolic ATP sensor ATeam1.03 with
MOI 1200. Time-lapse recordings of the cultures were captured while applying 2 µm FCCP and ei-
ther 0 µm or 10 µm kainate (kn). Measurements were done at 6 and 13 days after transduction. (a)
Initial calibrated ATP concentration in the cytosol and the minimum measured ATP concentration
in resting cells during FCCP application. (b) ATP consumption and regeneration rates during fccp
or fccp+kn application. Statistically significant differences were calculated with one-way ANOVA /
Tukey, ∗∗∗ p < 0.001; ∗∗ p < 0.01; ∗ p < 0.05.
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vector age (days) state init (mm) min (mm) cons (mmmin−1) regen (mmmin−1)
αS 6 resting 2.3± 0.067 1.9± 0.11 0.14± 0.039 0.47± 0.13
βS 6 resting 2.4± 0.083 1.8± 0.18 0.25± 0.071 0.55± 0.18
γS 6 resting 2.4± 0.087 2± 0.14 0.25± 0.043 0.5± 0.1
vehicle 6 resting 2.9± 0.13 2.4± 0.13 0.3± 0.064 0.54± 0.11
αS 13 resting 2.5± 0.16 1.6± 0.22 0.3± 0.044 0.55± 0.078
βS 13 resting 2.8± 0.13 2± 0.23 0.23± 0.053 0.48± 0.11
γS 13 resting 2.8± 0.086 2± 0.074 0.21± 0.037 0.49± 0.097
vehicle 13 resting 2.9± 0.077 1.9± 0.11 0.47± 0.067 0.86± 0.1
αS 6 active 2.3± 0.069 0.59± 0.053 1.3± 0.072
βS 6 active 2.3± 0.066 0.63± 0.079 1.2± 0.051
γS 6 active 2.3± 0.059 0.6± 0.071 1.3± 0.04
vehicle 6 active 2.9± 0.05 0.79± 0.083 1.2± 0.053
αS 13 active 2.4± 0.18 1.1± 0.12 1.3± 0.079
βS 13 active 2.8± 0.085 0.95± 0.16 1.4± 0.086
γS 13 active 2.9± 0.1 0.88± 0.082 1.3± 0.21
vehicle 13 active 2.9± 0.11 1.4± 0.11 1.2± 0.14
Table 3.1: Synuclein cytosolic ATP mean values
Table with mean values accompanying figure 3.25. Values are given as mean ± standard deviation.
The active min values are used during calibration and are therefor all 0 and so are missing from the
table.
that accumulate in negatively charged regions of both sides of the mitochondrial inner mem-
brane (Scaduto and Grotyohann, 1999). When the membrane potential is disturbed the dye
leaks out of the mitochondria and the ratio of mitochondrial to cytosolic fluorescence inten-
sity is a relative estimate of the membrane potential. The initial ΔΨm is estimated by decou-
pling the mitochondria which effectively nullifies the ΔΨm and the difference in fluorescence
ratio between before and after decoupling is taken as a measure for the ΔΨm. The ΔΨm is
established when the mitochondria pumps protons from the mitochondrial matrix to the in-
termembrane space during oxidative phosphorylation. An intact mitochondrial membrane
potential is required for mitochondrial fusion and loss of the potential results in rapid fission
of mitochondria (Legros et al., 2002). Also, during apoptosis the mitochondrial membrane
potential is disturbed (Gottlieb et al., 2003). A loss of ΔΨm in neurons overexpressing αSmight
therefor explain the change in morphology of mitochondria towards rounding and a frag-
mented appearance by lack of a functional physiological fusion machinery. It would also be
an indication that the cells with this mitochondrial morphology are in a stage of apoptosis.
To examine if this was the case, the relative ΔΨm was measured.
Neuronal cell cultures were transduced with αS+GFP, βS+GFP, γS+GFP and only GFP ex-
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pressing vectors with MOI of 12000. At either 6 or 13 days after transduction the cultures
were labeled with 5 nm tetramethylrhodamine-methylester (TMRM) for 30min and trans-
ferred to the imaging chamber of the microscope where they were continuously superfused
with aCSF-H containing 2.5 nm TMRM. After recording the initial baseline fluorescence in-
tensity, 2 µm FCCP was added to the aCSF-H superfusion media. This resulted in a rapid
decline of fluorescence intensity of mitochondria and simultaneous increase in intensity of
the surrounding areas. This is illustrated in figure 3.26a-c in which the trace depicts the
change from baseline of the ratio of fluorescence in mitochondria divided by the increase in
fluorescence of the surrounding cytosol. This change occurred with the same time course,
amplitude and localization regardless of the vector treatment that the cell cultures had under-
gone. This showed that mitochondrial membrane potential is not impaired as a direct effect
of αS overexpression nor from the mitochondrial fragmentation that accompanies it. It also
suggests that these neurons are not in the process of apoptosis, at least not at a stage were
loss of ΔΨm and release of cytochrome c has occurred. That the ΔΨm was intact for neurons
that express the “toxic” levels of αS (MOI 12000) and this also at the late time point of 13 DPT
indicates that the mitochondria are functional up until the neurons die and detach from the
culture.
After washing out of the FCCP, mitochondria once again became clearly distinguishable from
the cytosol indicating that TMRM reaccumulated in the mitochondria and that the mitochon-
dria were able to restore their membrane potential. This occurred with all treatments with
the same time course (not shown). The shape of mitochondria after recovery from FCCP was
altered towards a more rounded appearance.
No impairment of mitochondrial membrane potential (ΔΨm) was found for any of the synucleins
or GFP. This was expected considering that calcium handling and ATP production are dependent
on the mitochondrial membrane potential.
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Figure 3.26: Mitochondrial membrane potential in neurons expressing αSyn
Neuronal cell culture transduced with αS+GFP, βS+GFP, γS+GFP or only GFP with MOI 12000 and
labelled with 5 nm TMRM for 30min. (a-c) The change in intensities of a neuronal cell body before
(a), during (b) and after (c) applying 2 µm FCCP. (d,e)The relative change in mitochondrial membrane
potential (ΔΨm) assessed from the change in ratio of intensity between mitochondria and surrounding
cytosol before and after decoupling at 6 days (d) and 13 days (e) after transduction.
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This thesis has as its main objective the characterization of changes in mitochondrial func-
tion and morphology in neurons that are overexpressing α-Synuclein (αS) as a model for
Parkinson’s disease (PD) and is trying to compare this to changes caused by the other two
synucleins, β-Synuclein (βS) and γ-Synuclein (γS). Genetically encoded sensors (GESs) are
modern tools for the study of physiological systems and a number of novel sensors were
employed in this study. In addition, the GESs were targeted to neurons and the mitochon-
dria in order to specifically characterize and isolate the effects of αS to these locations. The
following sections discuss the results described in the previous chapter and tries to show
how the conclusion can be reached that even though αS affects mitochondrial morphology
and dynamics of neurons in cell culture, it does not lead to loss of mitochondrial function.
First however, is a discussion of the results pertaining to GESs, the difficulties and necessary
controls that need to be carried out when using them as well as their general usefulness in
the study of neurodegenerative disease.
4.1 Genetically encoded sensors
4.1.1 Targeting of genetically encoded sensors
Targeting of GESs can refer to the expression of the sensors in specific tissue regions or cell
subtypes. This can be accomplished using different vector systems and/or promoters driving
the expression. For this thesis all expression of sensors was done using adeno-associated
virus (AAV) vectors and all constructs were using the human synapsin promoter (hSyn) to
restrict expression to neurons (Kügler et al., 2003; Dodiya et al., 2010; Weinberg et al., 2013).
Targeting can also refer to expression in specific subcellular compartments. Sensors can be
coupled as fusion constructs to other proteins that gets transported and sequestered in spe-
cific regions or targeting sequences can be added. I used mitochondrial targeting sequences
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(MTSs) to target sensors to mitochondria and this was successful. However, larger sensors,
like the Förster resonance energy transfer (FRET) sensors based on cyan fluorescent protein
(CFP) and yellow fluorescent protein (YFP), were not expressed without leakage to the cy-
tosol when using only one copy of the MTS. Instead, a repeated sequence was necessary and
with a 4x repeat of the MTS from cytochrome c oxidase (COX) subunit VIII, targeting was
efficient as shown in section 3.1.2. The necessity for multiple copies of the MTS for efficient
targeting has been demonstrated previously (Filippin et al., 2005; Palmer et al., 2006). Palmer
et al. (2006) observed inefficient targeting and leakage to the cytosol in 20% of cells with 4x
repeated MTS from COX subunit VIII. This was reduced to 1% with an 8 times repeat. This is
different frommy results in that I did not observe any cytosol staining when using a 4x repeat
of the MTS. This could be due to differences in the cell types used, Palmer et al. (2006) were
expressing in HeLa cells. More likely however, it is due to differences in the level of expres-
sion. Palmer et al. (2006) used FuGENE, a non-liposomal cationic lipid (Arnold et al., 2006)
to transfect cultured HeLa cells and their constructs had been cloned into pcDNA3 plasmids
that drive expression from the cytomegalovirus (CMV) promoter. Even though transfection
efficiency is lower with non-viral vectors compared to AAV (Djurovic et al., 2004), actual pro-
tein expression in successfully transfected cells is higher. Additionally, the CMV promoter
generally produces stronger expression thanwhen expression is driven by hSyn (Kügler et al.,
2003), the promoter used in the constructs described for this thesis. It is therefor likely that
stronger expression levels in the HeLa cells were responsible for a higher rate of non-specific
targeting i.e. leakage to the cytosol. Single fluorescent protein (FP) based GES were found to
be targeted successfully with only one copy of the MTS. This suggests that the efficiency of
targeting is based on the size of the protein.
4.1.2 Characterization of the genetically encoded sensors used
Published values for properties like ΔF/F0 and Kd for a particular sensor are useful when
choosing which variant to use. However, the actual properties often differ when the sensor
is expressed in a system that is different from that which was used to obtain those values
(Linse et al., 1991). Since the results from measurements using GESs were going to be used
quantitatively and in order to compare properties between cells and preparations, it was
deemed necessary to first characterize the sensors in the primary cortical cell culture prepa-
rations where they were to be used. For all sensors this meant finding proper expression
levels, especially for targeted versions, that were not toxic or produced cells with apparent
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changes in morphology due to expression of the sensor. Also, the practical max ΔF/F0 or
complete dynamic range (Fmax/Fmin) was established in cell where possible.
D3cpV and RCaMP1e
For genetically encoded calcium indicators (GECIs), the dynamic range is fairly small and the
difference between the resting cytosolic free-Ca2+ in neurons and the level of free-Ca2+ after
high potassium depolarization or another strong stimuli is large, between ∼100 nm at rest and
several µm after stimuli (Ross, 1989; Marambaud et al., 2009). This means that a GECI with a
dynamic range of 10 will still get saturated upon calcium influx in a neuron that is stimulated
if the sensor has a high enough affinity for Ca2+. Thus, the sensor needs to be chosen based
on its Kd, dynamic range and the type of stimuli that it shall be able to measure the response
to. For this thesis, the interest lie with physiological stimuli of neurons and the stimuli used
was trains of action potentials at 10Hz.
For D3cpV and RCaMP1e the dynamic range was established by applying ionomycin which
led to very high responses of the respective sensor signals. Ionomycin, a ionophore capable of
acting as amobile ion carrier to transport cations across solvent barriers (C Liu andHermann,
1978; Erdahl et al., 1994), is commonly used for in cell determination of the dynamic range
of both genetically encoded and organic calcium indicators. It facilitates the equilibration of
the intracellular calcium concentration with that of the extracellular media (A Takahashi et
al., 1999). If a sufficiently high extracellular calcium concentration is applied, it will saturate
the sensor while ionomycin is present. To measure the response of a sensor to zero level
of free Ca2+ within a cell, ionomycin can be applied together with a chelator for calcium
ions such ethylene glycol tetraacetic acid (EGTA). Calcium ions that leaks out from the cell,
facilitated by ionomycin, will be sequestered by EGTA and eventually all calcium will have
left the cell. The dynamic range acquired from ionomycin treatment was compared with
the typical response to a physiological stimuli from field stimulation (FS) at 10Hz. For both
GECIs, the response from FS was within 75% of the sensor range measured with saturating
stimuli with ionomycin and both sensors were thus usable for comparison experiments in the
primary neuronal cell cultures used. Although not as important for this thesis, the dynamic
range (Rmax/Rmin) measured from D3cpV of ∼4 (section 3.1.4) corresponded with previously
published values by Palmer et al. (2006). Likewise for RCaMP1e, for which only themaximum
ΔF/F0wasmeasured (∼3.5), correspondedwithwhat has recently been reported for RCaMP1e
by Akerboom et al. (2013).
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When targeted to the mitochondria, the responses from either of D3cpV or RCaMP1e was un-
reliable when applying ionomycin. High potassium depolarization produced larger changes
of the FRET ratio for 4mtD3cpV and the ΔF/F0 for mtRCaMP1e than did 10mm Ca2+ + ion-
omycin, suggesting that the Ca2+ was not able to properly enter the mitochondria. When
neurons were depolarized with high potassium, the response in the mitochondria was nev-
ertheless higher than that caused by the FS stimuli used for later experiments. This showed
that also in the mitochondria was a depolarizing stimuli using FS not enough to saturate the
sensor and proved that it was feasible to use both D3cpV and RCaMP1e for mitochondrial
measurements of calcium.
When the dissociation constant Kd, as well as the minimum and maximum response (Rmin
and Rmax ) values are known, the measured ratio or response from ratiometric and single
wavelength GECIs can be converted into approximate free-Ca2+ concentrations according
to the methods for single wavelength and ratiometric indicators put forth by Grynkiewicz
et al. (1985). The Kd values are taken from literature or determined in vitro using purified
sensor protein. However, there are no guarantees that the values acquired correspond to
actual intracellular calcium levels and there are problems associated with these conversions
such as the sensitivity of indicators to photobleaching of the chromophore (Becker and Fay,
1987; Fowler and Tiger, 1997). Also, the binding properties of calmodulin (CaM), the binding
protein domain used in both D3cpV and RCaMP1e, can be influenced by ionic strength and
pH (Ogawa and Tanokura, 1984; Linse et al., 1991). Because of these issues and since a
determination of absolute intracellular Ca2+ levels was not deemed necessary, the data from
experiments with GECIs is presented “raw”, without conversion to calcium concentration.
ATeam1.03
In addition to GECIs, ATeam1.03, a GES sensitive to changes in ATP levels was employed
to study the effects of the synucleins on ATP consumption and regeneration from oxidative
phosphorylation. Previously, measurements of ATP levels in neurons have established the
resting ATP concentration to be between 1 and 3mm. These values come from enzymatic
measurements on whole brain lysates (Veech et al., 1979) or luciferase luminescence based
assays on primary neuronal cell culture lysates (Fukuda et al., 1983) or from intact cells using
genetically encoded luciferase (Ainscow et al., 2002; Mironov, 2007).
ATeam1.03 is a newly developed sensor created and characterized by Imamura et al. (2009).
It relies on FRET between CFP (mseCFP) and YFP (cp173-mVenus) facilitated by binding
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of ATP to the ε subunit of bacterial F0F1. When the work for this thesis started, the only
publication mentioning the usage of this sensor was the original description. Therefor, a
more in depth characterization of ATeam1.03 in the primary cortical cell cultures used here
was deemed necessary. In section 3.1.6 an attempt was made to calibrate ATeam1.03 in cells
of primary cortical cell culture according to a method described for other sensors (Dittmer
et al., 2009). Cells were permeabilized with β-escin and superfused with media containing
different extracellular ATP concentrations. The parameters from a fit of this calibration gave
values for Kd (3.13mm) andHill coefficient (2.16) that correspondedwith the published values
from in vitro characterization (3.3mm and 2.1 respectively) (Imamura et al., 2009). However,
the FRET ratio initially reported by the sensor, before permeabilization, was never recovered
even with 10 or 100mm ATP, which should saturate the sensor according to Imamura et
al. (2009). Some possible reasons for this behavior was already mentioned in section 3.1.6.
Another reason might be what Willemse et al. (2007) reports on regarding ATP and FRET.
While creating a FRET based GES for ATP, they found that a sensor construct incorporating
CFP and YFPwith an protease cleavage linker, which should not interact withATP, responded
to changes in ATP concentrations in vitro. They show that this is likely to be related directly
to FRET since it was not present in individual CFP or YFP units and it did not change the
ratio measured from constructs were the two FPs where located far enough from each other
to not allow FRET to occur. They also found that the effect most likely stems from interaction
with Mg2+ since variations in Mg2+/ATP concentrations had dose dependent effects on the
FRET ratios. This conclusion is not unreasonable considering the fluorescent properties and
their modification by Mg2+ of ATP (Amat et al., 2005). It has also been reported that ATP can
quench the fluorescence of other fluorophores (C Li et al., 2005). That this does not occur
with single FPs can be explained by considering the protected nature of the chromophore in
FPs, due to the surrounding β-barrel. This also makes this unlikely to be an issue for single FP
based sensors. This has consequences for all FRET based sensors however, and arguably, the
issues for ATeam1.03 are of least concern since it is a sensor which has been characterized
in regards to its behavior in the presence of ATP, something GESs usually have not. As for
the other FRET based sensor used in this thesis, D3cpV, this is unlikely to affect the results.
The results presented in this thesis shows that ATP levels in the cytosol of active neurons,
i.e. stimulated with either kainate or FS, is hardly perturbed if the mitochondria is active and
able to compensate with increased ATP production. This means that for measurements using
D3cpV in the cytosol, no changes in ATP levels that might interfere with the FRET efficiency
of the sensor was present. However, it is known that stimuli that causes uptake of Ca2+ to the
cytosol also increases oxidative phosphorylation, leading to transient increased ATP levels
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in the mitochondria (Nakano et al., 2011). From the results in section 3.1.6 we can infer such
an increase is happening as well since the production rate was higher after cells had been
stimulatedwith kainate. Figure 3.12d shows this especially well. Nakano et al. (2011) targeted
amodified version of ATeam1.03 to the mitochondria of HeLa cells andmeasured increases in
ATP levels in response to elevated cytosolic Ca2+ levels. They did not calibrate their sensor in
the mitochondria but comparing their measured FRET ratio change within the mitochondria
to their in vitro data for the sensor, the response in the mitochondria that they measured
corresponded to an increase of approximately 20% or ∼3.5mm. The data by Willemse et al.
(2007) shows that for a FRET construct incorporating a short Xa protease-sensitive cleavage
linker, a change from 1 to 5mm ATP produces a 24% decrease in FRET ratio. However, for a
construct with a inosine monophosphate dehydrogenase type II (IMPDH2) domain linking
the two FPs, the change was only ∼4%. This estimation tells us that in the worst case scenario,
a FRET sensor such as D3cpV will, when targeted to the mitochondria and responding to
changes induced by a large increase of cytosolic Ca2+, report with ∼24% smaller ratio change
due to interference from elevated ATP levels. For the results in this thesis this can be ignored
since:
1. the response of D3cpV expressed in the mitochondria was within ∼50% of the sensor
range when using FS. Assuming that this is 24% less due to ATP interference, the actual
sensor response would be ∼74% which is still significantly below saturation.
2. the production rates of ATP from oxidative phosphorylation was the same between
all synuclein treatments and control. This suggests that the ATP increase in the mi-
tochondria is also the same and thus the interference from ATP was the same for all
treatments and is not hiding differences in Ca2+ accumulation in the mitochondria.
Interestingly, in cell calibration of ATeam1.03 has since been tried by another group (Ando
et al., 2012) who did not report any inconsistencies. They used digitonin to permeabilize
Huh-7 cells expressing ATeam1.03 in a fusion construct that targeted the sensor to hepatitis
C virus (HCV) ribonucleic acid (RNA) replication sites. A ATP concentration of ∼5mm was
reported at these sites with a cytosolic concentration of 1mm.
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4.1.3 Genetically encoded sensors for use in the study of
neurodegenerative disease
As tools for studying the mechanisms behind neurodegenerative diseases, GESs can be very
useful. It is fairly straight forward to construct sensors that respond to changes in the intra-
cellular environment by combining FRET between FPs and binding domains from bacterial
and other species. So far, most of the GESs that are available, respond either to changes in
ligand concentrations, cleavage of peptide sequences or in some cases modifications such as
phosphorylation (Tyas et al., 2000; Takao et al., 2005). For αS or any other disease involving
the aggregation of proteins, a sensor that would report on the aggregation state or specific
species of aggregation would be very useful.
Bimolecular fluorescence complementation (BiFC) provides a tool for studying dimerization
of proteins and has been used to study αS (Outeiro et al., 2008) but it has some drawbacks.
The main one being the very high affinity of the two green fluorescent protein (GFP) halves
preventing dissociation and thus without proper controls (Morell et al., 2008) it is actually a
measure of the association constant of the two halves of GFP rather than dimerization of fu-
sion protein (Kerppola, 2006). A protein domain that would detect and change conformation
in the presence of dimerized or oligomerized species of αS would be a great advantage over
BiFC. New tools are becoming available that can recognize proteins, such as aptamers and
nanobodies, and with clever engineering these have the potential to enable the construction
of sensors for the detection of oligomerized species.
The clinical symptoms of PD are due to degeneration of dopaminergic neurons in the SNCA
(PARK1). This is indication that these neurons are primarily affected in regards to the dis-
ease. Studying the effects of suspected mediators of the disease such as αS would therefore
preferably be done in these neurons. However, the tools available for this are limited to im-
mortalized cell lines such as the LUHMES cells (Lotharius et al., 2002) or primary cell cultures
based on midbrain. Midbrain cultures have the drawback of, in the best case, having only
about 10% dopaminergic neurons (Sawamoto et al., 2001). This then requires the subsequent
fixing, labeling, identification and correlation of these neurons to those imaged during live
cell imaging, a time consuming and tedious practice. Promoters such as hSyn can be used
to drive expression of the sensor in only specific subtypes of cells. One idea would be to use
a promoter that is more or less specific to dopaminergic neurons. Some progress has been
made in this using the promoter from tyrosine hydroxylase (TH) (Matsushita et al., 2002; Oh
et al., 2009). Another alternative for studying the possible effects of dopaminewithin neurons
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other than naturally dopaminergic neurons is to use AAV vectors coding for the expression of
two enzymes necessary for converting L-dopa into dopamine. DOPA decarboxylase (DDC)
is the enzyme responsible for converting L-dopa to dopamine (Burkhard et al., 2001) and
vesicular monoamine transporter (VMAT) utilizes the proton gradient of synaptic vesicles
to load them with dopamine (Eiden et al., 2004). Then one would add L-dopa to the growth
media before experiments to induce production of intracellular dopamine. This has been
successfully tried by our group (Maddalena, 2012) but the necessity of using two viruses for
dopamine production and loading plus two viruses for a sensor and αS made this strategy
difficult. Nonetheless, Maddalena (2012) demonstrated that the presence of dopamine to-
gether with αS in primary cortical neurons did not reduce the viability of the neurons, nor
did it promote aggregation of αS.
Characterization of the GECIs RCaMP1e and D3cpV both in the cytosol and targeted to the mito-
chondria showed that their dynamic range was adequate to allow comparative studies between
neurons undergoing FS.
Even though in cell calibration of ATeam1.03 in the primary cortical cultures was inconclusive,
and so determination of absolute ATP levels excluded, the usefulness of ATeam1.03 remains in its
ability to report on relative levels and changes in ATP concentrations. ATP consumption during
activity increases ∼3-fold in neurons and this is answered with a similarly high increase in ATP
production by the mitochondria.
4.2 Overexpression of synucleins in neurons
The major topic of the work done for this thesis concerned the effects of overexpression
of synucleins in neurons in cell culture. The general toxicity was examined as well as the
abilities of the neurons to handle raised intracellular Ca2+ levels in response to depolarizing
stimuli. Of special interest was the effects on mitochondrial morphology and in particular
the ability of the mitochondria to carry out its major functions. The mitochondria was exam-
ined in multiple ways including its ability for calcium handling, ATP turnover, mitochondrial
membrane potential (ΔΨm) and motility. What came out of this study was that αS has a pro-
found negative effect on the survivability of neurons in cell culture and that this is strongly
correlated with the amount of the AAV coding for αS being present. At low multiplicity of
infection (MOI), the integrity of neurites, soma and mitochondria were still intact as com-
pared with neurons expressing only GFP. That βS has a similar albeit smaller toxic effect as
that of αS was new and surprising since it has previously been described as being protective
(Hashimoto et al., 2001; Hashimoto et al., 2004) in neurons. The results also showed that
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mitochondria in neurons that overexpress αS and to a lesser degree βS changes their appear-
ance towards a rounded morphological phenotype. It could also be shown that for αS but
not the other synucleins or GFP, the motility of mitochondria is reduced. These results led
to the suspicion that overexpression of αS but also to some extent βS would produce some
functional changes in mitochondria. However, none of the different modes of mitochondrial
function that were examined showed any changes that could be attributed to the effects of
αS.
4.2.1 Neuronal toxicity
As was laid out in section 1.1 and section 1.2, the main symptom in PD is the degeneration
of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the midbrain. An
important question is then whether αS itself has any properties that could cause such de-
generation. This has been tested with different forms of αS, mutated and wild type (WT),
in different model systems and the conclusion has been that αS does have toxic properties
(Karpinar et al., 2009; Winner et al., 2011) suggesting a link to the disease. As for αS, the
physiological function and possible pathological mechanisms behind βS are still unclear. Pre-
viously, βS has not been considered an actor in the etiology or progression of aggregopathies
like PD. Instead, several studies have suggested an at least partially protective role for βS.
These studies examined the interaction of βS with αS and showed that βS can prevent or re-
duce αS induced neurotoxicity in cell culture, transgenic (TG) animals and viral vector based
models (Hashimoto et al., 2001; Hashimoto et al., 2004). Another view is emerging though
since a contribution of βS and possibly also of γS to neurodegenerative processes have been
documented. Both βS and γS have been detected at pre-synaptic and axonal sites associated
with pathology in brains of sporadic PD and dementia with Lewy bodies (DLB) patients,
but not in controls (Galvin et al., 1999). Also, a DLB linked mutation (P123H) in SNCB, the
gene coding for βS, has been shown to produce axonal swellings, astrogliosis and memory
deficits in TG mice (Fujita et al., 2010). Crossing these mice with αS TG mice led to an en-
hanced pathologic phenotype in showing neuronal cell loss and dopaminergic dysfunction.
This further suggests an interplay between αS and βS function. For γS, the ability to cause
neurodegeneration has been demonstrated by overexpression in mice (Ninkina et al., 2009).
Those findings showed aggregation of γS and the appearance of various inclusions in neu-
ronal cell bodies throughout the nervous system but interestingly more prominently in the
spinal cord with loss of motor neurons.
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The results on the toxicity of the synucleins presented here confirms that αS overexpression
leads to neuronal cell loss in this system. A non-linear relationship between MOI and the
number of remaining neurons in culture was found. This suggests that most neurons tolerate
some overexpression of αS but above some level, αS abruptly becomes toxic. However, the
relationship between the MOI used and the protein level expressed as seen by western blot
(figure 3.15c,d) was not linear which suggests that protein expression is limited at high MOI.
This could mean that the relationship between αS expression level and remaining number of
neurons is more linear in reality.
The results also show that βS overexpression also leads to cell loss but that γS remains non-
toxic compared to control. The toxicity of αS can be said to be higher than that of βS since
the progression of cell loss is faster for αS and the total number of remaining cells is higher
for βS than for αS using the same MOI. A view of βS as irrelevant or protective in neurode-
generative disease can not be accepted considering these findings. Instead further studies
should be conducted on the role that βS plays and its possible interactions with αS in disease
progression.
The toxicity of αS has been demonstrated before but this is the first time that βS has been shown
to be toxic in neuronal cell cultures. Previously, a protective role for βS has been assumed, a view
that this work challenges. Further studies are needed to find out what role βS plays in PD.
4.2.2 Mitochondrial morphology and dynamics
Since many of the proteins that has been found with mutations related to PD have direct
or implied association with mitochondria, it lies close at hand to suspect involvement of
these with mitochondrial fission/fusion. In fact, recently, parkin (PARK2) has been found to
ubiquitylate mitofusins, targeting them for proteasomal degradation as a step in mitophagy
(Youle andNarendra, 2011). It is thought that this inhibits re-fusion of damagedmitochondria
thereby segregating them for mitophagy. In turn, P-TEN-induced putative kinase 1 (PINK1)
is imported to mitochondria were it seems to normally be degraded and maintained at low
levels. If a mitochondria becomes damaged, the levels of PINK1 rises within the mitochon-
dria, which signals the recruitment of parkin (Youle and Narendra, 2011).
Mitochondrial fragmentation due to αS has been demonstrated by others while the work for
this thesis was underway (Kamp et al., 2010; K Nakamura et al., 2011) and my findings in
neuronal cell culture confirms their findings for both αS and βS. The finding that overex-
pression of βS also causes fragmentation is novel and again suggests a possible role for βS in
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disease. In in vitro experiments, Kamp et al. (2010) found that αS directly prevented the fu-
sion of small unilamellar vesicles in a concentration dependent fashion. They were also able
to demonstrate mitochondrial fragmentation induced by overexpression of αS in Caenorhab-
ditis elegans and the human derived cell line SH-SY5Y. Both their results and the results of
K Nakamura et al. (2011) showed mitochondrial fragmentation in αS overexpressing cells to
occur without the requirement of dynamin related protein 1 (Drp1), suggesting that fission
is caused by αS directly also in cells. Kamp et al. (2010) also examined the expression of
mitofusin 1 (Mfn1) and mitofusin 2 (Mfn2) together with αS and could show an increase in
elongated mitochondria upon expression of the mitofusins that was partly restored to con-
trol levels by αS. They do not seem to have examined the possible role of αS in regulation of
the mitofusins. The results presented in this thesis on mitochondrial fragmentation supports
the findings by these two groups. The data shows αS to cause fragmentation in primary cor-
tical cell culture and that the level of fragmentation increases with age of the cultures. βS
has no effect on fragmentation in young cultures but causes fragmentation when the cul-
tures age, suggesting a similar function but with reduced potential for βS compared to αS.
Mitochondrial fragmentation was never seen when overexpressing γS, neither in young or
old cultures where the fragmentation was always comparable to that of control. All three
of the synucleins have lipid binding N-terminal regions and can associate with membranes
(Ducas and Rhoades, 2012). The reason why αS and to a lesser extent βS and not γS causes
fragmentation is not known.
I also examined the effects αS on average and maximum movement speed of mitochondria
in primary cortical cell culture. In cells with decreased fission or fusion, the speed of mi-
tochondrial movement is known to decrease (H Chen and Chan, 2009). The reason for the
reduced motility in fusion deficient cells is unclear but these mitochondria have been shown
to become stuck or move according to Brownian motion, without directionality (H Chen et
al., 2003). Different movement speeds of mitochondria in neurons have been reported, but
my results of 0.7-0.87 µm s−1 (42-52 µmmin−1) average and 1.33-1.58 µm s−1 (80-95 µmmin−1)
maximum speed depending on age of culture matches that of others (De Vos et al., 2003;
MacAskill and Kittler, 2010). Considering the relation between mitochondrial fragmenta-
tion/fission and movement (section 1.3) it is not surprising that a decrease in mitochondrial
movement speed in neurons expressing αS was found as well. This was only present in old
cultures even though fragmentation was present also in the younger cultures. This suggests
that the fragmentation caused by αS precedes the impairment in movement. Since I found no
fragmentation in γS overexpressing neurons, I did not expect to see impairment of movement
either. βS however might have been expected to affect the movement of mitochondria since
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it also causes fragmentation. That I did not see this for βS might have to do with the level
of fragmentation and the age of the cultures. The level of fragmentation caused by βS did
not equal that of αS even at 13 days post transduction (DPT). Thus a decrease in mitochon-
drial movement might only be detected when a majority of the mitochondria have become
fragmented.
Mitochondrial fusion/fission is normally regulated by dynamins. A mechanism for αS in prevent-
ing fusion of mitochondria has been suggested. I found mitochondrial fragmentation in response
to αS overexpression but without correlation with changes in calcium handling. This suggests
that fragmentation by αS is unrelated to fission of mitochondria from elevated calcium levels. βS
was also found to cause fragmentation of mitochondria, casting further doubt on a protective role
for the protein.
4.2.3 Mitochondrial function
Numerous mechanisms of action for αS toxicity has been proposed, including generation of
reactive oxygen species (ROS) through inhibition or interaction with complex I of the elec-
tron transport chain (ETC) and changes in ion handling through the association with ion
channels or pore formation in membranes. It is not clear how increased ROS production in
the mitochondria leads to apoptosis and cell death but mechanisms have been suggested that
include the destruction of mtDNA (Ricci et al., 2008) or cytochrome c release due to oxidation
of cardiolipin, an important component of the inner mitochondrial membrane (IMM) (Ott et
al., 2007). ROS is a normal byproduct from the ETC and 1-2% of all oxygen consumed under
physiological conditions is converted into radicals (Chance et al., 1979; Orrenius et al., 2007).
An intuitive connection between ROS induced damage and the degeneration of dopamin-
ergic neurons seen in PD exists in monoamine oxidase (MAO). MAO has been shown to
produce H2O2 and can be the source of up to ∼50-fold more ROS than oxidative phospho-
rylation (Hauptmann et al., 1996; Maurel et al., 2003). ATP depletion and ROS production
through inhibition of complex I has been proposed as the mechanisms behind Rotenone and
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced parkinsonian symptoms (Ali
et al., 1994; N Li et al., 2003). Mitochondrial fission has not been shown to occur from ROS
production but starvation of cells caused fragmentation andmitophagy as well as moderately
elevated ROS levels in at least one recent study (Frank et al., 2012). In in vitro experiments
on mitochondria isolated from dopaminergic cells overexpressing αS and mitochondria from
SNpc of PD patients demonstrated increased ROS production and complex I inhibition with
increasing αS levels (Devi et al., 2008). They also show that αS in this system was taken up
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by mitochondria through the outer mitochondrial membrane (OMM) transport outer mem-
brane (TOM) complex in an energy dependent fashion. My results show no impairment in
ATP production which suggests that mitochondrial fragmentation precedes any interference
with the ETC caused by αS overexpression. This is further supported by the fact that I also
did not observe any changes in mitochondrial membrane potential, something which has
also been observed by others (Kamp et al., 2010; K Nakamura et al., 2011). Therefor I sug-
gest that in contrast to the situation in isolated mitochondria, complex I inhibition is not the
major cause of toxicity in primary cortical neurons.
Another suggested mechanism for αS toxicity is through interaction with membranes. Mem-
brane binding, permeabilization and pore formation by αS have been demonstrated in vitro
by several groups (Kim et al., 2009; Feng et al., 2010; Stöckl et al., 2013). This seems to occur
preferentially by oligomeric (Kim et al., 2009) and monomeric (Zakharov et al., 2007) forms
of αS but not larger structures such as fibrils. Lower membrane affinity has been reported for
the A30P mutant of αS, most likely due to disruption of the α-helix due to the proline muta-
tion (Jensen et al., 1998; Wislet-Gendebien et al., 2008). Conflicting reports exists regarding
the ability of A30P to induce permeabilization and undergo pore formation in membranes
(Zakharov et al., 2007; Camilleri et al., 2013). That membrane permeability in response to αS
is not only occurring in artificial systems has been shown by Feng et al. (2010) who found in-
creased membrane conductance in MN9 cells overexpressing αS. Another group reported no
increase in membrane conductance for WT αS but increase for the A53T mutant in SH-SY5Y
cells (Furukawa et al., 2006). This same group also found elevated basal and peak cytoso-
lic Ca2+ levels in response to high potassium depolarization for the A53T mutant. Another
group, working with the same cell line, as well found increased peak levels of cytosolic Ca2+
from high potassium stimuli (Hettiarachchi et al., 2009). They found the reverse behavior in
that the A53T mutant took up lower amounts of Ca2+ than WT αS. My own results showed a
much smaller increase in peak levels of Ca2+ upon high potassium depolarization for primary
cortical neurons that overexpressed αS suggesting differences in the membrane conductance
depending on cell type. When I used physiological stimuli such as FS of frequencies com-
monly present in neuronal systems, I did not observe any changes in Ca2+ handling however.
This suggests that high levels of αS is not enough to impair calcium handling and normal
action potential (AP) firing of neurons is not causing increases in intracellular calcium due
to αS, something which could otherwise lead to apoptosis as seen in excitotoxicity from glu-
tamate receptor overactivation (Pivovarova and Andrews, 2010).
αS might cause permeabilization of other membranes than the plasmamembrane (PM). Since
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αS has been shown to be able to cross the IMM, at least in isolated mitochondria (Devi et al.,
2008), it is possible that αS forms a pathological pore in the IMM resembling the mitochon-
drial permeability transition (MPT) pore. I did not see any changes in mitochondrial mem-
brane potential however, suggesting that this is not the case. But in contrast to elevated ROS
production and its apoptotic response which can be assumed to be slower, the release of even
very small amounts of cytochrome c is known to initiate apoptosis and it is possible that this
is what leads to the toxicity of αS observed in cell culture.
It has been shown that αS prefers binding to membranes with high curvature. Middleton
and Rhoades (2010) found a 10x stronger binding to vesicles with 46 nm than 77 nm. This
is interesting since it fits with preferential binding to small synaptic vesicles in dopamin-
ergic neurons which have similar size (∼30-60 nm) (Rayport et al., 1992; Nirenberg et al.,
1996). The PM and OMM (∼0.5-1 µm) have significantly lower curvature (Frey and Mannella,
2000). The IMMhowever, have invaginations forming the cristae and these havemuch higher
curvature. Cristae junctions for example have a reported diameter of 12-40 nm (Rabl et al.,
2009) and tubular cristae 30-40 nm (Frey and Mannella, 2000). These dimensions are simi-
lar to those of small synaptic vesicles, and the diameters reportedly preferred by αS. In PD,
perhaps αS looses its binding to synaptic vesicles, either due to crowding from too high con-
centration of αS or from some yet unknown mechanism, thus becoming present at higher
levels close to mitochondria where it crosses the OMM. In the intermembrane space it could
associate with the IMM at regions of high curvature, causing swelling and eventual release
of cytochrome c through a MPT like mechanism. In this scenario, no reduced mitochondrial
function or impaired mitochondrial membrane potential is necessary until cytochrome c is
released, at which moment apoptosis might occur rapidly.
A role for αS in complex I impairment has been suggested from studies on isolated mitochondria.
Such an impairment would reduce the ability of the mitochondria to produce ATP and lower the
ΔΨm but none of these changes were measured. This suggests that complex I inhibition is not the
primary cause of toxicity from αS in neurons.
Pore formation in the IMM is another possible cause of toxicity. If these pores exists, they are
either not permeable to calcium or they are transient enough to not cause any impaired calcium
handling. It is possible however, that the loss of neurons observed in the cell cultures occur
through apoptosis from cytochrome c release in response to MPT induced by αS mediated per-
meability.
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4.3 Conclusion and perspectives
The results presented in this thesis demonstrate that αS overexpression does not affect mi-
tochondrial function in primary neuronal cell culture, neither that of calcium handling or
ATP production through oxidative phosphorylation. A functional mitochondria was also
supported by the presence of an intact mitochondrial membrane potential. But this does
not mean that αS is in no way affecting or contributing to pathology through a mechanism
involving the mitochondria. In fact, I found that αS overexpression does affect both mito-
chondrial morphology and motility. Since mitochondrial morphology, integrity and fission
especially, is related to mitochondrially regulated apoptosis, this suggests a connection be-
tween αS and cell death, which requires further study.
The really surprising finding however, was that βS, previously thought to protect against αS
toxicity, is toxic by itself and that it too, leads to fragmentation of mitochondria. But as for
αS, no other impairment of mitochondrial function was found.
It was also interesting to discover that calcium influx in response to depolarization, some-
thing previously found to be greatly increased for the SH-SY5Y cell line when expressing αS,
was hardly affected in primary cortical neurons. This reveals the difficulties and risks of mis-
interpretation when working in vitro and shows the importance of taking these experiments
to in vivo studies in the future. Our lab has developed and adapted methods for in vivo imag-
ing in live animals using two-photon microscopy. The intention is to transfer the methods
from primary cell culture to the intact animal and assess the effects of the synucleins there.
Preliminary experiments by our lab show that the loss of neurons by αS and βS can be
prevented or reduced by co-expressing mitochondrial anti-apoptotic proteins such as B-cell
lymphoma-extra large (Bcl-xl). The immediate work which will be carried out upon the com-
pletion of this thesis is the examination of what effects this has onmitochondrial morphology
as well as if these “protected” neurons show signs of mitochondrial dysfunction.
The present study also shows that GES hold great potential for use in research on neurode-
generative diseases. AAV vectors coding for the expression of several additional GESs than
those covered in this thesis have already been generated. A mitochondrially targeted ver-
sion of ATeam1.03 is ready and I hope that this can be used to further examine effects on ATP
turnover in the mitochondria by the synucleins. Both cytosolic and mitochondrial ROS sen-
sors are also available and it will be interesting to see if these can show increased oxidative
state of the cell due to overexpression of αS.
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Parkinson’s disease (PD) is the secondmost common neurodegenerative disease and it affects
more than 1% of the worlds population over the age of 65. A hallmark of PD is the appear-
ance of Lewy bodies (LBs) throughout the brain and a major component of these intracellular
inclusions is the small soluble protein α-Synuclein (αS). Rare familial mutations as well as
duplications and triplications of the gene coding for αS leads to early onset PD and this makes
a role for αS in the etiology of PD likely but exactly how αS contributes to the disease is still
unknown. No genetic link to PD has so far been described for the other two members of the
synuclein family, β-Synuclein (βS) and γ-Synuclein (γS) but βS has recently been suggested
to have neuroprotective properties, evidence of which comes from experiments showing that
it reduces αS induced neurotoxicity. However, a mutation in βS is linked to dementia with
Lewy bodies (DLB) and has been shown to cause neurodegeneration in transgenic (TG) mice.
For this thesis, the effects of overexpression of the synucleins in primary cortical neurons
were examined. Because αS has been shown to reduce the activity of complex I of the elec-
tron transport chain (ETC) in mitochondria isolated from patients, a special interest was the
effects on the mitochondria, its function and morphology. Overexpression of αS as well as
βS but not γS led to degeneration of neurons. The mitochondria was also affected, αS and
βS both led to a fragmented morphology that worsened with time whereas the mitochon-
dria in γS overexpressing neurons were unaffected. Nevertheless, these mitochondria were
still functionally intact. Not only were they able to handle influx of calcium, they were also
able to regenerate ATP after depletion at the same rate as control. This suggests that oxida-
tive phosphorylation and as a consequence complex I is not significantly impaired in these
neurons. Therefor, the toxicity of αS is not likely to be due to a direct impairment of mito-
chondrial function. The fact that βS has similar effects as those of αS in terms of toxicity and
mitochondrial morphology was new and suggests a role for βS in PD that will require further
study.
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DDC DOPA decarboxylase. 106
VMAT vesicular monoamine transporter. 4, 106
A. victoria A bioluminescent hydrozoan jellyfish from which GFP was first isolated. 18
aa amino acid. 3, 5–7, 17
AAV adeno-associated virus. 27–30, 35, 36, 44, 45, 49–58, 61, 63–66, 68, 70, 71, 73–82, 84–89,
91–93, 95, 99, 100, 106, 113, 117, 119
AB antibody. 14, 37, 77
AD Alzheimer’s disease. 1, 5
AFM atomic force microscopy. 13
ANOVA analysis of variance. 43, 80, 82, 84, 87–89, 91, 95
AP action potential. 46, 53, 54, 57–59, 85, 90, 111
Aβ amyloid-beta. 5
BAD Bcl-2-associated death promoter. 9
BAX Bcl-2-associated X protein. 9
Bcl-xl B-cell lymphoma-extra large. 113
BFP Engineered variant of GFP for blue shifted excitation and emission. 19
BiFC bimolecular fluorescence complementation. 105
BSA bovine serum albumin. 25
C. elegans A transparent nematode extensively used as a model organism in biological re-
search. 109
CaM A calcium binding messenger protein. 28, 102
CCD charge-coupled device. 56
CFP Engineered variant of GFP for blue shifted excitation and emission. 20, 21, 60, 69–72,
100, 102, 103
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CK-1 casein kinase 1. 9
CK-2 casein kinase 2. 9
CMV cytomegalovirus. 100
COX cytochrome c oxidase. 28, 29, 45, 46, 49, 100
CSPα cysteine string protein α. 8
cytochrome c A small heme protein associated with the inner mitochondrial membrane.
Responsible for the transfer of electrons between complex III and complex IV in the
electron transport chain. 16, 17, 28, 45, 97, 100, 110, 112, 116
DAT dopamine active transporter. 4
DIV days in vitro. 75, 76, 78, 80, 81
DJ-1 PARK7 is the gene coding for the human DJ-1 protein. 2, 3, 17
DLB dementia with Lewy bodies. 10, 11, 107, 114
DMSO dimethyl sulfoxide. 25
DNA deoxyribonucleic acid. 17, 32–35, 117
DPT days post transduction. 49, 50, 52, 53, 55, 56, 61, 66, 68, 75–79, 81–84, 87–94, 97, 110
Drosophila A species of fly in the Drosophilidae family commonly known as fruit fly. Used
extensively as a model organism in biological research. 17
Drp1 dynamin related protein 1. 15, 17, 109
EDTA ethylenediaminetetraacetic acid. 25
EGFP enhanced green fluorescent protein. 19
EGTA ethylene glycol tetraacetic acid. 101
EM electron microscopy. 13, 14
ER endoplasmic reticulum. 67
ETC electron transport chain. 4, 16, 23, 73, 92, 110, 111, 114
FCCP carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone. 25, 63–69, 93–95, 97, 98
FCS fetal calf serum. 24, 25
FP fluorescent protein. 19–22, 45–47, 49, 51, 56, 58, 100, 103–105
FPLC fast protein liquid chromatography. 36
FPS frames per second. 54
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FRET Förster resonance energy transfer. 20–22, 27, 42, 43, 46, 49, 51, 53, 55, 59, 60, 62–66,
72, 100, 102–105
FS field stimulation. 51, 53, 54, 57–59, 68–71, 85–87, 90, 92, 93, 101–104, 106, 111
GECI genetically encoded calcium indicator. 20, 21, 28, 45, 46, 49, 51, 56, 71, 72, 85, 86, 101,
102, 106
GES genetically encoded sensor. 19–23, 27, 37, 44, 45, 47, 49, 69, 70, 73, 99, 100, 102, 103,
105, 113
GFP A fluorescent protein originally isolated in 1962 from the jellyfish Aequorea victoria.
Absorption peak 395 nm and emission peak at 509 nm. Most common engineered form
is EGFP which has a red-shifted excitation peak at 488 nm. 18–20, 27, 29, 30, 45–47, 49,
56, 69–72, 74–84, 87–92, 96–98, 105–107, 119
GPCR G protein-coupled receptor. 9, 117
GRK G protein-coupled receptor (GPCR) kinase. 9
GWAS genome-wide association study. 12
HCV hepatitis C virus. 104
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid. 25
hSyn The promoter region from the human synapsin gene. 27, 45, 73, 74, 99, 100, 105
IMM inner mitochondrial membrane. 16, 110, 112
IMPDH2 inosine monophosphate dehydrogenase type II. 104
in vitro Designation for experiments on components of a biological system that has been
isolated from its original surrounding such as a dissociated and cultured neuron or
purified mitochondria. 11–13, 43, 102–104, 109–111, 113
in vivo Designation for experiments on a complete living organism such as animal testing.
4, 9, 11, 16, 20, 113
ITR Parts of the adeno-associated virus (AAV) genome. Forms hairpins that contribute to
self priming for the synthesis of the second deoxyribonucleic acid (DNA) strand. The
only sequences required in the plasmid for packaging of AAVwhen the structural (cap)
and packaging (rep) genes are delivered by co-transfection. 27, 34, 35
KO knock out. 8, 11, 14
LB Lewy body. 2–4, 9–12, 114
LN Lewy neurite. 2, 10, 11
117
Glossary
LRRK2 leucine-rich repeat kinase 2. 2, 3, 17
LUT lookup table. 66
MAO monoamine oxidase. 4, 110
MCS multiple cloning site. 30, 45
Mfn1 mitofusin 1. 15, 109
Mfn2 mitofusin 2. 15, 109
MgCl2 magnesium chloride. 31
MOI A physical quantity for viral infection defined as vector genomes divided by the num-
ber of cells being infected.. 37, 47, 49, 50, 52, 53, 55–58, 61, 66, 68, 75–79, 81, 82, 84–89,
91–93, 95, 97, 98, 106, 108
MPDP+ 1-methyl-4-phenyl-2,3-dihydropyridinium. 4
MPP+ 1-methyl-4-phenylpyridinium. 4
MPPP 1-methyl-4-phenyl-4-propionoxypiperidine. 3, 4
MPT mitochondrial permeability transition. 16, 17, 23, 112
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 4, 14, 16, 110
MTS mitochondrial targeting sequence. 28, 29, 45–47, 49, 54, 58, 59, 99, 100
MW molecular weight. 45, 46
NAC non-Aβ component. 5, 118
NACP non-Aβ component (NAC) protein. 5
NBM neurobasal medium. 24
NSF N-ethylmaleimide sensitive fusion protein. 8, 119
OMM outer mitochondrial membrane. 14–17, 111, 112
parkin PARK2 is the gene coding for the human Parkin protein. 2, 3, 17, 108
PCD programmed cell death. 1, 9, 15, 16
PCR polymerase chain reaction. 30–32, 35, 36
PD Parkinson’s disease. 1–5, 10–14, 16, 18, 21, 73, 79, 84, 99, 105, 107, 108, 110, 112, 114
PINK1 P-TEN-induced putative kinase 1. 2, 3, 17, 108
PLK polo-like kinase. 9
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PM plasma membrane. 67, 111, 112
PMCA plasma membrane Ca2+-ATPase. 67
PTFE polytetrafluoroethylene. 38
RNA ribonucleic acid. 9, 104
ROI region of interest. 42, 46, 48
ROS reactive oxygen species. 14, 16, 17, 47, 110, 112, 113
SD standard deviation. 43, 52, 55
SDS sodium dodecyl sulfate. 25, 36
SERCA sarco/endoplasmic reticulum Ca2+-ATPase. 67
SH-SY5Y Human derived cell line isolated from bone marrow biopsy from patient with
neuroblastoma. 13, 14, 85, 109, 111, 113
SNAP soluble N-ethylmaleimide sensitive fusion protein (NSF) attachment protein. 8, 119
SNARE soluble NSF attachment protein (SNAP) receptor. 8, 9, 15
SNCA The gene coding for α-Synuclein.. 2, 3, 6, 10, 73, 105, 119
SNCB The gene coding for β-Synuclein.. 6, 11, 73, 107, 119
SNCG The gene coding for γ-Synuclein.. 6, 119
SNpc A part of the substantia nigra, a region of the midbrain. 1–3, 18, 107, 110
sph1 synphilin-1. 17
SURE electroporation-competent cells, “stop unwanted rearrangement events”. 34
αS α-Synuclein is a small soluble protein implicated as the toxic entity in Parkinson’s dis-
eases. Coded for in humans by the SNCA (PARK1) gene. For the AAV vector used for
expression see AAV6-s-aSynWT-WB under the “Vectors” heading or for the bicistronic
variant with green fluorescent protein (GFP) expression see AAV6-s-aSynWT-SEIS-
WB. 2, 4–16, 21, 23, 44, 73–99, 105–114
βS β-Synuclein is a small soluble protein in the synuclein family coded for by the SNCB
gene.. 5, 6, 9, 11, 21, 44, 73–75, 79–84, 87–96, 98, 99, 106–110, 113, 114
γS γ-Synuclein is a small soluble protein in the synuclein family coded for by the SNCG
gene.. 5, 6, 8, 9, 11, 21, 23, 44, 73–75, 79–84, 87–96, 98, 99, 107–109, 114
TB transcription blocker. 27
TG transgenic. 11, 14, 15, 21, 107, 114
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TH tyrosine hydroxylase. 105
TMRM tetramethylrhodamine-methylester. 25, 97, 98
TOM transport outer membrane. 111
TTL transistor–transistor logic. 41
UPS ubiquitin proteasome system. 3
vehicle Refers to the non-expressing vector control used throughout the experiments. See
AAV6-3TB-EWB under the “Vectors” heading. 85
WHP woodchuck hepatitis virus. 27, 74, 120
WPRE woodchuck hepatitis virus (WHP) posttranscriptional regulatory element. 27, 74–76,
80
WT wild type. 6, 8, 9, 12–14, 74, 75, 77, 85, 107
YFP Engineered variant of GFP for red shifted excitation and emission. 19–21, 69–72, 100,
102, 103
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